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SUMMARY 
 
Skin is the largest organ in the human body and serves as a barrier that protects the underlying 
tissue of the host from infection. Injury, however, destroys this protective barrier and provides 
a perfect opportunity for microorganisms to invade the host and cause infection, thereby 
affecting the normal wound healing processes. Furthermore, the ability of microbial 
pathogens to rapidly develop resistance towards a variety of antimicrobial compounds 
hampers the effective treatment and control of infections. Antimicrobial-resistant pathogens 
are increasingly being isolated from patients, placing a huge burden on the health care sector. 
The search for new and novel antimicrobial agents and treatments is thus of utmost 
importance and will continue to play an integral role in medical research. 
 Antimicrobial peptides (AMPs) may serve as possible alternatives to antibiotics, or 
may be used in combination with antibiotics to reduce the risk of antimicrobial resistance. 
AMPs play a role in innate defence and are produced by a variety of mammals, plants, 
reptiles, amphibians, birds, fish and insects. The AMPs of bacteria (bacteriocins), especially 
those of lactic acid bacteria (LAB), are receiving increased attention as antimicrobial agents 
to treat bacterial infections.  
Electrospun nanofibers have characteristics that make them suitable as wound 
dressings, i.e. high oxygen permeability, variable pore size, high surface area to volume ratio 
and nanofibers are morphologically similar to the extracellular matrix. The ability to 
incorporate of a variety of biologically active compounds into nanofibers increases their 
potential as wound dressings. A novel approach would be to incorporate bacteriocins from 
LAB into nanofiber scaffolds to generate antimicrobial wound dressings.  
In this study, the feasibility of co-electrospinning bacteriocins from LAB into 
nanofibers was investigated. Plantaricin 423, produced by Lactobacillus plantarum 423, was 
successfully co-electrospun into poly(ethylene oxide) (PEO) nanofibers. Plantaricin 423 
retained activity after the electrospinning process and continued to inhibit the growth of 
Lactobacillus sakei DSM 20017
T
 and Enterococcus faecium HKLHS. Viable cells of L. 
plantarum 423 were also successfully co-electrospun into PEO nanofibers, albeit with a slight 
reduction in viability. A nanofiber drug delivery system was developed for plantaricin 423 
and bacteriocin ST4SA, produced by Enterococcus mundtii ST4SA, by blending PEO and 
poly(D,L-lactide) (PDLLA) in a suitable solvent before electrospinning. Nanofibers were 
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produced that released the bacteriocins over an extended time period. The PEO:PDLLA 
(50:50) nanofiber scaffold retained its structure the best upon incubation at 37 °C and released 
active plantaricin 423 and bacteriocin ST4SA. Nisin A was also successfully co-electrospun 
into a PEO:PDLLA (50:50) nanofiber scaffold and nisin A, released from the nanofibers, 
inhibited the growth of Staphylococcus aureus in vitro. Nisin A-containing nanofiber 
scaffolds significantly reduced viable S. aureus cells in infected skin wounds and promoted 
wound healing in non-infected wounds. As far as we could determine we are the first to show 
that bacteriocin-eluting nanofiber scaffolds can be used to treat skin infections and influence 
wound healing. 
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OPSOMMING 
 
Vel is die grootse orgaan in die menslike liggaam en dien as buitelaag wat die gasheer se 
onderliggende weefsel teen infeksie beskerm. Beskadigde vel verloor egter hierdie 
beskermende eienskap en gee mikroörganismes die geleentheid om die liggaam binne te 
dring, infeksie te veroorsaak en die normale prosesse geassosieer met wondgenesing te 
beïnvloed. Die suksesvolle behandeling en beheer van infeksies word gedemp deur die 
vermoë van mikroörganismes om vinnig weerstand teen antimikrobiese middels te ontwikkel. 
Mikroörganismes met antimikrobiese weerstand word geredelik van pasiënte geïsoleer en dit 
plaas enorme druk op die gesondheidssektor. Die soeke na nuwe antimikrobiese middels en 
behandelings is dus van uiterste belang en sal altyd ‘n integrale rol in geneeskunde navorsing 
speel. 
 Antimikrobiese peptiede (AMPe) kan moontlik as alternatief tot antibiotika dien, of 
kan in kombinasie daarmee gebruik word om die ontwikkeling van antimikrobiese- 
weerstandbiedenheid te verhoed. AMPe speel ‘n rol in ingebore beskerming en word deur 
soogdiere, plante, reptiele, voëls, visse en insekte geproduseer. AMPe van bakterieë 
(bakteriosiene), veral die van melksuurbakterieë (MSB), wek toenemende belangstelling as 
antimikrobiese middels vir die behandeling van bakteriële infeksies.  
Nanovesels, wat deur middel van ‘n elektrospin proses geproduseer word, het 
eienskappe wat hul aanloklik maak as wondbedekking, naamlik hoë suurstof 
deurlaatbaarheid, verskeie porie grottes, ‘n hoë oppervlakte tot volume verhouding, sowel as 
‘n morfologiese struktuur wat die ekstrasellulêre matriks naboots. Die vermoë om ‘n 
verskeidenheid biologies aktiewe komponente in nanovesels te inkorporeer verhoog hul 
potensiaal as wondbedekkingsmateriaal. ‘n Unieke benadering is die inkorporasie van 
bakteriosiene van MSB in nanovesels om ‘n antimikrobiese wondbedekking te ontwikkel. 
In hierdie studie is die vermoë om bakteriosiene van MSB in nanovesels te 
inkorporeer, deur middel van ‘n mede-elektrospin proses, ondersoek. Plantarisien 423, 
geproduseer deur Lactobacillus plantarum 423, was suksesvol deur die mede-elektrospin 
proses in poliëtileen oksied (PEO) nanovesels geinkorporeer. Plantarisien 423 het na die 
elektrospin proses steeds sy antimikrobiese aktiwiteit behou en het die groei van 
Lactobacillus sakei DSM 20017
T
 en Enterococcus faecium HKLHS geïnhibeer. Lewende 
selle van L. plantarum 423 was ook suksesvol deur die mede-elektrospin proses in PEO 
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nanovesels geinkorporeer, alhoewel die lewensvatbaarheid van die selle effens afgeneem het. 
‘n Nanovesel matriks is ontwikkel om die vrystelling van plantarisien 423 en bakteriosien 
ST4SA, geproduseer deur Enterococcus mundtii ST4SA, te beheer deur PEO en poli(D,L-
melksuur) (PDLMS) in ‘n geskikte oplosmiddel te vermeng voor die elektrospin proses. 
Nanovesels is geproduseer wat die bakteriosiene oor ‘n verlengde tydperk kon vrystel. ‘n 
PEO:PDLMS (50:50) nanovesel matriks het sy stuktuur die beste behou tydens inkubasie by 
37 °C en het aktiewe plantarisien 423 en bakteriosien ST4SA vrygestel. Nisien A was met 
dieselfde tegniek in PEO:PDLMS (50:50) geinkorporeer en nisien A, wat deur die nanovesels 
vrygestel was, het die groei van Staphylococcus aureus in vitro geïnhibeer. Die nisien A-
bevattende nanovesel matriks het die aantal lewende selle van S. aureus noemenswaardig 
verminder in geïnfekteerde wonde en kon die genesing van wonde, wat nie geïnfekteer was, 
stimuleer. Sover ons kon vastel is hierdie die eerste gepubliseerde navorsing wat toon dat 
bakteriosiene, geinkorporeer in nanovesels, gebruik kan word om vel infeksies te beheer en 
wondgenesing te stimuleer. 
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INTRODUCTION 
 
Severe damage disrupts the protective skin barrier and exposes underlying tissue to microbial 
invasion (Altoparlak et al., 2004). S. aureus is a major pathogen implicated in skin and soft-
tissue infections and is frequently isolated from patients (Daum, 2007). Antibiotic-resistant 
strains of S. aureus have also emerged which cause major problems in hospitals, as well as the 
community environment (Chang et al., 2003, Kim, 2009, Tsiodras et al., 2001). Antibiotic 
resistance in bacterial pathogens is becoming problematic and it has now been described as 
the “end of the antibiotic era” (Alanis, 2005, Hancock, 2007, Neu, 1992). This is emphasized 
by the fact that no new classes of antibiotics were introduced between 1962 and 2000, 
followed by only three new classes up to 2010 (Fischbach and Walsh, 2009). There is thus a 
need to investigate new antimicrobial agents to pave the way forward in infection control.  
Bacteria produce a variety of ribosomally synthesized antimicrobial peptides 
(bacteriocins) that are usually active against closely related species. Some bacteriocins, 
however, show a broader spectrum of activity (Jack et al., 1995, Kleanhammer, 1993). 
Bacteriocins can be divided into different classes, which include Class I (post-translationally 
modified bacteriocins), class II (unmodified bacteriocins) and the bacteriolysins, formerly 
class III bacteriocins (Cotter et al., 2005). Bacteriocins from LAB have attracted increased 
attention as antimicrobial agents and may have various biomedical applications (Dicks et al., 
2011). Some bacteriocins are active against antibiotic-resistant pathogens including 
methicillin-resistant S. aureus, vancomycin-resistant enterococci and heterogeneous 
vancomycin-intermediate S. aureus (Piper et al., 2011) and can play an integral role as future 
antimicrobial agents. Bacteriocins also have potential to be used in conjunction with 
antibiotics to treat infections and prevent the development of resistant microorganisms (Diep 
et al., 2007).  
Nanofibers are polymeric fibers with diameters in the nanometer range and can be 
produced by various techniques, including electrospinning (Huang et al., 2003). 
Electrospinning is a process where an electric charge is applied to a polymer solution to form 
thin fibers at a collector plate (Huang et al., 2003). Electrospun nanofibers have been 
extensively investigated for the incorporation and release of various molecules, including 
antibiotics, growth factors, proteins, antifungals, nucleic acids, anti-inflammatories, silver 
particles as well as bacteria, viruses and mammalian cells (Agarwal et al., 2008). Nanofibers 
have also been extensively investigated for tissue regeneration and to stimulate wound healing 
Stellenbosch University http://scholar.sun.ac.za
3 
 
(Agarwal et al., 2008, Zahedi et al., 2010). The ideal wound dressing should facilitate healing 
by forming a barrier to prevent microbial colonization and at the same time be able to treat 
infection, absorb wound exudate, allow gas exchange, be non-immunogenic and non-toxic 
and must be easily removable without causing damage (Zahedi et al., 2010). Nanofibers fulfil 
some of the abovementioned roles by having high oxygen permeability, variable pore size, a 
high surface area to volume ratio and show morphological similarity to the extracellular 
matrix (Smith and Ma, 2004, Zahedi et al., 2010, Zhou et al., 2008). The ability to co-
electrospin a variety of bioactive molecules into nanofibers can increase this potential to 
develop a wound dressing that fulfils all of these properties. 
A novel approach to wound treatment would be to incorporate bacteriocins from LAB 
into nanofibers to develop an antimicrobial wound dressing. The challenge, however, is to 
develop a wound dressing that would release the bacteriocins in a localized and controlled 
manner to inhibit the growth of bacteria in the wound and at the same time promote the 
healing process. 
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LITERATURE REVIEW 
1. Skin Infection: Issues and Concerns Regarding Staphylococcus aureus 
1.1 The wound healing process 
Skin protects the host from infection and plays a role in thermoregulation and maintaining of 
homeostasis, it has immunological, neurosensory and metabolic functions. Skin is divided 
into the epidermis and the dermis, which form layers above the subcutaneous fat (Church et 
al., 2000). The epidermis is the outermost layer of skin and consists of epidermal cells, 
whereas the dermis consists mainly of collagen. Severe skin damage exposes underlying 
tissue to microbial invasion (Altoparlak et al., 2004, Vindenes and Bjerknes, 1995). If 
preventative measures are not taken, pathogens can develop biofilms, rendering wounds even 
more difficult to treat (Ceri et al., 1999, Costerton et al., 1999, de Beer et al., 1994, Edwards 
and Harding, 2004). Biofilms consist of a complex community of microorganisms aggregated 
in an extracellular polysaccharide matrix (Costerton et al., 1999). These organisms undergo a 
phenotypic change, channels are formed in the biofilms to transport nutrients and waste 
products, and they respond to environmental stimuli as a unit (de Beer et al., 1994, Edwards 
and Harding, 2004).  
Infection prevents successful wound healing, which can be divided into different, but 
overlapping stages, including homeostasis, inflammation, new tissue formation, remodeling 
and maturation (Gurtner et al., 2008, Nishio et al., 2008). Components of the coagulation 
cascade, inflammatory pathways and immune system are involved immediately after injury 
and play an important role in preventing further blood and fluid loss, removing dead and 
dying tissue, as well as preventing infection (Gurtner et al., 2008). Homeostasis is rapidly 
established directly after injury with vascular constrictions and formation of a platelet plug 
(consisting of platelet, red- and white blood cells), followed by a fibrin-fibronectin matrix 
(Guo and DiPietro, 2010, Rodero and Khosrotehrani, 2010, Valenick et al., 2005). The fibrin 
matrix forms a scaffold for cells infiltrating the wound. The platelet plug and surrounding 
tissue release pro-inflammatory cytokines and growth factors, including transforming growth 
factor (TGF)-β, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), as 
well as epidermal growth factor (EGF) (Guo and DiPietro, 2010). 
The inflammatory phase, or cellular phase, is characterized by infiltration of 
polymorphonuclear neutrophils (PMN’s), one hour after injury, which plays a role in 
degrading bacterial products, prevention of bacterial invasion and the removal of debris 
(Grose and Werner, 2004, Guo and DiPietro, 2010). They produce proteases and reactive 
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oxygen species, which facilitate this process, but may also damage host tissue (Greenhalgh, 
1998, Guo and DiPietro, 2010). PMN’s are attracted to the wound by growth factors and 
inflammatory cytokines produced by endothelial cells as well as by degradation products from 
pathogens (Rodero and Khosrotehrani, 2010). They are the dominant cells in the wound 
during the initial stages and reach a peak 24 h after injury (Kim et al., 2008). PMN’s undergo 
apoptosis once they have completed their task in the wound healing process and release pro-
inflammatory cytokines [such as interleukins 1 alpha and beta (IL-α and β) and tumor 
necrosis factor alpha (TNF-α)], which activate local fibroblasts and keratinocytes and play an 
important role in macrophage recruitment (Hübner et al., 1996, Martin and Leibovich, 2005, 
Rodero and Khosrotehrani, 2010). Monocytes infiltrate the wound and differentiate into 
macrophages 2-3 days after injury (Gurtner et al., 2008, Nishio et al., 2008). They play an 
important role in wound healing and replace PMN’s as the dominant cell type. Macrophages 
engulf (phagocytise) and degrade bacteria, apoptotic PMN’s, as well as damaged tissue (Guo 
and DiPietro, 2010). They debride tissue by releasing proteases and will release cytokines and 
growth factors, which stimulate keratinocytes and fibroblasts to promote tissue regeneration 
ending the inflammatory phase (Guo and DiPietro, 2010, Meszaros et al., 2000, Mosser and 
Edwards, 2008).  
The new tissue formation phase, or proliferative phase, usually overlaps with the 
inflammatory phase and occurs 2-10 days after injury. It is characterized by cellular 
proliferation and re-epithelialization of the wound (Guo and DiPietro, 2010, Gurtner et al., 
2008). Keratinocytes, from the wound edges, will initially migrate over the injured dermis and 
migration is facilitated by the production of specific proteases, such as collagenase, to 
degrade the extracellular matrix (ECM) (Gurtner et al., 2008, Pilcher et al., 1997). Fibroblasts 
and endothelial cells support capillary growth (which can provide oxygen and nutrients to the 
new/healing tissue), collagen formation and, together with angiogenesis (growth of new blood 
vessels), forms granulation tissue (Guo and DiPietro, 2010, Gurtner et al., 2008). Granulation 
tissue forms a substrate for further keratinocyte migration, which will eventually restore the 
barrier function (Werner and Grose, 2003). Fibroblasts migrate across the wound and some 
are stimulated by macrophages to differentiate into myofibroblasts, which contract the wound 
during the healing process (Opalenik and Davidson, 2005). Fibroblasts, together with 
myofibroblasts, initiate the production of collagen, glycosaminoglycans and proteoglycans, all 
of which play a role in formation of new ECM (Guo and DiPietro, 2010, Werner et al., 2007). 
Production of collagen is a very important function of the fibroblasts, as this increases the 
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strength of the wound and forms a scaffold for cells to grow and differentiate (Greenhalgh, 
1998).  
The final stage of wound healing, the remodeling or maturation phase, is initiated after 
cellular proliferation and ECM synthesis, usually within 2-3 weeks after injury and can last 
for years (Guo and DiPietro, 2010, Gurtner et al., 2008). Healing processes halt or scale down 
and most endothelial cells, macrophages and myofibroblasts will either undergo apoptosis or 
leave the wound while type I collagen replaces type III collagen (Gurtner et al., 2008). During 
this phase the vascular density returns to normal and the ECM regenerates to a scaffold 
similar to that of normal tissue (Guo and DiPietro, 2010, Gurtner et al., 2008). 
 
1.2 S. aureus and antibiotic-resistant strains of S. aureus  
S. aureus is a virulent pathogen responsible for superficial and invasive skin and soft-tissue 
infections (SSTIs), endovascular infections, necrotizing pneumonia, septic arthritis, 
endocarditis, osteomyelitis, sepsis, empyema, musculoskeletal infections including 
pyomyositis, necrotizing fasciitis, purpura fulminans, as well as disseminated infections with 
septic emboli (Bagget et al., 2003, Daum, 2007, Fergie and Purcell, 2001, Francis et al., 2005, 
Fridkin et al., 2005, Gonzales et al., 2005a,b, Martínez-Aguilar et al., 2003, Miller et al., 
2005, Mongkolrattanothai et al., 2003). S. aureus is a Gram-positive coccus and a normal 
member of the skin microflora. It can thus rapidly colonize a wound within a few hours and 
can cause minor infections or more severe life-threatening infections (Chambers, 2001, 
Martinez et al., 2009). The close association of S. aureus with the medical sector has resulted 
in rapid increase in antibiotic resistance. It is estimated that 90 to 95% of clinical S. aureus 
strains are resistant to penicillin and furthermore that 60-70% of strains are now resistant to 
methicillin (MRSA) (Kim, 2009).  
MRSA was first reported in 1960’s after methicillin, a penicillinase-resistant 
penicillin, was introduced to treat infections caused by S. aureus (Chambers, 2001). The 
Center for Disease Control and Prevention estimates that there are 10 000 cases of life 
threatening MRSA infection annually in the US and MRSA now accounts for 40-70% of all S. 
aureus infections in intensive care units (Klevens et al., 2007, Ray et al., 2012). Methicillin 
resistance is attributed to a gene (mecA) that encodes for a low-antibiotic affinity penicillin-
binding protein, known as PBP2a (Kim, 2009). This protein confers resistance to β-lactam 
concentrations which would normally be inhibitory to native PBPs (Kim, 2009). The mecA 
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gene (2.1kb) is located on the S. aureus chromosome and is carried on a genetic element 
known as the staphylococcal chromosomal cassette mec (SCCmec) (Ito et al., 2001). This 
SCCmec element includes the mecA gene, variants of a regulatory gene, mecR1, an insertion 
sequence element (IS431) and cassette chromosome recombinase (ccr) genes (Deurenberg 
and Stobberingh, 2008, Ito et al., 2001). Five different SCCmec types have been identified to 
date (Type I, II, III, IV and V) (Ito et al., 2003, 2004). MRSA can cause infections in patients 
in health care facilities (nosocomial infections), which is known as health care-associated 
MRSA or HA-MRSA infections, or can be acquired in the general population. The latter is 
known as community-acquired MRSA, or CA-MRSA (Herold et al., 1998, Naimi et al., 
2003). The CA-MRSA strains are genetically distinct from the HA-MRSA strains, in that they 
predominantly contain the SCCmec type IV and V, whereas the HA-MRSA strains usually 
contain type I, II and III (Daum et al., 2002, Kim, 2009). SCCmec type IV, like type I, confers 
resistance typically only to β-lactam antibiotics as it does not contain additional resistance 
genes, whereas the SCCmec II and III types confers resistance to multiple antibiotics (Daum 
et al., 2002, Fey et al., 2003, Ito et al., 2004, Ma et al., 2002). This is because SCCmec type II 
and III contain additional antibiotic resistant genes (Kim, 2009). Even though CA-MRSA is 
usually only resistant to β-lactam antibiotics, it is frequently more virulent than HA-MRSA 
and has serious medical implications. This could be due to the fact that CA-MRSA grows 
faster than HA-MRSA (CA-MRSA contains SCCmec type IV which is the smallest of all the 
SCCmec types and offers less of a metabolic burden) and as a result of containing Panton-
Valentine leukocidin (PVL) (Kim, 2009). PVL is a bacterial cytolysin that is associated with 
skin infections, as well as necrotizing pneumonias (Gillet et al., 2002, Kaneko and Kamio, 
2004, Lina et al., 1999). CA-MRSA isolates containing SCCmec type I, II, or III have also 
been reported (Deurenberg and Stobberingh, 2008). 
Vancomycin, a glycopeptide that inhibits cell wall synthesis by binding to the D-Ala-
D-Ala moiety of lipid II, served as best defence against the emerging threat of MRSA (Groves 
et al., 1994). However, vancomycin use has led to the emergence of vancomycin-resistant 
pathogens, such as vancomycin-resistant enterococci (VRE). Decreased sensitivity towards 
vancomycin soon followed in S. aureus, with the emergence of heterogeneous vancomycin-
intermediate S. aureus (hVISA), vancomycin-intermediate S. aureus (VISA) and 
vancomycin-resistant S. aureus (VRSA). hVISA strains show low vancomycin MIC 
(minimum inhibitory concentration) levels in the range of 1-4 µg/ml, whereas VISA strains 
have MICs in the range of 4-8 µg/ml and VRSA strains have MICs of ≥16 µg/ml (de 
Niederhäusern et al., 2011, Liu and Chambers, 2003). Increased vancomycin resistance was 
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first reported in MRSA isolates from Japan in 1997, showing intermediate resistance (VISA) 
with an MIC of 8 µg/ml (Hiramatsu et al., 1997). The first VRSA strain was isolated in 
Michigan in 2002 and resistance was mediated by the vanA gene (Chang et al., 2003). Since 
then, numerous other VRSA strains have been isolated from all over the world (Aligholi et 
al., 2008, CDC, 2004, Palazzo et al., 2005, Saha et al., 2008, Tiwari and Sen, 2006). VISA 
strains develop after prolonged exposure to vancomycin and result from adaptation, including 
thickening of the cell wall, reduced autolytic activity, as well as reduced biofilm forming 
ability (Howden et al., 2006). VISA strains usually have lower growth rates (Cui et al., 2003, 
Howden et al., 2006, Smith et al., 1999). Transfer of vancomycin resistance elements (such as 
vanA, which confers high level vancomycin resistance by converting the D-Ala-D-Ala 
recognition site of vancomycin to D-Ala-D-Lac) has been shown in vitro, as well as in vivo, 
from VRE to S. aureus (Cetinkaya et al., 2000, de Niederhäusern et al., 2011, Hughes, 2003, 
Noble et al., 1992). High resistance levels of VRSA can be attributed to the horizontal 
transfer of a Inc18-like plasmid with a transposon (designated Tn1456) containing the vanA 
gene (de Niederhäusern et al., 2011, Zhu et al., 2008, 2010). VRSA and VRE are usually co-
isolated from the same body site of an infected individual or subsequently isolated from a 
different body site (Zhu et al., 2010). The emergence of VRSA is thus thought to occur by in 
vivo transfer of vanA from a vanA-containing Enterococcus isolate to an S. aureus isolate 
(Zhu et al., 2010).  
The first reported case of linezolid-resistant S. aureus (LRSA) appeared in 2001. 
However, recently increased reports on the occurrence of LRSA have surfaced (Endimiani et 
al., 2011, Hill et al., 2010, Sánchez García et al., 2010, Tsiodras et al., 2001). Linezolid, an 
oxazolidinone, inhibits proteins synthesis by binding to the catalytic site of the 50S ribosomal 
subunit and in doing so prevents initiation complex formation with the 30S ribosomal subunit, 
formylmethionyl-tRNA and mRNA (Ippolito et al., 2008, Leach et al., 2007, Swaney et al., 
1998, Wilson et al., 2008). Resistance has been attributed to mutations in the V domain of the 
23S rRNA as well as by acquisition of a chloramphenicol-florfenicol resistance gene, 
designated Cfr (Morales et al., 2010, Stefani et al., 2010). This gene encodes for a RNA 
methyltransferase which results in methylation of A2503 in the 23S rRNA gene (Kehrenberg 
et al., 2005).  
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1.3 New-generation anti-staphylococcal agents  
The relative ease and high frequency of pathogens to develop antibiotic resistance places an 
immense burden to search for new and novel antimicrobial agents active against these 
antibiotic-resistant pathogens. A variety of compounds are in different developmental stages 
for treatment of infections caused by a variety of Gram-positive bacteria, including S. aureus. 
Ramoplanin, a lipoglycodepsipeptide produced by Actinoplanes ATCC 33076, has 
reached phase III clinical trials for the treatment of Gram-positive bacterial infections 
(McCafferty et al., 2002). The use of ramoplanin has, however, been limited by its instability 
in blood and poor tolerance (van Bambeke, 2006). It is in development as treatment for 
systemic nosocomial infections caused by VRE as well as treatment for Clostridium difficile-
associated diarrhoea (Gerding et al., 2008, Walker et al., 2005). Ramoplanin binds to the 
pyrophosphate moiety of lipid II, sequestering it and thereby inhibiting peptidoglycan 
biosynthesis, much like the lantibiotic nisin (Cudic et al., 2002, Fang et al., 2006).  
Dalbavancin, televancin and oritavancin are all derivatives of vancomycin, termed 
lipoglycoproteins, and contain modifications to the disaccharide moiety of the heptapeptide 
core (van Bambeke, 2004). Dalbavancin and ortivancin are currently in phase III clinical trials 
for treatment of acute bacterial skin and skin structure infections (BSSSIs) and treatment of 
serious Gram-positive infections, respectively (Zhanel et al., 2010). Ortivancin has been 
registered for two new studies (SOLO I and SOLO II) (van Hal and Paterson, 2011). 
Dalbavancin forms a complex with D-Ala-D-Ala in lipid II and inhibits cell wall synthesis, 
much like other glycopeptides, and is able to dimerise and anchor its lipophilic side chain in 
membranes (Chen et al., 2007, Ciabatti and Malabarba, 1997, Streit et al., 2004). Oritavancin 
has interaction with dipeptidyl residues of peptidoglycan precursors and blocks the 
transglycosylation step in peptidoglycan biosynthesis, hampering bacterial cell wall synthesis 
(Allen and Nicas, 2003). It can also dissipate the membrane potential and inhibit bacterial 
RNA synthesis (Zhanel et al., 2010). Televancin has received FDA approval for treatment of 
complicated BSSSIs caused by susceptible Gram-positive bacteria, including MRSA and 
methicillin-susceptible S. aureus (MSSA) (Corey et al., 2009). Televancin has a dual mode of 
action by binding to D-Ala-D-Ala of lipid II and hampering bacterial cell wall synthesis, as 
well as being able to disrupt bacterial membranes (Higgins et al., 2005, Saravolatz et al., 
2009). Interestingly, dalbavancin, televancin and oritavancin are active against some 
vancomycin-resistant bacterial pathogens, even though they are derived from vancomycin. 
Delbavancin shows activity towards vancomycin-susceptible enterococci as well as VRE, 
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with an MIC of 0.03-0.12 µg/ml. However, it has poor activity against VRE strains containing 
the vanA gene (Chen et al., 2007). Ortivancin is active against vanA- and vanB-containing 
VRE (Zhanel et al., 2010). Televancin and dalbavancin are active against vanB-containing 
enterococci, as well as VISA and hVISA strains, however display poor activity towards 
VRSA strains (Leuthner et al., 2006, Zhanel et al., 2010). Ortivancin on the other hand 
displays good activity towards both VISA and VRSA strains (Allen and Nicas, 2003). 
Ortivancin shows activity towards vanA strains as it is able to inhibit cell wall synthesis, 
dissipate membrane potential, inhibit bacterial RNA synthesis and most importantly able to 
bind to D-Ala-D-Lac (Zhanel et al., 2010). 
 Ceftobiprole and ceftaroline, two new cephalosporins, have been developed for 
treatment of MRSA. Ceftaroline has received FDA approval in 2010 for treatment of complex 
SSTIs, whereas the approval of ceftobiprole has been denied (van Hal and Paterson, 2011). 
Ceftaroline is able to bind to PBPs and inhibits their transpeptidase activity in cell wall 
synthesis (Villegas-Estrada et al., 2008).  
Iclaprim, a novel diaminopyrimidine, interacts with bacterial dihydrofolate reductases 
which are crucial in producing tetrahydrofolate and recycling it after reoxidation in the 
formation of thymidylate from deoxyuridylate, and thereby serves as a dihydrofolate inhibitor 
(Schneider et al., 2003). Inhibition of this enzyme arrests DNA synthesis and cell division, 
leading to cell death (Oefner et al., 2009). Iclaprim shows activity towards Gram-positive 
bacteria, including MRSA, VISA and F98Y trimethoprim-resistant strains (Oefner et al., 
2009). 
Tomopenem, a novel 1β-methylcarbapenem, binds to PBPs and shows broad spectrum 
activity against Gram-positive and Gram-negative pathogens including MRSA, penicillin-
resistant Streptococcus pneumoniae, Haemophilus influenzae, members of the family 
Enterobacteriaceae, as well as Pseudomonas aeruginosa (Koga et al., 2005, Tanaka et al., 
2009, Thomson and Moland, 2004). 
More recently, several new and novel antibiotics have entered human clinical trials. 
GSK1322322 (a hydrazinopyrimidine) is in development (phase II developmental stage) for 
treating complicated BSSSIs, as well as hospitalized community-acquired bacterial 
pneumonia (Moir et al., 2012). GSK1322322 is a peptide deformylase (PDF) inhibitor and 
prevents the removal of N-formyl groups on the first methionine during peptide elongation, 
preventing protein synthesis (Johnson et al., 2005). This compound shows in vitro activity 
against multidrug-resistant S. pneumonia, MRSA, Moraxella catarrhalis and Streptococcus 
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pyogenes, and promising results have been obtained in in vivo animal models, especially 
against S. aureus infections (Moir et al., 2012). AFN-1252 (a benzofuran naphthyridinone in 
phase I developmental stage) is in development for treatment of susceptible and/or multidrug-
resistant staphylococci, by inhibiting the enoyl-acyl carrier protein reductase (encoded by 
fabI) playing a role in bacterial fatty acid biosynthesis (Moir et al., 2012). AFN-1252 shows 
in vitro activity against MSSA, MRSA, methicillin-susceptible S. epidermidis (MSSE), and 
methicillin-resistant S. epidermidis (MRSE) (Karlowsky et al., 2007). AFN-1252 was more 
efficacious than linezolid when tested in vivo and had lower ED50 values when compared to 
that of linezolid (Moir et al., 2012). AFN-1252 was safe and well tolerated in a phase I study. 
MUT056399 (also known as FAB001) and CG400549 are both triclosan analogs and also 
inhibitors of FabI, thus inhibiting fatty acid biosynthesis (Escaich et al., 2011, Moir et al., 
2012). MUT056399 shows in vitro activity against MSSA, MRSA, LRSA, coagulase-
negative staphylococci, multidrug-resistant strains as well as FabI-containing Gram-negative 
bacteria including E. coli, H. influenzae, Neisseria gonorrhoeae, Neisseria meningitides, 
Helicobacter pylori and M. catarrhalis (Escaich et al., 2011). Strains resistant to MUT056399 
could be detected at low frequency and all had mutations in the fabI gene (Escaich et al., 
2011). MUT056399 also showed promising results when tested in vivo against MSSA, MRSA 
and VISA strains (Escaich et al., 2011). XF-73 is a dicationic porphyrin derivative (phase I 
development) in development for post-surgical staphylococcal, including MSSA and MRSA, 
infections (Moir et al., 2012). XF-73 seems to act on the bacterial membrane and leads to 
inhibition of DNA, RNA and protein synthesis and a loss of K
+
 and ATP, however, does not 
seem to lyse the bacterial cells (Ooi et al., 2009). A phase I clinical study showed promising 
result with regards to tolerability and preliminary data indicates anti-staphylococcal activity, 
an additional phase I trial is being initiated for XF-73 (Moir et al., 2012). Lastly, TD-1792 is 
a heterodimer antibiotic, generated by chemical linking of vancomycin to a cephalosporin, 
with reported activity against Gram-positive bacteria including MRSA and VISA strains 
(Blais et al., 2012, Leuthner et al., 2010, Long et al., 2008).  
 
1.4 In vivo animal models for studying skin infection and wound healing  
Various animal models have been used to induce and study skin infections. These animal 
models include: (1) punch biopsies, resulting in excisional wounds (2) tape-stripping skin 
aberration models (3) burn wound models (4) skin-suture wound models, as well as (5) 
subcutaneous infection models. 
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1.4.1 Punch biopsies generating excisional wounds 
Full-thickness excisional wounds were generated on the back of BALB/c mice by single 
punch biopsy, after which the wounds were infected with a MRSA strain (10
7
 cfu/ml) and 
subsequently treated with nitric oxide nanoparticles (NO-np) (Martinez et al., 2009). NO-np 
treatment resulted in reduced MRSA counts and collagen degradation was prevented by NO-
np treatment. NO-np increased wound healing and caused a reduction in the size of the eschar, 
as compared to controls. 
The antimicrobial peptide ranalexin, in combination with lysostaphin, was more effective 
in treating excisional wounds infected with MRSA (10
9 
cfu) in New Zealand rabbits 
compared to the peptides on their own, as well as compared to vancomycin (Desbois et al., 
2010). Combined treatments reduced MRSA counts from 7.5 log10 cfu (control) to 3 log10 cfu.  
1.4.2 Tape stripping skin aberration models 
During tape stripping, the fur and epidermal layer on the dorsal surface of an animal (i.e. 
mouse) is removed by successive applications of an adhesive bandage (Kugelberg et al., 
2005). Kugelberg et al. (2005) tape stripped an area of 2 cm
2
 on the back of female BALB/c 
mice and subsequently infected the wounds with either S. aureus or S. pyogenes (10
7 
cfu). 
Tape stripping resulted in disruption of the skin barrier and homogeneous removal of the 
upper epidermal layers was achieved. The wounds were treated with 2% fusidic acid in 
ointment, resulting in significant reduction in bacterial counts. S. aureus and S. pyogenes 
infection induced an acute inflammatory response, as neutrophils, lymphocytes, histiocytes, 
and fibrin deposition was observed and the inflammatory response included most of the skin 
layers. 
Tape stripping was used to study the toxicity of penicillin-conjugated nanoparticle 
emulsions in female CF1 mice (Greenhalgh and Turos, 2009). Mice receiving lower solid-
content emulsions (5% or 2%) took longer to heal than mice with higher solid-content 
emulsions (7% or 9 %). Healing occurred on day 5 and 6 in the lower solid-content emulsion 
group, whereas mice receiving 9% took 2 days to heal. No significant inflammatory response 
was seen in mice receiving nanoparticle treatments, as IL-6 levels stayed the same between 
control and treated groups.  
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1.4.3 Burn wound models 
1.4.3.1  Burns induced by brass blocks 
The hair of BALB/c mice was removed and mice were anesthetized by ether fumes, followed 
by inducing a burn by applying a heated brass bar on the dorsal surface of the mice for 45 s 
(Kumari et al., 2010). After 30 min the mice were infected with 10
2
-10
10
 cfu/ml Klebsiella 
pneumonia to determine a lethal dose, which was determined at 10
8 
cfu/ml K. pneumonia. 
Infected mice were subsequently treated with hydroxyl propyl methyl cellulose hydrogels 
(HPMC) with Kpn5 (Klebsiella bacteriophage Kpn 5), honey or aloe vera gel. Hydrogels 
showed no signs of toxicity in the mice, when using a single- and three-patch application test. 
Topically applied honey and aloe vera gel resulted in survival rates of 33.3% and 26.7% 
respectively, whereas the control had 0% survival rate. Mice receiving high phage titers (10
10 
pfu/ml), suspended in 3% HPMC, showed high survival rates of 66.7%, whereas the control 
had 0% survival. Phage Kpn 5 had good stability in 3% HPMC. Addition of honey and aloe 
vera gel to phage Kpn 5 did not result in increased survival rates. 
The dorsal surface of BALB/c mice was shaved and excess hair was removed with 
Nair, followed by inducing a burn by placing two heated brass blocks (92-95 °C) on the mice 
(10-60 s) (Dai et al., 2009). Mice were subsequently resuscitated with intraperitoneal 
injection of saline and infected with either 10
7
-10
9
 cfu/ml of P. aeruginosa (Xen 5) or with 
10
8
 cfu/ml P. mirabilis (Xen 44) on 10- and 30-s burns. Both strains were purchased from 
Xenogen and contain the entire bacterial lux operon, which allowed in vivo bioluminescent 
imaging. A 10 s burn with 10
7 
cfu/ml P. aeruginosa Xen 5 and a 30 s burn with 10
8
 cfu/ml P. 
mirabilis (Xen 44) was used in subsequent experiments. A decrease in bioluminescent signal 
was observed in mice receiving chitosan acetate and silver dressings as compared to the 
control, when mice were infected with P. aeruginosa Xen 5. Survival rates of the mice after 4 
weeks were 73.3%, 27.3% and 13.3% for the chitosan acetate, silver dressing and control 
groups, respectively. No bioluminescent P. aeruginosa Xen 5 was observed in the blood of 
mice. Survival rates of mice infected with 10
8
 cfu/ml P. mirabilis were 66.7%, 62.5% and 0% 
for chitosan acetate, silver dressing and the control groups, respectively. Bioluminescent P. 
mirabilis was detected in the blood of mice.  
Burns were induced by applying a hot metal weight (1 g, 11 mm in diameter and 90 
°C) for 2 min on the dorsal surface of female CD-1 mice (Ostorhazi et al., 2010). Mice were 
subsequently infected with either 10
3
, 10
9
 or 10
11
 cfu/wound Acinetobacter baumannii, 
respectively. Treatment with synthetic peptide A3-APO resulted in <1000 cfu/mg wound and 
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wounds showed signs of regeneration of the epithelial layer, had no pus and showed 
decreased levels of inflamed granulation. The control group had large amounts of necrotic 
tissue with polymorphonuclear pus cells and loose granulation tissue. 
1.4.3.2  Burns induced by water 
Skin of Wistar rats were disinfected with ethanol and water (95 °C) was placed on the skin for 
10 s to induce a burn (Ribeiro et al., 2009). Damaged skin was removed with surgical scissors 
and forceps, 2 h after the burn was induced and treated with chitosan hydrogels. The chitosan 
hydrogels accelerated wound healing, which was significant for the first 9 days.  
Dorsal hair of Sprague-Dawley rats was clipped and removed with depilatory cream, 
after which rats were placed in an insulated mold that exposed 20% of the total body surface 
(Hemmila et al., 2010). Rats were placed in a 60 °C water bath for 25 s to induce burns, 
which were scrub debrided with saline. Wounds were subsequently infected with 10
6
 cfu/ml 
P. aeruginosa and treated with nanoemulsion compound NB-201. Saline and 5% mafenide 
acetate served as controls. Nanoemulsion NB-201 was able to reduce P. aeruginosa cell 
numbers significantly, as well as decrease levels of pro-inflammatory cytokines (interleukin 
[IL]-1β and IL-6). The degree of hair follicle cell apoptosis in skin, compared to saline-treated 
controls, was also reduced. 
Suzuki et al. (1991) developed a burn model based on skin contact with a glass 
chamber through which water circulates at a predetermined temperature. Kiyozumi et al. 
(2007) used this model to compare the efficacy of a chitosan hydrogel, containing 
DMEM/F12 medium (medium-Az-CH-LA), and a collagen sponge on deep dermal burns. 
Both treatments healed the wound in the same time, however re-epithelialization occurred 
faster (day 4) around the edges of the medium-Az-CH-LA-treated wounds, as compared to the 
collagen sponge-treated group (day 8). Granulation tissue thickness was also greater in this 
group and degradation and neovascularization occurred earlier, compared to the collagen 
sponge-treated group. 
1.4.3.3  Burns induced by ethanol 
Stieritz and Holder (1975) developed an ethanol bath burn model in mice, where an asbestos 
board was placed against the dorsal surface of female CF1 mice, exposing 30% of the total 
body surface area. Ethanol was spread over the exposed surface and set alight for 10 s. P. 
aeruginosa infected burn wounds were induced by subcutaneous injection (100 cfu). 
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1.4.4 Skin-suture wound model 
Sutures were soaked in a 1:100 dilution of S. aureus and/or S. pyogenes, before being placed 
between the skin layers and the panniculus carnosus of male MF1 mice (Boon and Beale, 
1987). Subsequently, a 1 cm incision was made through the skin, along the length of the 
suture and mice were treated orally with either amoxicillin or amoxicillin-clavulanic acid. 
Amoxicillin and amoxicillin-clavulanic acid were both effective in reducing S. pyogenes 
numbers in wounds. However, amoxicillin failed to eliminate S. pyogenes from a mixed 
infection, containing S. aureus and S. pyogenes. S. aureus numbers were reduced by 
amoxicillin-clavulanic acid treatment and controlled the S. aureus infection, whereas 
amoxicillin was ineffective.  
Sutures, which had been soaked in bacterial suspensions (10
8
 cfu/ml S. aureus or S. 
pyogenes), were inserted under the skin of female MF1 mice and male golden Syrian 
hamsters and an incision made along the length of the suture (Gisby and Bryant, 2000). The 
wound was closed with an adhesive skin closure and treated with mupiricin cream, mupirocin 
ointment, their respective vehicle placebos, or fusidic acid cream. Oral administration of 
erythromycin, cephalexin and flucloxacillin was also investigated as treatment. In female 
MF1 mice, mupirocin cream was not significantly better than mupirocin ointment in reducing 
bacterial numbers. It had similar efficacy to oral flucloxacillin, however was significantly 
more effective than oral erythromycin. Similar efficacy to cephalexin against S. pyogenes, but 
superior efficacy against S. aureus was observed for mupirocin cream. It had similar efficacy 
to fusidic acid cream against S. aureus but was significantly superior against S. pyogenes. In a 
hamster model, infected with S. aureus, mupirocin cream had similar efficacy to mupirocin 
ointment and was not significantly different from fusidic acid cream or neomycin-bacitracin 
cream. It had, however, better efficacy than oral erythromycin and cephalexin. The authors 
concluded that mupirocin cream was as effective as, or superior to, oral and other topical 
agents commonly used for skin infections. 
1.4.5 Subcutaneous infection 
Fernandez et al. (2010) studied the effect of ceftobiprole, cefazolin, vancomycin, or linezolid 
on S. aureus infection, as well as ceftobiprole, medocaril, cefepime, or meropenem-cilastatin 
on P. aeruginosa infection, in female SKH1 mice. Mice received a subcutaneous injection of 
Cytodex (dextran microbeads) inoculum containing S. aureus Smith OC 4172 on the left flank 
and Cytodex suspension containing MRSA OC 8525 on the right flank. Ceftobiprole was 
shown to be more effective in reducing bacterial number in the skin than cefazolin, 
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vancomycin, or linezolid. Skin lesions were 19 to 29% lower than those for the other groups 
(treated with cefazolin, vancomycin, or linezolid). Lesion size, in mice treated with 
ceftobiprole, was 34% less compared to cefazolin or linezolid treated groups, when MRSA 
infections were studied. Later, immunocompromised female SKH1 mice received a 
subcutaneous injection of Cytodex P. aeruginosa OC 4351 (with an inducible AmpC β-
lactamase) and P. aeruginosa OC 4354 (overproducing AmpC β-lactamase) in the left and 
right flank, respectively. Ceftobiprole, showed similar results when compared to meropenem-
cilastatin. Both of these treatments were more effective than cefepime against P. aeruginosa 
OC 4351. Ceftobiprole showed similar results to meropenem-cilastatin and was more 
effective than cefepime in reducing the size of the lesions caused by either of P. aeruginosa 
strains. 
Immune response in different mouse strain backgrounds (C57BL6, BALBc and DBA2 
mice) as a result of subcutaneous S. aureus infection was studied by Nippe
 
et al. (2011). Mice 
were inoculated subcutaneously with 2 × 10
7
 cfu of S. aureus. C57BL/6 mice were more 
susceptible than BALB/c and DBA/2 mice. They had significantly higher footpad swelling 
and bacterial load, as well as increased dissemination of bacteria into inguinal lymph nodes 
and kidneys. Resistance correlated with a S. aureus-specific Th2-cell response in BALB/c and 
DBA/2 mice, whereas susceptible C57BL/6 mice generated a Th1-cell response. 
 
1.5 Bioluminescent imaging (BLI) for monitoring infections in real time  
The use of bioluminescent pathogens has become a powerful tool to monitor infection in real 
time in animal model systems and can have significant power to increase the success rate of 
preclinical studies of antimicrobial agents. Classical methods have drawbacks where large 
quantities of animals are needed for statistically significant data and animals need to be 
euthanized to determine pathogen numbers, thus making comparisons more difficult with 
inter sample differences (Andreu et al., 2011). Bioluminescent imaging (BLI) overcomes this 
problem as it is possible to use the same animal during the course of the experiment. This 
reduces the number of animals needed for each experiment as well as eliminate inter sample 
differences. The bioluminescent system also has lower background noise, as compared to 
fluorescence based reporter systems, especially in vivo (Andreu et al., 2011). In vivo BLI is 
made possible by various imaging systems such as the In Vivo Imaging System (IVIS), 
manufactured by Caliper Life Sciences (Hopkinton, MA), which detects the bioluminescent 
signal emitted from lux-tagged pathogens. A specialized charged coupled device (CCD) 
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camera captures the photons emitted, converts the photons to electrons and generates an 
image by encoding it into electrical patterns. Background noise is substantially reduced by 
using a cooled CCD camera (-90°C). Bacterial bioluminescence has been used to study 
promoters in a variety of Gram-negative organisms (Waidmann et al., 2011). The lux operon 
from Photorhabdus luminescens is ideal for in vivo BLI and has been extensively studied and 
used in this regard, as the luciferase is thermally stable (Meighen, 1991). Bacterial 
bioluminescence is encoded by several lux genes and involves the production of detectable 
light (emitted at 490 nm) by the oxidation of luciferin and reduced flavin mononucleotide 
(FMNH2), catalysed by a luciferase (Meighen, 1991). LuxAB encodes for the α and β subunit 
of the luciferase and luxCDE encodes for a transferase, synthetase and reductase, respectively. 
These proteins play a role in the conversion of fatty acids into long chain fatty aldehydes 
needed for the bioluminescent reaction (Meighen, 1991). The luxCDABE operon has been 
successfully cloned into Gram-negative bacteria including, Salmonella enterica serovar 
Typhimurium, E. coli, Citrobacter rodentium as well as Campylobacter jejuni (Allen and 
Griffiths, 2001, Beeston and Surrette, 2002, Belkin et al., 1996, Contag et al., 1995, Wiles et 
al., 2004). After the introduction of Gram-positive ribosome binding sites and reshuffling of 
the gene order (from luxCDABE to luxABCDE) it was also functionally expressed in Gram-
positive bacteria (Francis et al., 2000). Another approach for expression in Gram-positive 
bacteria was to introduce optimized Gram-positive translational signals in front of luxA, C and 
E (Qazi et al., 2001). Bioluminescent Gram-positive bacteria have also been constructed 
using a novel Gram-positive lux transposon cassette, which is integrated into the host 
chromosome. This overcame problems with plasmid based approaches (Francis et al., 2001). 
Bioluminescent pathogens have been used to study infection, including skin infections, 
implant related infections (including biofilm formation), lung infections, muscle infections, 
endocarditis, peritonitis infections, as well as bacterial meningitis (Bernthal et al., 2010, Dai 
et al., 2009, Engelsman et al., 2008, Francis et al., 2000, 2001, Kadurugamuwa et al., 2003, 
2005a,b, Kuklin et al., 2003, Li et al., 2008, Mortin et al., 2007, Xiong et al., 2005). The first 
in vivo BLI study was conducted by Contag et al. (1995) with mice infected with a lux-tagged 
S. enterica serovar Typhimurium. Since then various other bioluminescent pathogens have 
been used for BLI, including S. aureus, P. aeruginosa, A. baumannii, S. pneumonia, C. 
rodentium as well as eukaryotic pathogens including Candida albicans (Dai et al., 2009, 
2011, Francis et al., 2000, 2001, Kadurugamuwa et al., 2003, Wiles et al., 2006). 
In vivo BLI, however, has some drawbacks and certain factors need to be considered 
when conclusions are drawn from in vivo experiments. Photon intensity is reduced 10 fold 
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with an increase of 1 cm in tissue depth (Contag et al., 1995). Oxygen and adenosine-5'-
triphosphate (ATP) is also very important as they are needed by the luciferase to oxidize 
luciferin (Andreu et al., 2011, Meighen, 1991). Bioluminescent signal emitted from these 
pathogens is thus an indicator of the metabolic state of the cells, as the luciferase is an energy 
requiring oxygenase needing ATP, as previously mentioned (Andreu et al., 2011). In vivo BLI 
of pathogens in oxygen scarce environments could be problematic, however, some successful 
studies have been reported. C. rodentium was able to colonize and emit a bioluminescent 
signal from the murine colon and bioluminescence from S. enterica serovar Typhimurium 
was detected from the cecum of animals (Contag et al., 1995, Wiles et al., 2006). Some 
studies showed that bioluminescence correlated well with viable cell numbers, however, 
discrepancies have been reported in others in vitro as well as in vivo (Francis et al., 2000, 
2001, Kadurugamuwa et al., 2003, Marincs, 2000, Marques et al., 2005). Detection limit is 
another factor to consider. It has been shown that the detection limit of bioluminescence from 
Bacillus anthracis ranged from 3 x 10
3
 to 2 x 10
5
 in the ear, superficial parotid lymph node, 
spleen and right lung, respectively (Glomski et al., 2007). Wiles et al. (2004) reported that 10
3
 
cfu was the detection limit for bioluminescence from C. rodentium in the foci of mice. Thus, 
for accurate conclusions to be drawn there is still a need to verify the in vivo bioluminescent 
measurements with classical methods if infection studies are conducted.  
 
2. Bacteriocins of Gram-positive Bacteria: Next-Generation Antimicrobials? 
2.1 Introduction and classification 
Bacteriocins are bacterial ribosomally synthesized proteins which usually show antibacterial 
activity against closely related species. A few bacteriocins, however, have a broader spectrum 
of activity, i.e. bactericidal or bacteriostatic against species genetically not closely related to 
the producer strain (De Vuyst and Vandamme, 1994, Jack et al., 1995, Kleanhammer, 1993). 
Bacteriocins have been classified and re-classified as the wealth of knowledge increased and 
various classification systems have been proposed. The latest classification system has been 
proposed by Rea et al. (2011) and is built on that proposed by Cotter et al. (2005). The classes 
include class I (post-translationally modified bacteriocins), class II (unmodified bacteriocins) 
and the bacteriolysins (formerly class III bacteriocins). Class Ia (lantibiotics) are small 
peptides (<5 kDa and contain 19-28 amino acids) which undergo post-translational 
modification. They contain unusual amino acids such as dehydroalanine, dehydrobutyrine and 
D-alanine, as well as thioether bridges which form meso-lanthionine and β-methyllanthionine 
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as a result of post-translational modifications. Lantibiotics can further be divided into 12 
subclasses based on the sequence of the propeptides or the composition of the associated 
modification/transport systems (Cotter et al., 2005b, Piper et al., 2009, Willey and van der 
Donk, 2007). Class Ib (labyrinthopeptins) undergoes post-translational modification and have 
labionin, a carbacylic amino acid, in the peptide sequence. Class Ic (sactibiotics) are cyclic 
peptides that have cross-linkages between cysteine residues and α-carbons of other amino 
acids. Examples include subtilosin A (which has linkages between three cysteine residues and 
α-carbons of two phenylalanines and one threonine) and thuricin CD, a two peptide 
bacteriocin. Thuricin CD has linkages between three cysteine residues and α-carbons of serine 
and two threonines in the one peptide (Trn-α) and linkages between three cysteine residues 
and α-carbons of threonine, alanine, tyrosine in the other peptide (Trn-β) (Rea et al., 2011). 
Class Ic can further be sub-divided into two groups, including single- and two-peptide 
sactibiotics (Rea et al., 2011). 
Class IIa are the pediocin-like bacteriocins. These peptides are all active against 
Listeria monocytogenes, have a conserved N-terminal amino acid sequence, 
YGNGVXCXK/NXXC (where X is any amino acid), termed the “pediocin-box” and a double 
glycine processing site (Cotter et al., 2005b, Rea et al., 2011). Variants with an alternate 
YGNGL sequence have also been identified as class IIa bacteriocins (Atrih et al., 2001, 
Yamazaki et al., 2005). It has thus been proposed that the N-terminal “pediocin-box” of class 
IIa bacteriocins be amended to include this sequence with YGNG[V/L] (Beluguesmia et al., 
2011b). Class IIb are two-peptide unmodified bacteriocins that require both peptides for 
optimal activity. The individual peptides possess little or no activity (Oppegard et al., 2007). 
Examples include plantaricin S, lactococcin G and plantaricin JK (Jiménez-Díaz et al., 1993, 
Rogne et al., 2008, 2009). Class IIc are circular bacteriocins that undergo post-translational 
modifications, which leads to their N- and C-terminus being covalently linked. They are heat 
stable and show resistance to proteolytic degradation (Rea et al., 2011). Examples of class IIc 
bacteriocins include enterocin AS-48 and carnocyclin A (Jimenez et al., 2005, Martin-
Visscher et al., 2009). Class IId contains the unmodified, linear, non-pediocin-like 
bacteriocins. These are all of the bacteriocins that do not fall in the other groups, based on the 
current classification systems, for example lactococcin A (Nissen-Meyer et al., 2009). 
Bacteriolysins, formerly known as the class III bacteriocins, are non-bacteriocin lytic 
proteins (Rea et al., 2011). They are large antimicrobial proteins that are heat-labile. 
Examples include millericin B, helveticin J and enterolycin A (Beukes et al., 2000, Hickey et 
al., 2003, Joerger and Kleanhammer, 1986). 
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2.2 Biosynthesis of bacteriocins  
2.2.1 Class I 
The operon encoding class I bacteriocins (lantibiotics), such as nisin, include a structural 
gene, genes encoding accessory proteins responsible for modifications (i.e. proteolytic 
processing of the leader peptide, dehydration, cyclization), transport genes (encoding an 
ABC-superfamily transport protein for peptide translocation), regulatory genes and immunity 
genes conferring resistance to the producer strain (de Vos et al., 1995, Jack et al., 1995, Sahl 
et al., 1995). The structural gene encodes an inactive precursor peptide (LanA) with a N-
terminal extension or leader peptide connected to the C-terminal of the propeptide (McAuliffe 
et al., 2001, Sahl and Bierbaum, 1998). The propeptide is modified and the leader peptide is 
cleaved to produce a mature, active peptide (McAuliffe et al., 2001). LanB dehydrates serines 
and threonines in the propeptide to form 2,3-didehydroalanine (Dha) and 2,3 
didehydrobutyrine (Dhb), respectively. LanC couples dehydrated residues to cysteines, via the 
reaction between the double bond of Dha and/or Dhb with the thiol (-SH) group of the 
cysteine to form meso-lanthionines (Ala-S-Ala) and β-methyllanthionines (Abu-S-Ala), 
respectively (Héchard and Sahl, 2002, McAuliffe et al., 2001, Sahl et al., 1995). The peptide 
will then be transported via the ABC transporter (LanT) and in most cases the leader peptide 
will be cleaved by a protease (LanP) to release the active peptide (Kleanhammer, 1993, 
McAuliffe et al., 2001, Sahl and Bierbaum, 1998, Willey and van der Donk, 2007). In some 
lantibiotics, such as mersacidin and lacticin 481, there is only one bifunctional enzyme 
responsible for dehydration and cyclization of the propeptide, designated LanM (Kuipers et 
al., 2011). Their LanT is also bifunctional in that it intracellularly processes the modified 
peptide, before it gets translocated (Willey and van der Donk, 2007). Two-component 
lantibiotics, such as lacticin 3147, contain two modifying enzymes (LtnM1 and LtnM2). One 
for each pre-peptide (LtnAα and LtnAβ) and after modification they are translocated by one 
LtnT enzyme (Kuipers et al., 2011). Lacticin 3147 contains an additional post-translational 
modifying enzyme (LtnJ), which converts dihydroalanines to D-alanines in the two peptides 
(Ryan et al., 1999b).  
2.2.2 Class II 
The genes involved in class II bacteriocin production include a structural gene (or 2 structural 
genes in the case of two-peptide bacteriocins), an immunity gene, genes encoding a 
membrane-associated ATP-dependent binding casette (ABC) transporter and an accessory 
protein (Ennahar et al., 2000, Kleanhammer, 1993). The structural genes encode a precursor 
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peptide with a leader peptide, which becomes active once the leader peptide is cleaved by a 
protease (Eijsink et al., 2002, Nes and Holo, 2000 Nissen-Meyer and Nes, 1997). Class IIa 
bacteriocins have a leader peptide with double-glycine residues, which acts as the processing 
site, and will be secreted once the leader peptide has been cleaved (Kleanhammer, 1993, 
Michiels et al., 2001). Class IIa peptides have a 3 component regulatory system which 
includes an inducer peptide (or pheromone peptide), a transmembrane histidine kinase 
(pheromone receptor) and a cytosolic response regulator (Nes and Eijsink, 1999). Once the 
inducer peptide exceeds a basal concentration, it will activate the transmembrane histidine 
kinase which will in turn interact with a response regulator. The phosphate group of the 
activated histidine kinase will be transferred to a conserved Asp residue in the response 
regulator and will then serve as transcriptional activator for bacteriocin biosynthesis (Cho et 
al., 2001, Nes and Eijsink, 1999). Some two-peptide bacteriocins (class IIb) also use a 3 
component regulatory systems (as described above), however others seem to be expressed 
constitutively (Nissen-Meyer et al., 2011). Circular bacteriocins (class IIc) are also produced 
as precursor peptides with an N-terminal leader peptide extension and undergo head to tail 
cyclization by the formation of an amide bond between the N- and C-terminal residues 
(Gabrielsen et al., 2012). The class IId bacteriocins are diverse and can contain a sec-type 
signal peptide, which will be secreted by the general secretion pathway, while others are 
produced without a leader peptide. Non-pediocin-like linear bacteriocins (also class IId) are 
synthesized with a sec-independent double-glycine-type leader sequence and are transported 
by dedicated ABC-transporters (Iwatani et al., 2011). 
 
2.3 Bacteriocin mode of action 
2.3.1 Class I 
Lantibiotics, especially nisin, have been extensively studied for their mode of action. Nisin 
has a dual mode of action, which includes inhibition of bacterial cell wall synthesis and pore 
formation (McAuliffe et al., 2001). Nisin inhibits bacterial cell wall synthesis by binding to 
lipid II, which then serves as a receptor site for targeted pore-formation. The A and B N-
terminal rings of nisin form a pyrophosphate cage that binds the pyrophosphate moiety of 
lipid II and the C-terminal tail inserts into the phospholipid bilayer, forming pores (Hsu et al., 
2004). Eight nisin molecules and four lipid II molecules are needed for pore formation 
(Hasper et al., 2004). Nisin sequesters lipid II from the septum, where cell wall biosynthesis 
is most active, in patches on the membrane (Hasper et al., 2006). The N-terminal AB ring 
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structure of nisin is conserved amongst other lantibiotics and can be seen as a lipid II binding 
and sequestering motif (Hasper et al., 2006). Other lantibiotics including epidermin and 
galledermin also have this lipid II binding motif in the N-terminal part of the peptide, 
however, the C-terminal parts are much shorter. They can thus inhibit cell wall synthesis, but 
cannot form pores in bacterial membranes (Bonelli et al., 2006, Willey and van der Donk, 
2007). Some class II lantibiotics are also pore formers, such as lacticin 481, where others can 
only inhibit cell wall biosynthesis, such as mersacidin (Brötz et al., 1998, Wiedemann et al., 
2006). Mersacidin inhibits the transglycosylation step in peptidoglycan synthesis, much like 
vancomycin (Brötz et al., 1997). Mersacidin, however, seems to target the disaccharide 
moiety of lipid II, whereas vancomycin uses the D-Ala-D-Ala pentapeptide of lipid II (Brötz 
et al., 1998, Hasper et al., 2006). Some lantibiotics, such as nisin and subtilin, are also able to 
inhibit the germination/outgrowth of bacterial spores (Liu and Hansen, 1993, Montville et al., 
2006, Scott and Taylor, 1981). Nisin was shown to target lipid II and that inhibition of 
Bacillus anthracis spore outgrowth was only achieved with lipid II-mediated pore formation 
and not only as a result of lipid II binding (Gut et al., 2011). Nisin has also been shown to 
induce autolysis (Bierbaum and Sahl, 1985). 
2.3.2 Class II 
Class IIa mainly permeabilize bacterial membranes by forming ion-selective pores in 
sensitive cells by recognizing specific protein receptors in the membrane (Drider et al., 2006). 
This leads to dissipation of the proton motif force (PMF), efflux of intracellular material and 
depletion of intracellular ATP (Chikindas et al., 1993). Class IIa bacteriocins target a 
mannose permease (EIIt) belonging to the phosphotransferase system (PTS) (Diep et al., 
2007, Héchard et al., 2001, Nes and Diep, 2009). Mannose permeases of the PTS consists of 
four domains (including IIA, IIB, IIC, and IID) arranged in two to four subunits and the 
extracellular loop of the membrane-located protein MptC has now been shown to be the 
recognition site of class IIa bacteriocins (Kjos et al., 2010). The N-terminal part of class IIa 
bacteriocins will form a three-stranded antiparallel β-sheet, whereas the C-terminal part will 
form amphiphilic α-helices in a hairpin-like structure (Drider et al., 2006). Initial binding is 
mediated by the electrostatic interaction of the positively charged amino acids in the 
hydrophilic β-sheet of the peptide and the bacterial membranes, after which the C-terminal 
region of the peptide will insert into the hydrophobic regions of the cell membrane and induce 
pore formation (Belguesmia et al., 2011b, Chen et al., 1997). The C-terminal of class IIa 
bacteriocins is less conserved than the N-terminal and determines the antimicrobial spectrum 
of the specific peptide. This was shown by generating hybrid peptides, by interchanging 
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corresponding modules from various pediocin-like bacteriocins. The hybrid peptides 
displayed activity corresponding to the peptide from which the original C-terminal region was 
derived and not the N-terminal region (Fimland et al., 1996). Mesentericin Y105 is an 
exception to the general mode of action of class IIa bacteriocins and has also been shown to 
uncouple mitochondrial respiration (Maftah et al., 1993). 
Two-peptide bacteriocins (class IIb) require both peptides for optimal activity and 
induce membrane permeability by forming pores in sensitive cells, thereby once again 
causing an efflux of small molecules (Garneau et al., 2002). The peptides do not interact with 
each other without the presence of membrane-like structures and will only interact and 
structure each other in the presence thereof (Hauge et al., 1998, 1999). The peptides could 
thus bind to membrane proteins before they interact with each other and penetrate the 
hydrophobic regions of the cell membrane, as all characterized two-peptide bacteriocins 
contain a GxxxG motifs which is often involved in helix–helix interactions between 
transmembrane helices in membrane proteins (Nissen-Meyer et al., 2010, Senes et al., 2000, 
2004). However, to date no receptor has been identified for two-peptide bacteriocins and 
studies indicate that some two-peptide bacteriocins don’t need a receptor for activity 
(Marciset et al., 1997, Nissen-Meyer et al., 2010). 
Circular bacteriocins (class IIc), like most other bacteriocins, cause membrane 
permeability, dissipation of the proton motif force and an efflux of intracellular material 
(Martin-Visscher et al., 2011). Structural analysis of circular bacteriocins revealed that they 
share a compact globular structure, comprised of repeated α-helical motifs surrounding a 
hydrophobic core (Martin-Visscher et al., 2009). Basic amino acid residues result in a positive 
charge on the surface of circular bacteriocins, thought to play a role in initial binding to the 
cell membrane (Borrero et al., 2011). The first recognition site for circular bacteriocins has 
recently been reported and a maltose ABC transporter was shown to play a role in 
antimicrobial activity of garvicin ML (Gabrielsen et al., 2012) 
The Class IId bacteriocins are very diverse and contain a broad group of peptides. 
Some of these peptides (including lactococcin A and lactococcin B) have been shown to 
function similarly to the class IIa bacteriocins in that they also use the mannose permease of 
the PTS system as receptor (Diep et al., 2007). Lactococcin 972 inhibits the growth of 
susceptible cells by interfering with septum formation and does not target the membrane 
(Martínez et al., 2000). It was later shown that this bacteriocin specifically interacts with lipid 
II and is the first non-lanthionine-containing bacteriocin identified to do so (Martínez et al., 
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2008). Lacticin Q was shown to induce membrane permeabilization without the presence of a 
receptor and is the first bacteriocin from Gram-positive bacteria which uses a toroidal-pore 
mechanism (Yoneyama et al., 2009a,b). 
 
2.4 Biomedical applications of bacteriocins from Gram-positive bacteria 
The frequent use of antibiotics has led to a crisis in antibiotic resistance in human and animal 
pathogens (Neu, 1992). This has led to high selection pressures for pathogens to develop 
antibiotic resistance, including the well-known example of MRSA. Antibiotic resistance and 
the emergence of multidrug-resistant bacterial pathogens have led to the investigation of 
alternative antimicrobial agents, including bacteriocins from Gram-positive bacteria, to treat 
and prevent infections in both humans and animals. 
2.4.1 Treatment of infections 
2.4.1.1  Topical infections 
S. aureus is commonly isolated from skin infections and is becoming a serious problem, with 
the emergence of MRSA and VRSA (Chang et al., 2003, Daum, 2007). Lacticin 3147 shows 
activity towards antibiotic-resistant human pathogens including MRSA and VRE strains 
(Galvin et al., 1999). Nisin has been under investigation for topical use as antimicrobial and 
has been incorporated in topical formulations (Valenta et al., 1996). Patents have been filed 
for the use of nisin and lantibiotic combinations for the treatment of skin infection, as well as 
for mersacidin as treatment for skin- and systemic-infections (Dawson et al., 2009, Walsh et 
al., 2003). De Kwaadsteniet et al. (2010), however, reported on the inability of nisin F to treat 
subcutaneous S. aureus Xen 36 infections in mice when C57BL/6 mice were infected with 4.9 
x 10
6
 cfu S. aureus Xen 36 and treated subcutaneously with 256 AU nisin F. Nisin treated 
groups also showed infiltration of polymorphonuclear neutrophils. 
Propionibacterium acnes is a member of the normal skin flora of humans and is 
implicated in acne vulgaris, causing inflamed lesions (Leyden, 2001). Gallidermin, epidermin, 
mersacidin and lacticin 3147, all lantibiotics, are active against P. acnes and have the 
potential to be used in the treatment of acne (Galvin et al., 1999, Jung, 1991a,b, Kellner et al., 
1988, Niu and Neu, 1991). A patent has been filed for the use of bacteriocin-like inhibitory 
substances (BLIS) as treatment for acne (Margolis and Bowe, 2006). 
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2.4.1.2  Systemic infections 
Systemic infections affect the whole body, or multiple organs, and are caused by a variety of 
pathogens (Czuprynski et al., 2002, Harbarth et al., 1998, Klug et al., 1997). L. 
monocytogenes is a foodborne pathogen responsible for sepsis, meningitis, fetal loss, as well 
as gastroenteritis (Voetsch et al., 2007). Pediocin PA-1 reduced L. monocytogenes fecal 
numbers, as well as L. monocytogenes in the liver and spleen, when administered to ICR mice 
(Dabour et al., 2009). Pediocin PA-1 showed no deleterious effect on the intestinal flora of 
the mice, which is a desired characteristic for an antimicrobial. Piscolin 126 reduced the 
outgrowth of L. monocytogenes in the liver and spleen of BALB/c mice when injected 
intravenously into the tail vain (Ingham et al., 2003). None of the mice showed any signs of 
localized inflammation around the site of injection, vomiting, depression or other signs of 
toxicity. Rihakova et al. (2010) reported on the in vivo activity of divercin V41 and its 
structural variants against L. monocytogenes. Recombinant divercin RV4 was the most potent 
and significantly reduced L. monocytogenes numbers in the spleen of BALB/c mice. No side 
effects were observed when the mice were monitored for 72 h after intravenous administration 
of the peptides. Bacteriocin Abp118, produced in vivo by Lactobacillus salivarius UCC118, 
showed good activity against L. monocytogenes in infected mice, while a mutant lacking the 
ability to produce this bacteriocin was ineffective in protecting the mice (Corr et al., 2007). 
C. difficile is a major causative agent of hospital-acquired diarrhoea (Pépin et al., 
2005). Nisin and lacticin 3147 has in vitro activity against clinical C. difficile strains 
(Bartoloni et al., 2004, Rea et al., 2007) and has the potential to be used as treatment. 
Thuricin CD is a two-peptide bacteriocin (Trn-α and Trn-β), produced by Bacillus 
thuringiensis 6431, showing activity towards C. difficile, while showing low activity against 
members of the normal intestinal microflora (Rea et al., 2010).  
Nisin showed good activity against S. pneumoniae in vitro, as well as in vivo when 
mice were infected intraperitoneally with 10
2
-10
3
 S. pneumonia Felton and treated with nisin 
(Goldstein et al., 1998). Mice receiving 0.16 mg/kg nisin intravenously twice had survival 
rates of 100%, whereas a single intravenous dose of 0.63 mg/kg protected 80% of the mice.  
Mutacin B-Ny266 protected 100% of mice infected intraperitoneally with S. aureus 
Smith (Mota-Meira et al., 2005). Treatment (also intraperitoneally) followed directly after 
infection with 1, 3 and 10 mg/kg mutacin B-Ny266. Nisin F was, however, ineffective in 
controlling S. aureus Xen 36 infection in the peritoneal cavity in mice (Brand et al., 2010). A 
slight reduction in bioluminescent signal was observed in mice, infected with 10
8
S. aureus 
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Xen 36 and treated with 640 AU nisin F, within the first 15 min, however no difference in 
bioluminescent signal was observed thereafter. Microbisporicin, a lantibiotic, was effective in 
protecting ICR (CD-1) mice infected intraperitoneally with 10
6 
cells of S. aureus Smith 819 
(Castiglione et al., 2008). Protection was observed when microbisporicin was administered 
both intravenously and subcutaneously. Mice survived high doses of microbisporicin (≥200 
mg/kg), indicating a low toxicity profile. Recently, lacticin 3147 was shown to prevent the 
systemic spread of S. aureus Xen 29 in a murine model, when infected intraperitoneally with 
10
6
 cfu/ml (Piper et al., 2012). S. aureus numbers in the spleen, liver and kidney were in the 
range of 10
5
 cfu/ml organ, whereas control mice had numbers in the range of 10
6
 cfu/ml 
organ.  
H. pylori is a pathogenic organism that causes chronic bacterial infections in humans 
and is an important organisms causing ulcers. This organism causes gastric ulcers, as well as 
duodenal ulcers, and upper GIT disorders such as chronic gastritis, peptic ulcer disease, tissue 
lymphoma and gastric cancer (Isreal and Peek, 2001, Korman and Tytgat, 1995, Kusters et 
al., 2006). Nisin shows activity towards H. pylori and can serve as treatment for peptic ulcers 
(Delves-Broughton et al., 1996). Nisin (produced by AMBI, Purchase, New York), has 
successfully undergone phase I clinical trials and is being considered as treatment for stomach 
ulcers caused by H. pylori (Hancock and Chapple, 1999). However, nisin has not been further 
developed in this regard. Lacticins A164 and BH5 (produced by Lactococcus lactis subsp. 
lactis A164 and L. lactis BH5, respectively) showed strong in vitro antibacterial activity 
against H. pylori strains when using a broth micro-dilution assay (Kim et al., 2003). Spent 
culture supernatants of Lactobacillus acidophilus LB showed strong antimicrobial activity 
against H. pylori in vitro (Conconnier et al., 1998). However, was unable to completely 
diminish numbers of H. felis in the stomachs of BALB/c mice infected intragastrically. No 
inflammatory reaction was observed in the infected mice treated with the spent culture 
supernatants (Conconnier et al., 1998). Lactobacillus johnsonni La1 supernatants also 
inhibited H. pylori growth in vitro, but were unable to cure patients of H. pylori during a 
randomized, double-blind, controlled clinical trial. H. pylori was still detected in gastric 
biopsies and the supernatants only have a suppressive effect in vivo (Michetti et al., 1999).  
2.4.1.3   Device-related infections 
Biomedical implant-related infections can cause complications with prosthetic devices and 
can force patients back for repair or replacement surgery (Campoccia et al., 2005). It would 
be advantageous to the patient to minimize unwanted microbial adhesion to such devices. 
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Nisin adsorbed to salinized surfaces resulted in reduced growth and cell division of L. 
monocytogenes on nisin covered surfaces (Bower et al., 1995). Nisin-coated polyvinyl 
chloride (PVC) suction catheter tubing prevented colonization of S. aureus, S. epidermidis, 
and Streptococcus faecalis, whereas microbial colonization occurred in untreated catheter 
tubing (Bower et al., 2002). In vivo studies confirmed these results and nisin-coated Teflon
®
 
FEP intravenous catheters in sheep showed bactericidal properties up to 5 h, however no 
activity was reported after 7 days. The authors suggested that the antimicrobial activity of 
nisin may only have short-term benefits in environments such as blood. PVC
® 
tracheotomy 
tubes pretreated with nisin, showed promise in providing an antimicrobial barrier to prevent 
bacterial infection (Bower et al., 2002). Nisin, in combination with RNAIII-inhibiting 
peptide, showed promising results in vivo to inhibit S. epidermidis, as well as methicillin-
resistant S. epidermidis, colonization on implanted Dacron
®
 grafts in Wistar rats, with less 
than 10 cfu remaining on implants (Ghiselli et al., 2004). Incorporation of bacteriocins into 
bone cement has been reported to prevent bacterial colonization of implants. Gallidermin and 
a novel peptide (NI01) incorporated into polymethylmehacrylate (PMMA) bone cement was 
able to significantly reduce biofilm formation of clinical S. epidermidis 156 on the bone 
cement (Sandiford et al., 2012). Nisin F incorporated into brushite bone cement prevented the 
growth of S. aureus Xen 36 in vivo in a murine model (van Staden et al., 2012). No bacteria 
were detected in mice which received bone cement containing 5% (w/w) nisin and no adverse 
effects on blood parameters could be identified. 
2.4.1.4   Upper respiratory tract infections 
Tuberculosis is regarded as the second greatest killer worldwide, after HIV/AIDS, caused by 
a single infectious agent (WHO, 2012). Mycobacterium tuberculosis infected, and caused 
tuberculosis, in 8.8 million people in 2010, of which 1.4 million succumbed to this disease 
(WHO, 2012). Multidrug-resistant cases of tuberculosis have been on the increase over the 
last two years, with an increase from an estimated 150,000 cases in 2008 to 650,000 cases in 
2010 (WHO, 2011/2012). Antimycobacterial activity of bacteriocins has been reported. 
Bacteriocin (Bcn2-5) showed better in vitro activity against M. tuberculosis H37Rv when 
compared to rifampicin (Sosunov et al., 2007). Cytotoxicity was observed in a dose 
dependant manner, with no cytotoxicity observed at 0.1 mg/L. Bcn5 was unable to increase 
survival of C57BL/6JCit (B6) mice infected intravenously with M. tuberculosis H37Rv 2 x 
10
7
 cfu/mouse. A Bcn5-phosphatidylcholine-cardiolipin liposome complex was, however, 
able to increase survival of animals as compared to untreated controls (Sosunov et al., 2007). 
These bacteriocins thus have the potential to be used as alternative tuberculosis-drugs or can 
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be used in combination with other treatments to treat tuberculosis. This could help to impede 
the increase in antibiotic resistance in M. tuberculosis strains, especially with the development 
of multidrug-resistant strains. 
When tested in vivo, nisin F showed promise in the treatment of upper respiratory tract 
infections in immunocompromised Wistar rats, caused by S. aureus K. Rats were infected 
intranasally with 4 x 10
5
 cells of S. aureus K and treated with 8192 arbitrary units (AU) of 
nisin F. Symptoms of pneumonia were detected in the trachea and lungs of control animals, 
whereas nisin F-treated animals showed no signs of pneumonia (de Kwaadsteniet et al., 
2009). Mersacidin was able to protect mice and prevented MRSA colonization, when mice 
were infected intranasally with MRSA and treated with this peptide (Kruzewska et al., 2004). 
No MRSA could be detected in the blood, lungs, liver, kidney, spleen or nasal scrapings of 
mice treated with mersacidin. No adverse effects were observed in cytokine profiles of 
mersacidin treated mice (Kruszewska et al., 2004). Nisin was, however, ineffective in 
preventing S. aureus colonization when applied to the nasal tract of cotton rats (Kokai-Kun et 
al., 2003). 
Otitis media is a common disease diagnosed in children, with long term side effects 
including impaired hearing and delayed speech (Ryding et al., 1997, Segal et al., 2005, Teele 
et al., 1990). Peptide ST4SA showed promising results when tested against Gram-positive 
middle ear pathogens (Knoetze et al., 2008).  
2.4.2 Bioactive ingredients in personal care products  
The use of bacteriocins in health care products has also been proposed. Epidermin and 
gallidemin have activity against staphylococci and streptococci isolated from skin and have 
been proposed for use in deodorants (van Kraaij et al., 1999). The use of nisin in mouth wash, 
deodorants, as well as cosmetics has also been proposed (Molitor and Sahl, 1991, van Kraaij 
et al., 1999). Lantibiotics were shown to be effective in the prevention of tooth decay and 
gingivitis (Galvin et al., 1999, Howell et al., 1993). Nisin reduced plaque build-up and 
gingivitis in beagle dogs and treated groups had a lower gingival index score, as compared to 
untreated controls (Howell et al., 1993). Patents have been filed on the use of nisin in oral 
cavity applications (Blackburn et al., 1993). Lacticin 3147 shows activity towards 
Streptococcus mutans, which plays a role in dental decay in humans and could be used for 
oral hygiene (Galvin et al., 1999). BLIS K12 is a commercial product which contains 
Streptococcus salivarius (which produces salivaricin A2 and B) that inhibits bacteria causing 
bad breath (Tagg, 2004). A strain of S. mutans, producing mutacin 1140 which is active 
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against tooth decay bacteria, has been modified (termed SMaRT) to produce less lactic acid 
and evaluated as a replacement therapy to eliminate decay causing strains of S. mutans 
(Hillman et al., 2000). Preclinical tests showed that the SMaRT strain reduced tooth decay 
and displaced decay-causing S. mutans. No adverse reactions were reported in first Phase 1 
clinical trials. Lozenges containing S. salivarius, producing salivaricin A, are marketed as oral 
care products (Boakes and Wadman, 2008). 
2.4.3 Treatment of Mastitis in dairy cows 
Mastitis, inflammation of the mammary glands, is caused by microbial infection of the 
mammary glands of cows and causes huge economic losses in the dairy industry (Ryan et al., 
1998). Lacticin 3147 has been investigated as treatment for bovine mastitis and showed 
activity against mastitic staphylococci and streptococci (Ryan et al., 1998, Twomey et al., 
2000). A teat seal containing lacticin 3147 was effective in reducing infection, when 
Streptococcus dysgalactiae M (1.5 x 10
4
 cfu) was administered into the teat sinus of dairy 
cows. Lacticin 3147-containing teat seals did not elicit significant irritancy and only a 
temporary increase in somatic cell count (Ryan et al., 1999a). A bacteriocin produced by 
Bacillus subtilis LFB112 was active against S. aureus, Streptococcus bovis and S. equi subsp. 
zooepidemicus causing disease in animals (Xie et al., 2009). Nisin has also shown promise in 
treating and/or prevention of mastitis and is the active compound in two commercial products 
(Consept
®
 and WipeOut
®
) which are used as preventative measure for mastitis (Cotter et al., 
2005b). 
2.4.4 Anti-inflammatory agents 
Phospholipase A2 is an enzyme that releases arachidonic acids from cellular phospholipids 
and catalyses a rate-limiting step leading to the formation of potent mediators of inflammation 
and allergy, including the prostaglandins, leukotrienes and hydroxyeicosatetraenoic acids 
(Irvine, 1982, Johnson et al., 1983, Zipser and Laffi, 1985). Phospholipase A2 also plays a 
role in the formation of lyso-PAF, a precursor of platelet-activating factor (PAF) which is a 
pro-inflammatory mediator (Braquet et al., 1987). Cinnamycin-like lantibiotics show 
inhibitory activities towards human phospholipase A2 (Fredenhagen et al., 1990). The 
lantibiotics duramycin, duramycin B and C and cinnamycin were shown to inhibit 
phospholipase A2 indirectly, by sequestering the substrate phosphatidylethanolamine (Marki 
et al., 1991). These lantibiotics thus have potential as anti-inflammatory drugs (van Kraaij et 
al., 1999). 
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2.4.5 Regulation of blood pressure 
Angiotensin-converting enzyme plays an important role in the regulation of blood pressure 
and fluid balance (Zhang et al., 2000). It achieves this function by catalyzing the conversion 
of angiotensin I to angiotensin II and histidylleucine (Kido et al., 1983). Ancovenin, a 
lantibiotic produced by Streptomyces spp. was shown to be an inhibitor of angiotensin 
converting enzyme (Kido et al., 1983). Cinnamycin-like lantibiotics, cinnamycin and 
duramycin, can also inhibit angiotensin-converting enzyme (Kaletta et al., 1991, Kessler et 
al., 1991, Shiba et al., 1991). These lantibiotics can have potential in the regulation of blood 
pressure. 
2.4.6 Carrier molecules for increased absorption of bioactive molecules 
Insulin and many other therapeutic proteins are poorly absorbed through mucosal membranes 
and for that reason must be injected, rather than taken orally (Bower et al., 2001). Properties 
of certain compounds can enhance absorption of these therapeutic proteins and include 
molecules that are cationic, that are active at a low pH and molecules that have a relatively 
small molecular size (Bower et al., 2001, Natsume et al., 1999). Lantibiotics, such as nisin, 
have some of these properties and could potentially be used to enhance the absorption of 
therapeutic molecules through mucosal membranes (Bower et al., 2011). 
2.4.7 Contraceptives and potential applications in the urogenital tract 
Sexually transmitted diseases and HIV/AIDS hold a great health risk for sexually active 
individuals. It is estimated that a large majority of pregnancies occurring globally are 
unwanted, with 133 million unintended pregnancies occurring every year (Yedery and Reddy, 
2005). A safe and effective alternative to commercially available contraceptives would we 
useful to reduce the risk of sexually transmitted diseases and unplanned pregnancies. Nisin 
has shown good contraceptive activity in vitro and in vivo (Aranha et al., 2004, Reddy et al., 
2004). Nisin caused no abnormalities when applied intravaginally in rats and caused 
inhibition of sperm motility and prevented conception (Aranha et al., 2004). Intravaginal 
application of nisin also prevented conception in rabbits and showed no inflammation or 
damage to the vaginal epithelium when applied for 2 weeks (Reddy et al., 2004). In another 
study by Reddy et al. (2011) it was shown that nisin had no negative influence on rats, as well 
as their reproductive organs when administered orally. It had no effect on the reproductive 
performance of rats, as well as their offspring (Reddy et al., 2011). Subtilosin A, produced by 
B. amyloliquefaciens, was shown to have potent spermicidal activity in a dose dependant 
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manner, while showing low toxicity when using an EpiVaginal (VEC-100) human 
ectocervical tissue model (Sutyak et al., 2008a). Subtilosin also showed spermicidal activity 
when tested in various other animal systems (Silkin et al., 2008) Lacticin 3147 has also been 
proposed as potential spermicidal agent (Silkin et al., 2008). 
Subtilosin A was shown to be active against Gardneralla vaginalis, a major causative 
agent of bacterial vaginosis, whilst lacking activity against vaginal isolates of Lactobacillus 
(Sutyak et al., 2008b). 
2.4.8 Biosurfactants 
Surfactants are used to stabilize emulsions, such as oil in water, and are amphiphilic 
molecules (Singh and Cameotra, 2004). They contain hydrophilic and hydrophobic moieties 
that partition at the interface of fluids which have different polarities and hydrogen bonding. 
Nisin has been shown to be a good emulsifier and was able to stabilize oil droplets in water 
(Bani-Jaber et al., 2000). Emulsifying properties of nisin were dependent on nisin 
concentration and pH of the solution. Nisin has the potential to be used as alternative 
surfactant in pharmaceutical emulsions. These biosurfactants will have advantages because 
they are biodegradable and less toxic than some of the chemical surfactants and will have 
antimicrobial activity (Bower et al., 2001). 
2.4.9 Other 
Antiviral activity against Herpes simplex virus has been reported for lanthiopeptin and 
enterocin CR35 (Naruse et al., 1989, Wachsman et al., 1999). Duramycin is being developed 
for the treatment of reduced mucociliary clearance in cystic fibrosis (Kuipers et al., 2011). 
Duramycin caused improvements in pulmonary function parameters in cystic fibrosis patients 
when inhaled over 5 days, during a phase II clinical study (Grasemann et al., 2007) and 
showed no adverse effect on blood parameters of humans, when treated intranasally with 
aerosolized duramycin (Zeitlin et al., 2004). Duramycin has also entered phase II clinical trial 
for treating dry eyes (Grasemann et al., 2007). By opening calcium-activated chloride 
channels, duramycin is able to encourage hydration of the epithelial tissue (Kuipers et al., 
2011). 
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2.5 Cytotoxicity of bacteriocins 
2.5.1 In vitro on human cell lines 
Bacteriocins have numerous potential biomedical applications. However, cytotoxicity of 
bacteriocins needs to be determined before these peptides can be implemented in the 
pharmaceutical industry. Some bacteriocins have shown cytotoxic effects on human cell lines, 
however, this seems to be selective and dose-dependent. Subtle changes have also been 
shown to influence cytotoxicity. Cytotoxicity testing will thus have to be conducted on each 
peptide as safety assessment, before these peptides can reach end stages of clinical 
development. Gallidermin was less toxic than nisin A and the eukaryotic AMPs, magainnin I 
and II and melittin, towards two epithelial cell lines, HT29 and Caco-2 cells (Maher and 
McClean, 2006). A concentration dependent increase in membrane permeability was seen, 
with gallidermin showing significantly lower membrane permeability than the other peptides. 
The effect of a bacteriocin produced by Lactococcus sp. HY 449 has been tested on human 
fibroblasts (HNF, ATCC CCL-28) (Oh et al., 2006). Cell proliferation decreased in a dose-
dependent manner and a cytotoxicity test revealed that the LC50 of the bacteriocin was 50 
mg/ml after 24 h of treatment (Oh et al., 2006). Villarante et al. (2011) studied the effect of 
dialyzed and undialyzed bacteriocin (pediocin K2a2-3) fractions on the growth of two cancer 
lines, HT29 and HeLa cells. Inhibition of HT29 cells did not differ significantly, however 
undialysed bacteriocin inhibited significantly more of the HeLa cells (52.3 ± 6.0%), whereas 
only 15.6 ± 4.0% were inhibited by the dialysed bacteriocin. Toxicity was attributed to the 
low pH of the undialyzed fraction, pH 2, and that the HeLa cells were more sensitive towards 
low pH than the HT29 cells. The authors, however, concluded that the inhibitory effect on the 
HT29 cells were as a result of the bacteriocin and not that of the pH of the media. 
Carnobacteriocins, Cbn BM1 and Cbn B2, showed no cytotoxicity towards Caco-2 cells, as 
no significant effect was observed on growth rate and viability, when tested in combination at 
a final concentration of 100 mg/L (100x higher than needed for antimicrobial activity) for 48 
h. Cytotoxicity was only observed when Cbn B2 (100 mg/L) was used independently. 
However, the growth rate and the viability was still approximately 80% of that of the control 
(Jasniewski et al., 2009). Nisin, pediocin PA-1 and colicin E6 showed toxicity in a dose 
dependent manner when tested against Simian virus 40-transfected human colon (SV40-HC) 
and Vero monkey kidney (Vero) cells (Murinda et al., 2003). Highest toxicity was recorded at 
700 AU/ml. Colicins E1, E3 and E7 on the other hand showed lower toxicity towards these 
cells. Enterocin S37, a bacteriocin produced by Enterococcus faecalis S37, showed dose 
dependent toxicity when tested against undifferentiated Caco-2/TC7 cells (Belguesmia et al., 
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2011a). This bacteriocin was more cytotoxic towards undifferentiated Caco2-TC7 cells than 
nisin. However, no significant effects were seen on differentiated Caco-2/TC7 cells. Nisin 
also showed lower hemolytic activity (1.1% lysis) than enterocin S37 (74.2% lysis) at a 
concentration of 10 µg/ml, when tested against sheep erythrocytes. Microcin E492 has shown 
cytotoxicity towards HeLa in a dose dependent manner. Apoptosis was induced at lower 
levels of microcin E492, whereas at higher concentrations necrosis was induced (Hertz et al., 
2002). Plantaricin A, a bacteriocin produced by Lactobacillus plantarum, has been shown to 
increase cell proliferation, enhance migration and influence the expression of TGF-β1, FGF7, 
VEGF-A and IL-8 in vitro in human keratinocytes (Pinto et al., 2011). Subtle changes in 
amino acid composition of a peptide can also influence its hemolytic activity. Subtilosin A 
variants, with an isoleucine at position 6 instead of a threonine, showed higher levels of 
hemolytic activity (Huang et al., 2009). 
Because of the selective toxicity of some bacteriocins towards human cells it can be 
hypothesized that they use cell surface receptors to exert activity. Detailed information on the 
initial interaction of bacteriocins and subsequent cytotoxicity towards human cell lines is not 
available and only a few papers have addressed this topic. Hydrophobicity has been proposed 
to promote interaction with mammalian cell membranes thereby causing toxicity (Maher and 
McClean, 2006). However, more complex systems have been described. Pyocin S2, produced 
by P. aeruginosa, was shown to be active against some normal and malignant human cells. 
Pyocin S2 used certain carbohydrate moieties for attachment to the human cells, whereas it 
recognizes an iron-regulated outer membrane protein in sensitive bacteria (Watanabe and 
Saito, 1980). Tumor cells have also been shown to be selectively inhibited by colicins A and 
E1, which bind to the Vitamin B12 receptor BtuB (Cramer et al., 1995, Lazdunski et al., 
1998). 
2.5.2 In vivo cytotoxicity, pharmacokinetics and pharmacodynamics 
Bacteriocins, both class I and class II, show relatively low levels of toxicity when tested in 
vivo in animal models, as mentioned in the section on biomedical applications of bacteriocins. 
A bacteriocin derived from Lactococcus sp. HY449 showed no irritancy on human skin, with 
a patch test (Oh et al., 2006). Pediocin PA-1 also showed no negative side effects and did not 
alter the normal intestinal flora when administered to mice (Bernbom et al., 2009). Pediocin 
AcH was further shown to be non-immununogenic and did not elicit a response when 
administered to mice and rabbits (Bhunia et al., 1990). There are, however, a few exceptions, 
such as a natural subtilosin A variant with higher hemolytic activity and cytolycin, produced 
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by E. faecalis, with high toxicity levels towards both prokaryotic and eukaryotic cells (Huang 
et al., 2009).  
Mutacin 1140 has been shown to bind strongly to human serum with up to 92.7 ± 
2.0% bound to serum components (Ghobrial et al., 2010a). Human serum also negatively 
affected the antimicrobial activity of mutacin 1140 against S. pneumonia, however, strangely 
increased the activity against S. aureus. Further studies revealed that mutacin 1140 could be 
detected in blood plasma of Sprague-Dawley rats for up to 6 h after a single intravenous 
administration of 25 mg/kg (Ghobrial et al., 2010b). The elimination terminal half-life of 
mutacin 1140 was determined to be 1.6 h. A hypersensitive reaction was observed with rapid 
injection of mutacin 1140 which could be blocked by pretreatment with diphenhydramine. 
Intravenous administered duramycin (Moli1901) has been shown to be excreted in the feces 
and that it accumulated mainly in the liver, when administered to rats and mice (McNulty et 
al., 2003). Aerosolized duramycin showed high accumulation in the respiratory tract of mice 
and rats and also got excreted in the feces 2 days after treatment. Finally, duramycin was 
eliminated from the pulmonary system and once again excreted in the feces of mice and rats, 
with an elimination half-life of 52 days, following intratracheal administration (McNulty et 
al., 2003). 
 
2.6 Resistance towards bacteriocins 
2.6.1 Class I  
Nisin has been applied to food products for biopreservation all over the world and 
remarkably, very little resistance has been reported. As is the case with antibiotics, however, 
it is expected that resistance will develop once used in a clinical setting and mechanisms of 
resistance therefore needs to be elucidated. In the laboratory, spontaneous resistance to nisin 
can easily be induced upon incubation below the MIC, with subsequent increase in 
concentration (Kramer et al., 2004, Severina et al., 1998). Nisin resistance in L. 
monocytogenes can be ascribed to changes in fatty acid composition as well as the 
phospholipid composition. Decreased ratios of C15/C17 fatty acids, more zwitterionic 
phosphatidylethanolamine, less anionic phosphatidylglycerol and cardiolipin and a 
requirement for divalent cations (Mg
2+
, Ca 
2+
, Mn 
2+ 
and Ba
2+
) have been reported to be 
involved in resistance (Crandall and Montville, 1998, Mazzotta and Montville, 1997, Ming en 
Daeschel, 1993, 1995). Decreased phosphatidylglycerol results in a less negative cell surface 
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charge and can thus reduce the binding affinity of cationic antimicrobial peptides (Chatterjee 
et al., 2005). Increased straight chained, monounsaturated and saturated fatty acids, as well as 
less branched polyunsaturated fatty acids have been reported in resistant strains of L. 
monocytogenes and C. botulinum (Mazzotta and Montville, 1997, Ming en Daeschel, 1993). 
Increased C16:1 and C18:1 monounsaturated fatty acids were also identified in resistant P. 
acidilactici (Goulhen et al., 1998). Spontaneous nisin resistance in L. monocytogenes varied 
from 10
-2
 to 10
-7
 in a strain dependent manner (Gravesen et al., 2002a) and L. monocytogenes 
mutants were detected at a frequency of 10
-6
 to 10
-8
 which were resistant to 50 µg/ml nisin 
(Harris et al., 1991). It has also been proposed that nisin resistance in L. monocytogenes was 
due to shielding of lipid II (Gravesen et al., 2001, 2004). Increased expression was observed 
in a protein homologous to the glycosyltransferase domains of high molecular weight PBPs, 
as well as a protein histidine kinase which was directly involved in nisin resistance. Nisin 
resistance in M. flavus appeared to be independent of lipid II levels (Kramer et al., 2004). 
Nisin resistance in L. lactis was ascribed to various complex changes by preventing 
nisin from reaching the cytoplasmic membrane, reducing the acidity of the medium (resulting 
in the binding of nisin to the cell wall), preventing the insertion of nisin into the membrane, as 
well as possibly by transportation of nisin across the membrane or export of nisin out of the 
membrane (Kramer et al., 2006). Resistant strains showed increased thickness of the cell wall 
at the septum, indicating a potential shielding of lipid II to prevent nisin binding and 
translocation of lipid II. The resistant strains also showed increased D-alanyl esters and 
galactose in the cell walls, resulting in a less negatively charged cell wall. Shielding of lipid II 
appeared to be the main mechanism of resistance towards nisin (Kramer et al., 2006).  
S. aureus with a disrupted dltA (gene products which are involved in the synthesis of 
D-alanyl esters for substitution in lipoteichoic acids, resulting in the incorporation of positive 
charges) was more sensitive towards various cationic antimicrobial peptides including 
gallidermin and nisin (Peschel et al., 1999). Wild type S. aureus strains with additional copies 
of the dlt operon were less sensitive to cationic antimicrobial peptides as they had higher 
amounts of D-alanylation of their lipoteichoic acids and thus a more positive charge to hinder 
initial binding of the cationic AMPs (Peschel et al., 1999).  
Bacillus subtilis mutants (sigX, and dltA mutants) were also shown to be more 
sensitive towards nisin than wild type strains (Cao and Helmann, 2004). The 
extracytoplasmic-function (ECF) σX factor plays a role (in part) in regulation of expression of 
genes playing a role in phosphatidylethanolamine biosynthesis (pssA, psd and ybfm) as well as 
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D-alanylation of lipoteichoic and wall teichoic acids (dlt) (Chatterjee et al., 2005). Activation 
of (ECF) σX factor thus results in nisin resistance by inducing genes which causes alterations 
of cell surface properties (Cao and Helmann, 2004). 
A mutation in a putative histidine kinase (designated nsaS, nisin susceptibility 
associated) in S. aureus was recently shown to result in high level resistance to nisin (Blake et 
al., 2011). The nsaSR operon and a downstream operon (encoding an ABC transporter) forms 
part of a locus which encodes proteins that is paralogous to the graRS/vraFG cluster 
conferring resistance to vancomycin and polymixin B (Blake et al., 2011). NsaRS was further 
shown to regulate a downstream transporter NsaAB during nisin-induced stress and that 
NsaRS plays a role in sensing cell damage, after which it will modify gene expression of 
genes playing a role in cell envelope modification, conferring resistance (Kolar et al., 2011). 
Another group independently identified a two-component regulatory system (which they 
termed BraSR and BraDE, bacitracin resistance associated) as the main regulatory element 
controlling bacitracin and nisin resistance in S. aureus (Hiron et al., 2011). They showed that 
the two ABC transporters are involved in signal transduction and resistance, BraDE is 
involved in sensing and signalling through BraSR, whereas VraDE will finally aid in 
detoxification and conferring resistance. Two-component systems in L. monocytogenes have 
also been identified as playing a role in resistance towards nisin A (Cotter et al., 2002, Collins 
et al., 2012). Two-component regulatory systems (where genes encoding a sensor 
kinase/response regulator pair lie adjacent to genes encoding an ABC transporter) seem to 
play a major role in antimicrobial peptide resistance in not only S. aureus, but also the 
Firmicutes (Jordan et al., 2008). 
An enzyme, nisinase, can also potentially confer resistance to nisin. Nonproteolytic 
nisin inactivating enzymes has been reported for several Bacillus spp., with putative 
dehydroalanine reductase activity (Jarvis, 1967, Jarvis and Farr, 1971). 
2.6.2 Class II  
Resistance to class IIa bacteriocins commonly occur at frequencies of 10
-9
 to 10
-3
 in L. 
monocytogenes and can be very stable in some cases (Gravesen et al., 2002b, Tessema et al., 
2009). Inactivation of the rpoN gene (encoding the σ54 subunit of the bacterial RNA 
polymerase) in L. monocytogenes was shown to confer resistance to mesentericin Y105 and 
sensitivity was restored upon complementation with the wild type rpoN gene (Robichon et al., 
1997). The σ54 subunit is an alternative sigma factor for the transcription of a set of genes, 
including the mpt operon which encodes for a mannose permease of the PTS (Man-PTS) 
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(Belguesmia et al., 2011b, Gravesen et al., 2002b). L. monocytogenes resistance towards class 
II bacteriocins, as well lactococcin A, correlated with a reduction in the expression of the 
Man-PTS (Dalet et al., 2001, Héchard et al., 2001, Kjos et al., 2011). Down-regulation of 
Man-PTS thus appears to be one way to confer class II bacteriocin resistance. This was 
further supported by the fact that lower levels of Man-PTS expression were found in natural 
bacteriocin-resistant L. monocytogenes isolates (Kjos et al., 2011). The role of Man-PTS was 
further investigated by heterologous expression of the mptACD operon of L. monocytogenes 
in L. lactis. It was shown that mptC alone could confer resistance and as a result was 
identified as the target site of class IIa bacteriocins (Kjos et al., 2010). Transcriptional 
analysis of pediocin PA-1-resistant E. faecalis revealed that there was reduced expression of 
the mpt operon, as well as genes encoding glycolytic enzymes. The resistant strains were 
relieved from catabolite repression, more specifically glucose repression, and metabolism was 
shifted to mixed acid fermentation (Opsata et al., 2010). Some reports revealed that resistance 
can be more complex, as normal or even higher expression of genes in the Man-PTS system 
was found in the resistant strains. The presence of recombinant divercin RV41 caused a 
down-regulation of rpoN and glpQ gene expression and an up-regulation of mptR, mptC, and 
pde. The expression of mptB and mptD genes remained unchanged in the presence of 
recombinant divercin RV41 (Calvez et al., 2008). Three genes including, rpoN, glpQ 
(encoding a glycerolphosphoryl diester phosphodiesterase) and pde (putative 
phosphodiesterase) were identified to play a role in divercin V41 resistance in E. faecalis 
(Calvez et al., 2007). Mutants, deficient in synthesis of σ54 subunit of the bacterial RNA 
polymerase and glycerophosphoryl diester phosphodiesterase, differed from both the pde 
mutant and the wild-type strain in fatty acid and polysaccharide composition (Calvez et al., 
2010). Sakacin P-resistant L. monocytogenes strains showed differences in growth, stress 
tolerance, as well as biofilm-forming ability. Differences in polysaccharide, fatty acid, and 
protein regions in cell membranes were observed in resistant strains as compared to the wild 
type (Tessema et al., 2009). Resistance in L. monocytogenes has also been attributed to cell 
envelope changes including membrane fluidity and composition, especially alanine content, 
as well as cell surface charge (Vadyvaloo et al., 2002, 2004). Class II bacteriocin resistance is 
a complex phenotype and several resistance mechanisms can together impart resistance in 
bacteria at either a low or a high level. Low-level resistance (2 to 4-fold) to class IIa 
bacteriocins can be attributed to alterations in membrane lipid composition, whereas high-
level resistance (1000-fold) can be attributed to inactivation of the mptACD operon 
(Belguesmia et al., 2011b). Immunity genes have been identified in non bacteriocin-
producing bacterial strains and this immunity was termed “resistance through immune 
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mimicry” (Draper et al., 2009, Fimland et al., 2002, Møretrø et al., 2005). Efflux pumps 
which expel the bacteriocins from the cell and non-specific extracellular proteases have also 
been proposed to be involved in clas II bacteriocin resistance (Kjos et al., 2011). 
2.6.3 Cross-resistance 
Cross-resistance has been reported between different bacteriocins. Nisin resistance conferred 
cross-resistance to pediocin PA-1 and leuconocin S in L. monocytogenes (Crandall and 
Montville, 1998). Curvaticin 13 resistance in L. monocytogenes conferred resistance to 
camocin CP5 and pediocin AcH, two class IIa bacteriocins. No cross-resistance was, 
however, conferred to the class I bacteriocin nisin (Bouttefroy and Millière, 2000). Leucocin 
A-resistant strains of L. monocytogenes showed no significant cross-resistance towards 
nisaplin and the synthetic peptide ESF1-7GR, however were resistant to pediocin PA-2 
(Ramnath et al., 2000). Cross-resistance has been detected between pediocin PA-1 and 
bavaricin A in L. monocytogenes, however, once again no cross-resistance to nisin was 
detected (Rasch and Knøchel, 1998). Cross-resistance between pediocin PA-1, leucocin A and 
carnobacteriocin B2 have been reported in L. monocytogenes. Some cross-resistance between 
nisin and leucocin A has also been reported (Gravesen et al., 2004). Acquired nisin (A or Z) 
resistance in L. monocytogenes reduced susceptibility towards pediocin and divergicin. A 
divergicin resistant strain showed increased resistance to nisin Z, but strangely decreased 
resistance to nisin A, and pediocin resistant strains exhibited increased resistance to nisin Z, 
pediocin and divergicin but also decreased resistance to nisin A (Naghmouchi et al., 2007). 
Recently, L. lactis mutans have been isolated that are simultaneously resistant towards 
lactococcin 972 and nisin, as well as lysozyme and bacteriophage c2 (Roces et al., 2012). 
Almost no or very low levels of cross-resistance between bacteriocins and antibiotics 
have been found (Liu et al., 2011). However, some cross-resistance has been reported. 
Bacteriocin resistance was reported to decrease sensitivity towards various antibiotics, 
including ampicillin, chloramphenicol, erythromycin and tetracycline (Naghmouchi et al., 
2007). Bacteriocins and antibiotics can potentially be used together to prevent or hamper the 
emergence of resistant pathogens, because they have different modes of action and acquiring 
resistance towards two different antimicrobials is very unlikely (Diep et al., 2007). 
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2.7 Delivery systems for bacteriocins aimed at biomedical applications 
The stability or mode of in vivo application of bacteriocins can be problematic and needs to be 
overcome. Drug delivery systems will play an integral role in the successful application of 
bacteriocins in the biomedical industry. These delivery systems would potentially be able to 
protect the peptides from proteolytic enzymes, which will result in the peptide staying active 
for prolonged periods of time, and will be able to release the bacteriocins in a controlled 
manner to exert its antimicrobial activity. 
Most studies aimed at the delivery of bacteriocins have dealt with antimicrobial 
packaging films or materials aimed at food preservation and very few studies have been 
conducted to generate delivery systems for biomedical applications of bacteriocins 
(Bastarrachea et al., 2011). Some of these systems, aimed specifically at medical applications, 
have previously been described in this literature overview and include bacteriocin-absorbed 
catheters, bacteriocin-impregnated bone cements, bacteriocin-liposome complexes, as well as 
nisin-coated vascular implants. Nisin has also been encapsulated into poly(L-lactide) (PLA) 
nanoparticles by semicontinuous compressed CO2 anti-solvent precipitation (Salmaso et al., 
2004). Nisin was released in the active form for up to 1000 h and release was dependent on 
the salt concentration and the pH of the release medium. Nisin released from the PLA 
nanoparticles was able to inhibit the growth of Lactobacillus delbrueckeii spp. bulgaricus, 
when nisin-loaded PLA nanoparticles were incubacted in MRS containing the sensitive strain. 
These nanoparticles have been investigated for food preservation, however, could also 
potentially be used in antimicrobial pharmaceutical products. Pectin/HPMC was shown to 
protect nisin tablets during tests simulating colonic delivery. The authors reported that pectin 
on its own was not suitable in protecting nisin core tablets and that a 80:20 ratio of 
pectin:HPMC was the optimum composition to protect nisin, with the tablets maintaining 
integrity during a 6 h dissolution test (Urgurlu et al., 2007).  
 
3. Electrospun Nanofiber Scaffolds for Enhanced Wound Healing and Tissue 
Regeneration  
3.1 Electrospun nanofibers 
Nanofibers are polymeric fibers in the nanometer range with a large surface area to volume 
ratio and advanced mechanical properties (Agarwal et al., 2008, Chew et al., 2005, 
Maretschek et al., 2008). These properties, as well as ease of fabrication, have led to various 
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applications in diverse fields, including filtration, protective clothing, biosensors and 
biomedical engineering (Agarwal et al., 2008, Gibson et al., 2001, Huang et al., 2003, Theron 
et al., 2008, Yoon et al., 2006). In biomedical engineering the nanofibers are attractive 
substrates for controlled release of various drugs and growth factors, for tissue engineering, 
medical prostheses, for the immobilization of enzymes and as wound dressings (Chew et al., 
2005, Jiang et al., 2005, Kim et al., 2007, Liang et al., 2007, Maretschek et al., 2008, Porter 
et al., 2009, Quaglia, 2008). 
During electrospinning an electric field will be applied to a polymer solution or melt, 
causing the electrically charged polymer to form a Taylor cone (Huang et al., 2003, 
Maretschek et al., 2008). Once the electric forces overcome the surface tension a charged 
polymer jet will eject out of the Taylor cone and accelerate towards the collector. The 
polymer solution becomes very thin as it moves towards the collector, the solvent evaporates 
and fibers are collected (Agarwal et al., 2008, Liang et al., 2007, Zhou et al., 2008). These 
fibers are in the non-woven form and contain a high surface area to volume ratio. Three 
components needed for electrospinning include a high voltage supply, a long capillary tube 
and a collector (Liang et al., 2007). Various parameters influence successful electrospinning 
of polymer solutions into nanofibers, including solution properties (viscosity, molecular 
weight of polymer(s) used, solvent(s) used), electric field applied, distance between needle tip 
and collector, temperature of the solution and humidity (for more information see Deitzel et 
al., 2001, Huang et al., 2003, Jacobs et al., 2010). 
Modifications of conventional electrospinning have appeared with co-axial 
electrospinning, emulsion electrospining and electrospinning using dual spinnerets. Co-axial 
electrospinning utilizes a specialized needle setup to produce core shell structured nanofibers 
(Sun et al., 2003). During co-axial electrospinning a polymer solution in the outer parts of the 
needle will form the shell and the solution on the inner part of the needle will form the core, 
thus encapsulating the core material in the outer shell. The core material can be a polymer 
solution or a bioactive molecule to be encapsulated (antibiotics, growth factors, living 
organisms) or combinations thereof. Emulsion electrospinning is another approach to produce 
core-shell structured nanofibers without the need of the specialized needle setup (Xu et al., 
2006). During emulsion electrospinning an aqueous solution (bioactive molecule, hydrophilic 
polymer or a combination thereof) will be placed in an organic polymer solution and 
emulsified, with subsequent electrospinning using the conventional electrospinning setup 
(Maretschek et al., 2008). Molecules in the aqueous phase will thus also be encapsulated.  
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3.2 Nanofiber wound dressings and scaffolds for tissue regeneration  
It is beyond the scope of this review to cover all of the biomedical applications of electrospun 
nanofibers (for detailed reviews see Agarwal et al., 2008, Jayakumar et al., 2012, Meinel et 
al., 2012) and will mainly focus on electrospun nanofibers as wound dressing materials and 
for the delivery of compounds influencing wound healing. Wound dressing materials have 
evolved over the last few decades from merely substrates that cover wounds, to bioactive 
materials which promote wound healing (Zahedi et al., 2010). Optimal wound dressings 
should facilitate wound healing by forming a barrier to prevent microbial colonization, be 
able to treat infection in such instance, absorb wound educate, allow gas exchange, be non-
immunogenic and non-toxic and must be easily removable without causing damage (Zahedi et 
al., 2010). Electrospun nanofibers have various properties that make them suitable as wound 
dressing materials such as high oxygen permeability, variable pore size, a high surface area to 
volume ratio and morphological similarity to the extracellular matrix (EM) (Smith and Ma, 
2004, Zahedi et al., 2010, Zhou et al., 2008). Various natural and synthetic polymer/polymer 
blends have been electrospun into nanofibers to generate potential wound dressing materials. 
The ability to incorporate a variety of bioactive molecules (such as antimicrobials, anti-
inflammatories) into the nanofibers can increase the desirable wound healing (and wound 
dressing) properties.  
3.2.1 Nanofibers electrospun without the addition of bioactive molecules 
Hydrophobicity seems to be a very important characteristic influencing cell attachment and 
proliferation as more promising results are usually obtained with a higher degree of 
hydrophilicity in the nanofiber scaffolds. Blending of hydrophobic and hydrophilic polymers 
by either co-electrospinning, coating of fibers post-electrospinning or co-axial electrospinning 
is thus attractive ways to modify scaffold properties to enhance cell attachment and 
proliferation. 
Chitosan has received enormous attention as potential wound dressing biomaterial as 
it has beneficial properties such as biodegradability, biocompatibility, antibacterial- and 
wound healing-activity (Jayakumar et al., 2010). Chitin, a structural polysaccharide from 
arthropods, has been electrospun into nanofibers by Min et al. (2004) using 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) as solvent. Nanofibers had diameters ranging from 40 to 600 
nm with an average diameter of 110 nm. Chitosan nanofibers were formed by deacetylation of 
the chitin nanofibers by treatement with 40% NaOH at 100 °C for 120 min or for 1 day at 60 
°C (Min et al., 2004b). Human oral- and epidermal-keratinocytes (HOK and HEK, 
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respectively), as well as human gingival fibroblasts (HGF), seeded onto electrospun chitin 
nanofibers (163 nm) showed better cell attachment and spreading as compared to microfibers 
(8.77µm), however both showed inadequate cell attachment and spreading (Noh et al., 2006). 
Higher rates of attachment and proliferation were obtained on chitin nanofibers when coated 
with type I collagen and this significantly promoted the cellular response (Noh et al., 2006). 
Chitin nanofibers were stable for 7 days after implantation in Sprague-Dawley rats, however 
lymphocytes and macrophages (inflammatory cells) were observed on the fiber matrix. Signs 
of degradation were observed in the nanofibers 14 days after implantation and inflammatory 
cells reduced during this period. Chitosan/polyethylene glycol (PEG) nanofibers were 
stabilized in 1M NaOH, resulting in the dissolution of PEG, leaving chitosan nanofibers with 
diameters ranging from 50 to 200 nm, which promoted cell attachment and proliferation of 
human fibroblasts, endothelial cells and keratinocytes (Tchemtchoua et al., 2011). RT-PCR 
analysis revealed reduced keratin 14 expression, as well increased keratin 10 and involucrin 
expression in keratinocytes cultured on chitosan nanofibers, indicating differentiation of 
keratinocytes and low level cytotoxicity of the nanofibers. Chitosan nanofibers were fully 
biocompatible and promoted recovery of full-thickness wounds in BALB/c mice. 
Blending chitin or chitosan with other polymers have resulted in scaffolds with 
enhanced properties. Human epidermal fibroblasts (HEF) showed good attachment and 
proliferation on chitin/polyglycolic acid (PGA) blend nanofiber scaffolds, with promising 
results obtained as the PGA content increased (Park et al., 2006a). A chitin/PGA (75:25) 
blend showed an increase in adherent cells when coated with BSA. HEF and HEK also 
showed increased attachment and spreading on chitin/silk fibroin (SF) blend fibers (75:25) 
(Park et al., 2006b). Water-soluble carboxyethyl chitosan (CECS)/PVA (50:50) nanofibers, 
cross-linked with glutaraldehyde vapour, showed no toxicity towards mouse fibroblasts 
(L929) and promoted cell attachment and proliferation (Zhou et al., 2008). Nanofibers 
consisting of type I collagen, chitosan, and poly(ethylene oxide) (PEO) have been electrospun 
with subsequent cross-linking, using glutaraldehyde vapor (Chen et al., 2008b). Nanofibers 
showed good biocompatibility and promoted proliferation of NIH3T3 fibroblasts. These 
nanofibers were also comparable with a commercial collagen sponge, when wound healing 
was evaluated in SD rats (Chen et al., 2008b). Fibroblasts showed good viability on chitosan 
(CS)-poly(L-lactic acid-co-ɛ-caprolactone) P(LLA-CL) scaffolds, with best viability observed 
on the CS: P(LLA-CL) 1:2 nanofiber scaffold (Chen et al., 2008a). Electrospun chitin/poly(ɛ-
caprolactone) (PCL) nanofibers were washed in ethanol and neutralised with 0.1M sodium 
carbonate dissolved in 70% ethanol (Kim et al., 2012). Cellular attachment and proliferation 
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of human dermal fibroblasts (HDF) increased on scaffolds, as the chitin content in the 
nanofibers increased and showed increased density, formation of actin filaments and good 
overall morphology on the chitin/PCL nanofibers. Blending other polymers has also shown 
promising results. Enhanced NIH3T3 fibroblast attachment and proliferation was observed on 
nanofibers prepared by co-electrospinning keratin or gelatin with poly(lactic acid) (PLA), as 
compared to plain PLA nanofibers (Yuan et al., 2008). Xylan, natural hemicellulose 
(polysaccharide) present in hardwood, and PVA was successfully co-electrospun into 
nanofibers and subsequently cross-linked with glutaraldehyde vapour (Krishnan et al., 2012). 
Nanofiber diameters increased with cross-linking time and xylan/PVA fibers cross-linked for 
48 h improved human foreskin fibroblast attachment, cell morphology and proliferation and 
also showed best stability upon incubation. Normal human ﬁbroblasts were able to adhere and 
proliferate on polyethyleneimine (PEI) nanofibers, electrospun with succinic anhydride and 
subsequently cross-linked with 1,4-butanediol diglycidyl ether, and exhibited a normal 
phenotype when evaluated with immunoﬂuorescence (Khanam et al., 2007). PEI nanofibers 
was shown to be non-toxic and promoted cell-nanofiber scaffold interactions.  
Post-electrospinning modifications can also alter adherence and proliferation of 
mammalian cells. Increased attachment and proliferation of HOK, HEK and HGF were 
obtained on collagen-coated chitin nanofibers, as previously mentioned (Noh et al., 2006). 
HOK, HEK and NHGF were able to attach and proliferate on silk fibroin nanofibers (Min et 
al., 2004a). Nanofibers coated with type I collagen however showed increased adhesion and 
proliferation by cells. PCL nanofibers were coated with collagen using either a co-axial 
electrospinning setup (where PCL is the core and collagen the shell) or by immersion of PCL 
nanofibers in a collagen solution (Zhang et al., 2005). HDF showed better attachment and 
viability on co-axial electrospun nanofibers, than on post-electrospinning collagen coated 
nanofibers. No improvement over the controls was, however, observed. Poly(propyl 
carbonate) (PPC) and poly(cyclohexyl carbonate) (PCHC) was synthesized and electrospun 
into nanofibers with subsequent surface modification using low-power deep UV irradiation 
(Welle et al., 2007). L929 fibroblasts cultured on PPC nanofibers showed promising 
attachment and viability on the scaffolds. PGA, poly(L-lactic acid) (PLLA) and poly(lactic-
co-glycolic acid) (PLGA) has been electrospun into nanofibers and their surfaces chemically 
modified using oxygen plasma treatment and in situ grafting of hydrophilic acrylic acid (Park 
et al., 2007). Fibroblast adherence and proliferation was increased on modified nanofiber 
scaffolds, as compared to unmodified. Electrospun quaternized chitosan (QCh)/PVA 
nanofibers were cross-linked with the addition of a photo-cross-linking agent and UV light-
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irradiation, to render the nanofibers insoluble in aqueous environments (Ignatova et al., 2006). 
QCh/PVA nanofibers showed strong antimicrobial activity and were able to reduce viable 
cells of S. aureus and E. coli. Adherence, proliferation and/or viability of mammalian cells on 
these scaffolds were however not evaluated by the authors. A comprehensive in vivo wound 
healing evaluation on cross-linked PVA, wool protein-coated PVA (PVA-p-coated), wool 
protein/PVA co-electrospun (PVA-p-cospin), PVA containing silver nanoparticles (PVA-
nAg), PCL, wool protein-coated PCL (PCL-p-coated), polyacrylonitrile (PAN), cross-linked 
polyacrylonitrile-polyurethane blend nanofibers (PAN-PEU) and poly(vinylidene fluoride-co-
hexafluoropropene) (PVdF-HFP) nanofibers was conducted by Liu et al. (2010). Wounds 
covered with all nanofibers showed good fluid retention and wool protein seemed to enhance 
wound healing on day 10, as PVA-p-coated and PVA-p-cospin showed improved results over 
the control. PVA-p-coated also showed better healing on day 16, however PVA-p-cospin did 
not show improvements on the control. Cross-linked PVA showed enhanced wound healing 
over the control on day 16 and thus hydrophilic nanofibers were shown to increase wound 
healing ability, over the hydrophobic nanofibers. Very low levels of increased wound healing 
were however observed as compared to controls. Only PVA-nAg nanofibers showed 
antimicrobial activity towards E. coli. 
Electrospun collagen nanofibers have shown promise as wound dressing and tissue 
regeneration scaffolds, however (partial) denaturation of collagen has been reported by some 
authors when electrospinning in HFIP or 2,2,2-trifluoroethanol (Matthews et al., 2002, Yang 
et al., 2008, Zhong et al., 2005). Polyurethane (PU) nanofibers improved wound healing in 
full-thickness excisional wounds generated on male guinea pigs, when compared to 
Tegaderm™ (Khil et al., 2003). Histological analysis revealed that the PU nanofiber-treated 
group showed lower inflammatory cells, whereas inflammatory cells were still present in the 
Tegaderm™-treated groups. PU nanofiber-treated groups also showed increased 
epithelialization and a well-organized dermis could be observed (Khil et al., 2003). PCL and 
gelatin nanofibers, electrospun using needleless Nanospider
TM
 technology, were evaluated as 
wound dressings (Dubský et al., 2012). Gelatin nanofibers needed cross-linking with 
glutaraldehyde vapour. HDF and human dermal keratinocytes grew well on both gelatin and 
PCL nanofibers, however, gelatin nanofibers showed most promising results, with increased 
wound closure rate of full-thickness wounds in Wistar rats. Increased epithelialisation, 
increased depth of granulation tissue and increased myofibroblasts were observed in gelatin 
nanofiber-treated wounds. 
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Hemoglobin and myoglobin was successfully electrospun into fibers for potential delivery of 
oxygen to healing tissues (Barnes et al., 2006). Hemoglobin and myoglobin fibers were 
subsequently cross-linked with glutaraldehyde vapor and increased stiffness was observed 
with an increase in cross-linking time. Porosity of hemoglobin fibers was concentration-
dependent and increased as concentration increased. Platelet rich plasma was successfully 
electrospun into nano- and micro-fibers by Wolfe et al. (2011). Human platelet rich plasma 
was subjected to a freeze-thaw-freeze process, lyophilized to form a powdered preparation 
rich in growth factors (PRGF) and electrospun in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP). 
Protein release was observed from the fibers for at least 35 days, with the highest release 
observed on day 1. Human adipose derived stem cells and human umbilical artery smooth 
muscle cells were able to penetrate the PRGF fibers and increased penetration was observed 
as concentration (for electrospining) increased. Penetration was hypothesized to be a result of 
growth and chemotactic factors inherent to platelet rich plasma. 
 
3.2.2 Nanofibers co-electrospun with bioactive molecules 
Various drugs and proteins influencing wound healing (including antibiotics, silver 
nanoparticles, analgesics, growth factors, vitamins, antifungal agents, as well as herbal 
extracts) have been co-electrospun into nanofibers for controlled release. Polymer-drug 
interaction and solubility of the drug in the polymer solution will influence distribution of the 
drug in the nanofiber scaffold and will thus influence drug release profile. Drug stability in 
the solution is also an important factor to consider and addition of drugs and proteins to the 
solution can alter solution properties, thus influencing the electrospinning process. 
3.2.2.1  Antibiotics  
A low concentration of rifampin, co-electrospun with PLLA, was released from PLLA 
nanofibers when incubated in 0.05 M Tris-HCl buffer (Zeng et al., 2003). Rifampin was only 
released from the nanofibers when proteinase K was added to the buffer solution and 
degradation was thus the main factor influencing rifampin release (Zeng et al., 2003). 
Cefazolin was successfully co-electrospun into PLGA nanofibers without significantly 
altering scaffold properties, however cefazolin-containing nanofibers had slightly larger 
diameters as compared to PLGA nanofibers without antibiotic (Katti et al., 2004).  
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Tetracycline hydrochloride (TH) was released from poly(ethylene-co-vinyl acetate) (PEVA) 
nanofibers with a high initial burst, releasing 65% of the antibiotic in 120 h, whereas a 50:50 
blend of PLA and PEVA released 50% in the same time period (Kenawy et al., 2002). PLA 
showed a very high initial burst release, where after release was negligible. All nanofiber 
scaffolds and Actisite
®
, a commercial drug delivery system, showed an initial burst release 
upon incubation. TH increased fiber diameter and resulted in formation of less uniform fibers, 
when co-electrospun with PVA (Kanawung et al., 2007). Most of TH was released within a 6-
h period and increasing TH concentration reduced total release. A decrease in total release 
was also observed when the PVA fibers were coated by electrospinning PVA-sodium alginate 
nanofibers on top of the PVA-TH nanofibers.  
Mefoxin was released from poly(D,L-lactide) (PDLLA) nanofibers with a very high 
burst release within 48 h (Zong et al., 2002). Mefoxin also showed a high burst release from 
PLGA and poly(lactide-co-glycolide)/poly(lactic acid)/poly(ethylene glycol)-b-poly(lactic 
acid) PLGA/PEG-b-PLA diblock copolymer/PLA nanofibers (Kim et al., 2004). The 
mefoxin-loaded nanofibers showed an inhibitory effect on the growth of S. aureus when 
tested in liquid culture, as well as on solid agar plates. Electrospun PLGA and PLGA/PEG-
PLA blend fibers decreased abdominal adhesions in Sprague-Dawley rats, which underwent 
midline celiotomy (Zong et al., 2004). PLGA and PLGA/PEG-PLA fibers reduced abdominal 
adhesion with 40% and 22% incidence of adhesions, respectively, whilst the control showed 
an incidence of 78%. A further significant decrease in abdominal adhesion was observed upon 
co-electrospinning with mefoxin and mefoxin-loaded PLGA/PEG-PLA fibers completely 
inhibited formation of abdominal adhesions.  
Biteral was released with a high initial burst release from PCL nanofibers, releasing 
80% of the antibiotic within 3 h, and total release was seen after 18 h (Bölgen et al., 2007). 
The nanofibers prevented abdominal adhesions in Wistar-Albino rats and improved healing.  
Gentamycin sulfate (GS) was encapsulated into PCL fibers by co-axial 
electrospinning, where PCL forms the shell and GS the core of the fibers (Huang et al., 2006). 
GS release was dependent on fiber degradation, as Pseudomonas lipase added in the PBS 
release buffer resulted in GS release. The characteristic burst release was thus not observed in 
these fibers.  
In a study aimed at the release of multiple compounds Takur et al. (2008) used a dual 
spinneret electrospinning setup to co-electrospin lidocaine hydrochloride (LH), an anesthetic, 
and mupirocin, an antibiotic, into PLLA fibers. LH showed an initial burst release and 
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mupirocin a low burst release, followed by a more sustained release (biphasic). Mupirocin 
showed a much higher release profile, without the presence of LH. Addition of LH thus 
altered the release profile of mupirocin in the dual setup. A dual spinneret setup was also used 
to generate scaffolds containing both PLGA and poly(ester urethane) urea (PEUU) (Hong et 
al., 2008). TH was co-electrospun with the PLGA for drug release. Plain spun TH-PGLA 
nanofibers showed a high initial burst release with negligible release after 3 h. TH release was 
increased in the PEUU/TH-PLGA mixed nanofibers, with release being observed up to 96 h. 
PEUU/TH-PLGA nanofibers were able to inhibit the growth of E. coli for up to 7 days of 
incubation and prevented abscess formation and wound dehiscence in an abdominal model 
with fecal contamination in Lewis rats. 
3.2.2.2  Silver nanoparticles 
Silver (Ag) has been recognized as a strong antimicrobial compound for centuries and forms 
part of various commercial antimicrobial wound dressings (Zahedi et al., 2008). 
Electrospinning of Ag into nanofibers to generate antimicrobial nanomaterials is thus well 
established and actively researched by various groups. Son et al. (2006) incorporated silver 
nanoparticles (nAg) in cellulose acetate nanofibers by co-electrospinning with silver nitrate 
(AgNO3). Subsequent irradiation at 240 nm resulted in generation of nAg, with an average 
diameter of 21 nm, on the surface of the nanofibers. nAg-nanofibers showed strong 
antimicrobial activity towards S. aureus, E. coli, K. pneumoniae and P. aeruginosa after 18 h 
of incubation. Co-electrospun PCL and silver-loaded zirconium phosphate nanoparticles 
produced nanofibers that showed strong antimicrobial activity and was able to inhibit the 
growth of S. aureus and E. coli by 99.27% and 98.44%, respectively (Duan et al., 2007). 
Importantly, HDF were able to attach and proliferate when cultured on these scaffolds. 
Gelatin, co-electrospun with AgNO3, was subsequently cross-linked with glutaraldehyde to 
stabilize the nanofibers (Rujitanaroj et al., 2008). Ag
+
 from the gelatin nanofibers inhibited 
the growth of P. aeroginosa, S. aureus, E. coli and MRSA (Rujitanaroj et al., 2008). 
Antimicrobial nanofibers were also generated by co-electrospinning Nylon 6 with a nAg 
suspension (8 nm in diameter) (Park et al., 2009). Strong antimicrobial activity towards S. 
aureus and K. pneumonia was observed in a dose dependant manner, as the nAg content was 
increased from 100-1000 ppm in the nanofibers. PVA-nAg nanofibers were shown to inhibit 
E. coli growth (Liu et al., 2010). In another study PVA, co-electrospun with AgNO3, was 
cross-linked at 150 °C and needed UV irradiation to form nAg in the nanofibers (Chun et al., 
2010). PVA-nAg nanofibers however showed reduced adherence and proliferation of human 
epidermal keratinocytes and fibroblasts, indicating cytotoxicity of nAg. Ag
+
 ions and nAg 
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were both evenly cytotoxic and nitrate ions were also shown to effect cell adherence and 
proliferation.  
Cytotoxic effects of nAg have also been reported by other authors. nAg was shown to 
induce mitochondria-dependent apoptosis in NIH3T3 mouse fibroblasts (Hsin et al., 2008). 
Reactive oxygen species (ROS) formation and activation of c-Jun NH2-terminal kinases 
(JNK) was associated with nAg-induced apoptosis and subsequent inhibition of ROS and JNK 
inhibited apoptosis. nAg caused lung function changes and resulted in an increased 
inflammatory response when inhaled by Sprague-Dawley Rats (Sung et al., 2008). Thickened 
alveolar walls and small granulomatous lesions could be observed in exposed animals. nAg 
and gold nanoparticles (nAu) were shown to be cytotoxic towards J774 A1 murine 
macrophages and cytotoxicity increased as size of the particles decreased (Yen et al., 2009). It 
was however observed that nAg was not as toxic as nAu. nAg and nAu were observed inside 
the macrophages and it was hypothesized that the nanoparticles entered cells via endocytosis. 
nAg resulted in the formation of reactive oxygen species (ROS), reduced ATP, caused 
damage to mitochondria as well as DNA and resulted in cell cycle arrest (in G2/M phase) in 
human lung fibroblast cells (IMR-90) and human glioblastoma cells (U251) (AshaRani et al., 
2009). nAg were observed in endosomes near the cell membrane, in the cytoplasm, 
lysosomes, as well as in the nucleus of treated cells. nAg also seemed to enter cells via 
endocytosis. nAg also caused apoptosis in mouse peritoneal macrophages (RAW264.7) and 
nAg could be observed within the treated cells (Park et al., 2010). Later nAg was shown to 
exert cytotoxicity towards L929 fibroblasts and mouse peritoneal macrophage cells 
(RAW264.7), with the macrophages being more tolerant to nAg (Park et al., 2011). A recent 
study showed that polymer stabilizers could alter the cytotoxicity of nAg. Poly(oxyethylene)-
segmented imide (POEM), poly(styrene-co-maleic anhydride)-grafting poly(oxyalkylene) 
(SMA) and PVA was used as polymer stabilizers by Lin et al. (2012). SMA-nAg and PVA-
nAg showed lower cytotoxicity as compared to POEM-nAg, however cytotoxicity was still 
observed in a dose dependent manner in mouse skin fibroblasts (L929), human 
hepatocarcinoma cells (HepG2), and mouse monocyte macrophages (J774A1). Once again 
nAg entered L929 fibroblasts and HepG2 cells in a dose dependent manner. PVA-nAg 
showed no hemolysis up to 10 ppm, whereas POEM-nAg and SMA-nAg showed hemolysis at 
4 ppm and 6 ppm, respectively. Metallic silver in commercial wound dressings has also 
resulted in discoloration (blue-gray colour) of treated wounds (Jayakumar et al., 2012). Safety 
concerns thus exist with regards to long term safe usage of silver.  
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3.2.2.3  Analgesics and anti-inflammatory drugs 
Paracetamol has been co-electrospun into acid-labile fibers, prepared by reacting 3,9-
dimethylene-2,4,8,10-tetraoxaspiro [5.5] undecane with 1,10-decanediol or PEG with 
subsequent co-polymerization with D,L-lactide (Qi et al., 2008). Resulting fibers were 
designated PLAOED, PLAOEP and PDLA. Fibers were produced with mean diameters of 940, 
1490, and 1260 nm for PLAOED, PLAOEP and PDLA, respectively. Paracetamol was 
released from the fibers in a biphasic manner with an initial burst release, followed by a 
sustained release and release of paracetamol increased as pH decreased. PLAOED and 
PLAOE fibers released a higher percentage of paracetamol, compared to PDLA fibers. 
Diclofenac sodium (DS) was released from poly(ɛ-caprolactone/D,L-lactide) nanofibers with 
an initial burst, releasing up to 45% in 24 h (Nikkola et al., 2006). DS showed low total drug 
release with a high initial burst release in the first 1-1.5 h from PCL nanofibers (Kanawung et 
al., 2007). Ibuprofen also showed a burst release from PLGA nanofibers, releasing up to 85% 
over a 4 day period (Jiang et al., 2004). Ibuprofen release was improved by co-
electrospinning ibuprofen into PLGA-PEG-g-chitosan nanofibers and further improvements 
were obtained by covalent binding of ibuprofen to PLGA-PEG-g-chitosan nanofibers. 
Ketoprofen was co-electrospun into PVA nanofibers with subsequent incubation in methanol 
to cross-link the PVA nanofibers (Kenawy et al., 2007). PVA nanofibers cross-linked for 24 h 
showed a lower release profile, especially a lower initial burst release, as compared to PVA 
nanofibers cross-linked for 1 h and PVA nanofibers without cross-linking. Ketoprofen release 
was dependent on temperature and a higher total release was observed at 37 °C, compared to 
20 °C. Meloxicam was co-electrospun into PVA for transdermal delivery (Ngawhirunpat et 
al., 2009). Higher skin permeation was observed for meloxicam in meloxicam-loaded 
nanofibers, as compared to films, when skin permeation tests were conducted using shed 
snake skin of Elaphae obsolete. Skin permeation flux was shown to be time-dependent.  
3.2.2.4  Growth factors 
Epidermal growth factor (EGF) was slowly released from silk/PEO fibers in a time-dependent 
manner, with an initial burst release (Schneider et al., 2009). EGF-silk nanofibers promoted 
wound healing in a three-dimensional wound healing model and was able to increased re-
epithelialization and wound closure of model wounds.  
Nanofibers were electrospun from amine-terminated PCL-PEG/PCL with functional 
amine groups on the surface, to which recombinant EGF (rhEGF) was subsequently 
immobilized by chemical conjugation (Choi et al., 2008). Keratinocyte-specific gene (keratin 
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1 and loricrin) expression was upregulated when human primary keratinocytes (HPK) were 
cultured on rhEGF-PCL-PEG/PCL nanofibers and rhEGF-PCL-PEG/PCL nanofibers 
improved early wound healing in diabetic C57BL/6 mice. When rhEGF was added as solution 
on PCL-PEG/PCL nanofibers (i.e. not conjugated), it showed less promising results. In 
another study by Choi et al. (2011) amine-functionalized PCL/PEG block copolymers were 
electrospun using a co-axial electrospinning setup, forming the shell. The core consisted of a 
PVA solution containing basic fibroblast growth factor (bFGF). After electrospinning EGF 
was immobilized on the surface of the electrospun nanofibers, to generate scaffolds 
containing multiple growth factors (bFGF/EGF). Release of bFGF was observed from the 
fibers with a small initial burst release, followed by a sustained release whereas very low 
release, 2% in 7 days, was observed for the EGF. The bFGF/EGF nanofibers increased cell 
proliferation of HDF and HPK after 7 days of incubation. Increased wound healing in diabetic 
C57BL/7 mice treated with bFGF/EGF nanofibers was also observed at day 7. Nanofibers 
containing either bFGF or EGF also showed improved wound healing over plain nanofibers 
and controls. Wounds treated with bFGF/EGF nanofibers showed expression of keratin 1, 5 
and 14. The bFGF-nanofibers induced similar levels of expression of keratin 14 and a 75% 
lower expression of keratin 5, whereas EGF-nanofibers induced lower levels of keratin 5 and 
14 expression. This indicates that bFGF/EGF nanofibers resulted in remodeling of the wound 
into normal epidermis-like tissue (Choi et al., 2011).  
Two model proteins, BSA and epidermal growth factor (EGF), was encapsulated in 
electrospun fibers by first encapsulating the proteins into nanoparticles, mixing the particles 
and then subsequently electrospinning the solution into fibers (Dong, 2009) The proteins were 
found in different domains of the fibers. This method was also used to encapsulate dextran 
and BSA into electrospun fibers. The release of these compounds was not studied by the 
authors. 
3.2.2.5  Vitamins 
Vitamins play an important role in wound healing, where vitamin A plays a role in collagen 
synthesis and influencing epithelial differentiation, whereas vitamin C is essential in 
intracellular matrix of tissues (Zahedi et al., 2010). Vitamin A acid and vitamin E was 
successfully co-electrospun into cellulose acetate nanofibers for dermal delivery (Taepaiboon 
et al., 2007). Addition of vitamins did not alter fiber properties and fibers had diameters of 
253 and 247 nm, for vitamin A and vitamin E, respectively. An initial burst release of both 
vitamins was observed, followed by a sustained release with close to 100% being released in 
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acetate buffer containing 0.5 vol % Tween 80 and 10 vol % methanol over 6 h and 24 h, for 
vitamin A and vitamin E, respectively. Lower release profiles were obtained in acetate buffer 
containing 0.5 vol % Tween 80.  
3.2.2.6  Antifungals and herbal extracts 
Itraconazole, and antifungal agent, was co-electrospun into non-biodegradable PU fibers 
(Verreck et al., 2003). PU nanofibers with 10% itraconazole showed a linear drug release 
profile, whereas nanofibers containing 40% showed a biphasic release profile. 
Centella asiatica-herbal extract was co-electrospun into gelatin nanofibers, with 
subsequent cross-linking with glutaraldehyde vapour (Sikareepaisan et al., 2008). Centella 
asiatica is a medicinal plant widely known for its traditional medical applications including 
its wound healing ability (Sikareepaisan et al., 2008). Release of asiaticoside was measured, 
as this compound was identified as the most active in wound healing (Shukla et al., 1999). 
Asiaticoside was released from the fibers with a high initial burst release within the first 2 
days.  
 
4. Conclusion 
Wound healing is a complex process and infection can cause a delay in normal wound healing 
and recovery. Increased antibiotic resistance is becoming problematic and alternative 
antimicrobials can play an integral role in the future of successful wound treatment. 
Cytotoxicity of certain antimicrobials is of concern and alternatives need to be explored. 
Antimicrobial peptides, especially bacteriocins produced by Gram-positive bacteria, have 
enormous potential as next generation antimicrobials for treatment of various bacterial 
infections, including topical skin infections.  
A novel approach to generate antimicrobial wound dressings would be to co-
electrospin bacteriocins of LAB into nanofibers. Because of the large surface area to volume 
ratio, high amounts of bacteriocins could potentially be incorporated and can then directly be 
delivered to a site of infection. A controlled localized released of the bacteriocins can be 
obtained to inhibit and/or prevent the growth of pathogenic bacteria. These antimicrobial 
materials can have various applications, not only as wound dressing materials but also as 
coating for biomedical devices to combat device related infections. 
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Fig. 1 Classes of antibiotics introduced in the past (Fischbach and Walsh, 2009).  
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Fig. 2 Post-translational modification of nisin (A) and lacticin 481 (B). Nisin modification 
enzymes include two distinct enzymes responsible for dehydration and cyclization, whereas 
lacticin 481 is modified by one bifunctional enzyme (Cotter et al., 2005a). 
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Fig. 3 Mode of action of different bacteriocin classes (Cotter et al., 2005b). 
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Fig. 4 Electrospinning apparatus used in this study to generate nanofibers. 1-High voltage 
power supply, 2-capillary tube containing polymer solution and 3-collector with nanofibers 
visible. 
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Fig. 5 Electrospun PEO:PDLLA nanofibers (generated in this study) versus human hair. 
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AIMS OF THIS STUDY 
 
1. Evaluate the feasibility of co-electrospinning bacteriocins of lactic acid bacteria into 
nanofibers. 
 
2. Evaluate the feasibility of co-electrospinning viable L. plantarum 423 cells into 
nanofibers. 
 
3. Develop and characterize a suitable nanofiber drug delivery scaffold for bacteriocins 
of lactic acid bacteria. 
 
4. Evaluate the nanofiber drug delivery system as wound dressing material to treat S. 
aureus-induced skin infections in mice. 
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CHAPTER 3 
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Encapsulation of Lactobacillus plantarum 423 and its Bacteriocin in Nanofibers 
Abstract 
Plantaricin 423, produced by Lactobacillus plantarum 423, was encapsulated in nanofibers 
that were produced by the electrospinning of 18% (w/v) poly(ethylene oxide) (200 000 Da). 
The average diameter of the nanofibers was 288 nm. Plantaricin 423 activity decreased from 
51 200 AU/ml to 25 600 AU/ml and from 204 800 AU/ml to 51 200 AU/ml after 
electrospinning, as determined against Lactobacillus sakei DSM 20017
T
 and Enterococcus 
faecium HKLHS, respectively. Viable cells of L. plantarum 423 encapsulated in nanofibers 
decreased from 2.3 x 10
10
 cfu/ml before electrospinning to 4.7 x 10
8
 cfu/ml thereafter. Cells 
entrapped in the nanofibers continued to produce plantaricin 423. As far as we could 
determine this is the first report on the encapsulation of a bacteriocin and cells of L. 
plantarum in nanofibers. The method may be used to design a drug delivery system for 
bacteriocins and the encapsulation of probiotic lactic acid bacteria.  
Introduction 
Lactic acid bacteria (LAB) are generally regarded as safe and their antimicrobial peptides 
(bacteriocins) have been used in the preservation of many food products (De Vuyst and 
Vandamme, 1994). Various claims have been attributed to LAB with probiotic properties, e.g. 
reduction or prevention of gastrointestinal disorders, including inflammatory bowel disease, 
alleviation of lactose intolerance, lowering of serum cholesterol levels, stimulation of the 
immune system and control of tumor growth (Franz et al., 1999, Saarela et al., 2000) Some 
probiotic claims may be associated with the production of antimicrobial peptides 
(bacteriocins).  
 Bacteriocins are produced by many LAB, including species that are associated with 
humans, viz. the Lactobacillus acidophilus group (L. acidophilus, Lactobacillus amylovorus, 
Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus gasseri and Lactobacillus 
johnsonii), Lactobacillus reuteri, Lactobacillus casei, Lactobacillus fermentum and 
Lactobacillus plantarum (De Vuyst and Vandamme, 1994, Tahara and Kanatani, 1997). 
Many of the bacteriocins produced by these species are active against foodborne pathogens 
such as Listeria, Clostridium, Bacillus and Staphylococcus spp. (Schillinger et al., 1996).  
 The antimicrobial activity of bacteriocins in the gastrointestinal tract (GIT) is difficult 
to prove. Maré et al. (2006) showed that plantaricin 423 was produced by cells of L. 
plantarum 423 colonizing the ileum of piglets. Studies with real-time PCR have shown that 
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the gene encoding plantaricin 423 is constitutively expressed at conditions simulating the GIT 
(Ramiah et al., 2007). Different levels of plantaricin 423 production have also been recorded 
in each of the sections of a GIT model (Botes et al., 2008), supporting the hypothesis that 
plantaricin 423 may be produced in vivo. Plantaricin 423 inhibited the growth of Bacillus 
cereus, Clostridium sporogenes, Enterococcus faecalis, several Lactobacillus spp., 
Oenococcus oeni, Listeria innocua, Listeria monocytogenes, Pediococcus acidilactici, 
Pediococcus pentosaceus, Propionibacterium acidipropionici, Propionibacterium sp., 
Staphylococcus carnosum and Streptococcus thermophilus (van Reenen et al., 1998), and 
excluded Enterobacteriaceae, but not lactic acid bacteria, from the cecum and colon in Wistar 
rats (Ramiah et al., 2009).  
 Promising results were reported with lantibiotics regarding the control of pathogens in 
airways. Kruszewska et al. (2004) reported on growth repression of methicillin-resistant 
Staphylococcus aureus (MRSA) strains in the respiratory tract of mice with mersacidin, a 
lantibiotic produced by Bacillus sp. HIL Y-85,54728. Similar studies with nisin, a lantibiotic 
produced by Lactococcus lactis subsp. lactis, did not eradicate S. aureus from the nasal tract 
of rats (Kokai-Kun et al., 2003). Nisin F, a lantibiotic produced by L. lactis subsp. lactis, 
proved effective in the treatment of sinusitis in rats (de Kwaadsteniet et al., 2009), but less 
effective in treatment of skin infections in mice (de Kwaadsteniet et al., 2010). Reports on 
bacteriocins of LAB active against Gram-negative bacteria (Caridi, 2002, Ivanova et al., 
1998, Messi et al., 2001, Todorov and Dicks, 2005a,b) sparked a renewed interest in these 
peptides and their interaction with intestinal pathogens. Data generated from genome 
sequences of probiotic bacteria such as L. plantarum WCFS1, L. acidophilus NCFM and L. 
johnsonii NCC 533 (Alterman et al., 2005, Kleerebezem et al., 2003, Pridmore et al., 2004) 
and the application of DNA micro-array technology (de Vries et al., 2006) may provide 
valuable answers to in vivo gene expression.  
 Studies on the medical applications of bacteriocins need to be done under strictly 
controlled conditions, demanding the design of special drug delivery systems. In this chapter, 
a brief description of a novel drug delivery system for LAB and their bacteriocins are given.  
Materials and Methods 
Production and Isolation of Bacteriocins 
L. plantarum 423 was cultured in MRS broth (Biolab Diagnostics, Midrand, South Africa) at 
30 °C for 24 h. Cells were harvested (8000g, 10 min, 4 °C), the pH of the cell-free supernatant 
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adjusted to pH 6.5-7.0 with 1N NaOH and then heated at 80 °C for 10 min. Plantaricin 423 
was precipitated from the cell-free supernatant with 70% saturated ammonium sulfate 
(Sambrook et al., 1989) and desalted against distilled water by using a 1000 Da cutoff dialysis 
membrane (Spectrum Inc., CA, USA). The sample was freeze-dried and stored at -20 °C.  
 Bacteriocin activity tests were performed by using the agar-spot method described by 
van Reenen et al. (1998). Lactobacillus sakei DSM 20017
T
 and Enterococcus faecium 
HKLHS, cultured in MRS broth at 30 °C, were used as target strains. Antimicrobial activity 
was expressed as arbitrary units (AU) per ml. One AU was defined as the reciprocal of the 
highest dilution showing a clear zone of growth inhibition (van Reenen et al., 1998). 
Preparation of Nanofibers 
Poly(ethylene oxide) (PEO, 200 000 Da), obtained from Sigma-Aldrich (St. Louis, MO, 
USA), was dissolved (18%, w/v) in a solution of plantaricin 423 (204 800 AU/ml, as 
determined against E. faecium HKLHS) and carefully mixed. In another experiment, L. 
plantarum 423 was cultured at 37 °C for 24 h, harvested (8000g, 2 min) and the cells 
resuspended in sterile distilled water to ±2 x 10
11
 cfu/ml. From this suspension, 100 ul (2.3 x 
10
10
 cfu/ml) was mixed with 500 μl (18%, w/v) PEO dissolved in sterile distilled water.  
 The polymer solutions were each placed in a tapered sterile glass tube and fixed at a 
15° angle (Fig. 1). The positive electrode (cathode) was placed in the polymer solution, and 
the anode on a collector plate which was covered with sterile foil and positioned 15 cm from 
the cathode. A constant electric field of +10 kV was applied to the polymer solution and -5 
kV to the collector. The relative humidity was kept constant at 50% and the temperature at 25 
°C. Nanofibers, ejected from the tip of the tapered glass tube, were collected at the anode 
(Fig. 1). Nanofibers were coated with gold particles and visualized using a Leo
®
 1430VP 
Scanning Electron Microscope. The diameter of the nanofibers was determined by using the 
SEM Image Studio software (version 10.1). 
Evaluation of the Bacteriocin and Cell-Encapsulation in Nanofibers 
Nanofibers with plantaricin 423 were collected from the metal surface, and 25 mg suspended 
in 500 μl sterile distilled water by vigorous mixing on a vortex. The antimicrobial activity of 
the solution was determined by using the agar-spot method as described before. L. sakei DSM 
20017
T
 and E. faecium HKLHS served as target strains. The number of viable cells 
encapsulated in the nanofibers was determined by vortexing 25 mg fibers in 500 μl sterile 
saline (0.75%, w/v, NaCl). Serial dilutions were made in sterile saline and plated onto MRS 
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agar. Colonies were counted after 48 h of incubation at 37 °C. Plantaricin 423 production by 
encapsulated cells was evaluated by overlaying the colonies with E. faecium HKLHS 
embedded in MRS agar. The plates were incubated at 37 °C for 48 h and then inspected for 
formation of inhibition zones. 
Scanning Electron Microscopy of Lactobacillus plantarum 423 cells  
L. plantarum 423 was cultured, as described before, placed on a glass slide and air dried. 
Images of cells were recorded with a Leo
®
 1430VP Scanning Electron Microscope (SEM). 
Samples were coated with a thin layer of gold to increase conductivity for imaging. 
Results 
The activity of plantaricin 423 in the cell-free supernatant was recorded as 51 200 AU/ml 
against L. sakei DSM 20017
T
 and 204 800 AU/ml against E. faecium HKLHS. After 
electrospinning, the activity of plantaricin 423 in the nanofibers was 25 600 AU/ml against L. 
sakei and 51 200 AU/ml against E. faecium HKLHS (Fig. 2). The diameter of the fibers 
ranged from 169 nm to 465 nm, with a mean diameter of 288 nm (Fig. 3).  
 The cell numbers of L. plantarum 423 decreased from 2.3 x 10
10
 cfu/ml before 
electrospinning to 4.7 x 10
8
 cfu/ml thereafter, as determined by dissolving the fibers in sterile 
saline. Viable cells of L. plantarum 423 encapsulated in nanofibers and inhibition zones 
produced by encapsulated cells are presented in Fig. 5a and b, respectively.  
Discussion 
Several methods are used to produce ultrafine fibers, e.g. self assembly of polymers 
(Hartgerink et al., 2001, Nagai et al., 2006) template synthesis (Pender and Sneddon, 2000), 
phase separation (Tan and Lim, 2004) and electrospinning (Chew et al., 2005, Zhou et al., 
2008). Electrospinning is a versatile and relatively easy technique to produce large amounts of 
ultrathin fibers. During the electrospinning process, an electric field is applied to a polymer 
solution to form a Taylor cone (Taylor, 1969, Yarin et al., 2001). When the electric forces 
overcome the surface tension of the solution, a charged jet is ejected from the Taylor cone and 
accelerates toward the collector. The solvent evaporates and nanofibers are formed (Agarwal 
et al., 2008, Liang et al., 2007). The quality and characteristics of the final product are 
determined by the elasticity, viscosity, temperature, conductivity and surface tension of the 
polymer solution, strength of the electric field, distance between the Taylor cone and 
collector, and humidity (Huang et al., 2003, Liang et al., 2007).  
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Electrospinning has been used to incorporate antibiotics (Kenawy et al., 2002, Zeng et al., 
2003), growth factors, proteins (Chew et al., 2005, Li et al., 2008, Maretschek et al., 2008) 
and silver nanoparticles (Son et al., 2006). As far as we could determine, we are the first to 
report on the encapsulation of viable cells of L. plantarum and a bacteriocin. The slight 
decrease in antimicrobial activity of plantaricin 423 recorded after electrospinning could be 
due to the high voltage applied. However, Kim et al. (2007) have reported only a slight 
decrease (10%) in the activity of lysozyme after electrospinning. Human β-nerve growth 
factor released from electrospun fibers was still able to differentiate PC12 cells into neurons 
(Chew et al., 2005).  
 Judged from the decrease in cell numbers (from 2.3 x 10
10
 cfu/ml before 
electrospinning to 4.7 x 10
8
 cfu/ml when encapsulated), only 2% of the L. plantarum survived 
after encapsulation into nanofibers (Fig. 5). A higher percentage of cells might have been 
encapsulated, but could have been damaged by the high voltage, sudden change in osmotic 
pressure and whipping or shearing action of electrospinning. It is also possible that cells could 
have lost their viability after encapsulation. Only 0.1% of Escherichia coli cells encapsulated 
in PEO nanofibers survived, whereas 74% of Micrococcus luteus cells survived 
electrospinning (Gensheimer et al., 2007). It would seem as if smaller cells and Gram-positive 
bacteria are more resistant to electrospinning. Further research is needed to determine the 
exact fate of the cells. The small size of the fibers and the large surface to volume ratio 
provide for encapsulation of high cell numbers, thus compensating for the loss in viability. 
 In this chapter the feasibility of encapsulating lactic acid bacteria and bacteriocins into 
electrospun nanofibers was demonstrated. Encapsulation of bacteriocin-producing cells and 
cells with probiotic properties may have specific food and medical applications. Through 
careful selection of polymers, higher concentrations of bacteriocins and higher cell numbers 
may be spun into nanofibers.  
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Fig. 1 Schematic representation of the electrospinning process with a high voltage supply, 
tapered glass tube and collector. 
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Fig. 2 Activity of plantaricin 423 encapsulated in PEO nanofibers. The sensitive strains were 
(A) E. faecium HKLHS and (B) L. sakei DSM 20017
T
. 1-Plantaricin 423 before 
electrospinning (positive control), 2-Plantaricin 423 after electrospinning and 3-PEO polymer 
suspension (negative control). 
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Fig. 3 (A) SEM image of 18% (w/v) PEO nanofibers co-electrospun with plantaricin 423. (B) 
Variation of nanofiber sizes, ranging from 169 nm to 465 nm in diameter. Most nanofibers 
were in the 250 to 300 nm range (mean diameter = 288 nm). 
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Fig. 4 SEM image of L. plantarum 423 cells. 
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Fig. 5 (A) Viable cells of L. plantarum 423 encapsulated in 18% (w/v) PEO nanofibers, 
clearly showing a “bead” structure where cells were entrapped. (B) Growth inhibition of E. 
faecium HKLHS by plantaricin 423 produced from encapsulated cells.  
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Release of Bacteriocins from Nanofibers Prepared with Combinations of Poly(D,L-
lactide) (PDLLA) and Poly(Ethylene Oxide) (PEO) 
Abstract  
Plantaricin 423, produced by Lactobacillus plantarum 423, and bacteriocin ST4SA, produced 
by Enterococcus mundtii ST4SA, were electrospun into nanofibers prepared from different 
combinations of poly(D,L-lactide) (PDLLA) and poly(ethylene oxide) (PEO) dissolved in 
N,N-dimethylformamide (DMF). Both peptides were released from the nanofibers with a high 
initial burst and retained 88% of their original antimicrobial activity at 37 °C. Nanofibers 
have the potential to serve as carrier matrix for bacteriocins and open a new field in the 
development of controlled antimicrobial delivery systems for various applications.  
Introduction 
Bacteriocins (ribosomally synthesized antimicrobial peptides) and bacteriocin-like inhibitory 
substances (BLIS) are produced by several species of bacteria, including lactic acid bacteria 
that are generally recognized as safe (Cotter et al., 2005, Dicks et al., 2009, Todorov and 
Dicks, 2005). Bacteriocins are diverse peptides and can be divided into the Class I 
(lanthionine-containing post-translationally modified bacteriocins), Class II (non-lanthionine-
containing bacteriocins that do not undergo extensive post-translational modification) and the 
bacteriolysins (Cotter et al., 2005). Each of these groups can be further sub-divided. 
Bacteriocins are membrane active peptides and most form pores in the cell membranes of 
sensitive bacteria due to the cationic and amphiphilic nature of these peptides, however there 
are exceptions (Bauer and Dicks, 2005). Pore formation leads to the disruption of the proton 
motive force (PMF) and the efflux of intracellular material (Knoetze et al., 2008). 
Bacteriocins can have a narrow (active against closely related species) or broad spectrum of 
activity (Jack et al., 1995, Kleanhammer, 1993). Class Ia bacteriocins, or lantibiotics, use 
lipid II as target for their mode of action and kill sensitive bacteria by pore formation, or by 
hampering cell wall formation (McAuliffe et al., 2001). Lantibiotics can also inhibit the 
germination of spores (McAuliffe et al., 2001) Class IIa, or pediocin-like bacteriocins, mainly 
form pores in the membranes of sensitive cells (Cotter et al., 2005). 
More than 95% of Staphylococcus aureus isolates are resistant to penicillin. Of these, 
60 to 70% are resistant to methicillin (Kim, 2009). A few bacteriocins are active against 
methicillin-resistant strains of S. aureus (MRSA), and versus other bacteria of interest in 
human health, such as Pseudomonas aeruginosa, Streptococcus pneumonia and vancomycin-
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resistant enterococci (Chatterjee et al., 1992, Galvin et al., 1999). Bacteriocin ST4SA, 
produced by Enterococcus mundtii ST4SA, is a class IIa bacteriocin and is active against 
several pathogens, including Acinetobacter baumannii, P. aeruginosa, S. pneumonia, S. 
aureus and Enterococcus faecium (Knoetze et al., 2008). Bacteriocin ST4SA survived 
conditions in the animal gastro-intestinal tract (Dicks and ten Doeschate, 2010, Ramiah et al., 
2009) and was constitutively expressed (Granger et al., 2008). Nisin F, produced by 
Lactococcus lactis subsp. lactis F10, was effective in the treatment of S. aureus in respiratory 
tract infections (de Kwaadsteniet et al., 2009). Plantaricin 423, produced by Lactobacillus 
plantarum 423, displaced Clostridium sporogenes and Enterococcus faecalis from Caco-2 
cells (Ramiah et al., 2008). Plantaricin 423 is also a class IIa bacteriocin and shows activity 
against Bacillus cereus, C. sporogenes, E. faecalis, Lactobacillus brevis (Lactobacillus spp.), 
Listeria innocua, Listeria monocytogenes, Propionibacterium sp., Propionibacterium 
acidipropionic and Staphylococcus carnosum (van Reenen et al., 1998). Bacteriocins may 
thus offer an alternative to control bacterial infections, administered alone or in combination 
with antibiotics (Knoetze et al., 2008). The challenge would be to protect bacteriocins from 
proteolytic enzymes, keep the peptides in contact with the infected surface and extend the 
contact time for as long as possible. 
Electrospun nanofibers, prepared from selected polymers, may be used as carrier 
matrix for bacteriocins and other antimicrobial peptides (Heunis and Dicks, 2010). Nanofibers 
have been used to release antibiotics, proteins, growth factors, silver nanoparticles, plasmid 
DNA, as well as viable cells (Chew et al., 2005, Heunis and Dicks, 2010, Heunis et al., 2010, 
Kenawy et al., 2002, Kim et al., 2004, 2007, López-Rubio et al., 2009, Luu et al., 2003, 
Maretschek et al., 2008, Rujitanaroj et al., 2008). Specific structures can be designed, such as 
oxygen permeable membranes, matrices with a high surface to volume ratio and scaffolds that 
are morphologically similar to the extracellular matrix (Li et al., 2002, Smith and Ma, 2004, 
Yang et al., 2005, Zeng et al., 2003, Zhou et al., 2008). 
In this chapter the feasibility of electrospinning bacteriocins into nanofibers consisting 
of polymer blends was investigated, as well as the potential of the nanofibers to serve as a 
delivery system for the bacteriocins. Plantaricin 423 and bacteriocin ST4SA were used as 
model bacteriocins (class IIa) in this study. These bacteriocins were dissolved in N,N-
dimethylformamide (DMF) and electrospun into biodegradable nanofiber blends of poly(D,L-
lactide) (PDLLA) and poly(ethylene oxide) (PEO). The nanofiber scaffolds were evaluated 
(in vitro) for the release of the peptides and antimicrobial activity. 
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Materials and Methods 
Isolation of Antimicrobial Peptides 
L. plantarum 423 and E. mundtii ST4SA were cultured, separately, in MRS broth (Biolab, 
Biolab Diagnostics, Midrand, South Africa) for 24 h at 37 °C. Cells were harvested (8000g, 
10 min, 4 °C), the pH of the cell-free supernatant adjusted to between pH 6.5-7.0 with 10M 
NaOH and then heated at 80 °C for 10 min to inactivate proteolytic enzymes. Peptides were 
precipitated from the cell-free supernatant with 70% saturated ammonium sulfate (Sambrook 
et al., 1989) and desalted against distilled water by using a 1000 Da cut-off dialysis 
membrane (Spectrum Inc., CA, USA). Protein concentrations were determined by using the 
Micro-bicinchoninic Acid (BCA) kit (Pierce, Rockford, IL). Readings were recorded at 562 
nm. Samples were freeze-dried and stored at -20 °C. 
Electrospinning of Nanofibers 
Freeze-dried peptides were dissolved in N,N-dimethylformamide (DMF) and centrifuged 
(6000g, 1 min) to obtain the supernatants. From each of these supernatants, 2 ml was used as 
solvent for poly(D,L-lactide) (PDLLA, 75 000-120 000 Da, Sigma-Aldrich) blended with 
poly(ethylene oxide) (PEO, 200 000 Da, Sigma-Aldrich) (20-24%, w/v,) at a ratio of 10:90, 
30:70 and 50:50, respectively. Solutions were heated to 40 °C on a hot plate and then 
electrospun using a gravity system described by (Heunis et al., 2010). A constant electric field 
of +10 kV was applied to the polymer solution and -5 kV to the collector. The collector was 
placed 15 cm from the polymer solution. The relative humidity was kept constant between 50-
55%. 
Scanning Electron Microscopy of Electrospun Fibers  
Images of the nanofibers were recorded with a Leo
®
 1430VP Scanning Electron Microscope 
(SEM). Samples were coated with a thin layer of gold to increase conductivity. Fiber 
diameters were determined by using the SEM Image Studio Software (version 10.1). 
Fluorescent Labeling of Antimicrobial Peptides and Polymers 
Freeze-dried plantaricin 423 (20 mg) was suspended in 1 ml DMF and the supernatant was 
reacted with 20 mg rhodamine B isothiocyanate (RBITC) or fluorescein isothiocyanate 
(FITC) from Sigma-Aldrich, dissolved in the same volume. The solution was placed on an 
orbital shaker and incubated in the dark at 4 °C for 48 h. Unbound fluorescent marker was 
removed by dialyzing against sterile distilled water for 3 weeks at 4 °C. Dialyses bags with 
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1000 Da cut-off were used. Labeled peptides were freeze-dried, dissolved in DMF and 
electrospun into nanofibers as described before. 
PEO (0.2048 mg) was dissolved in 2 ml sterile distilled water containing RBITC (20 
mg/ml). The polymer solution was placed on an orbital shaker and incubated in the dark at 25 
°C for 48 h. Unbound fluorescent marker was removed through dialysis as described before 
and labeled PEO was freeze-dried. PDLLA (0.2048 mg) was dissolved in 2 ml DMF and was 
labeled with FITC (20 mg/ml) for 48 h on an orbital shaker and incubated in the dark at 25 
°C.  
The labeled peptides and polymer solutions were electrospun into nanofibers as 
described before. Nanofibers were excited at 472 nm and 572 nm, respectively, by using a 
Xenon-Arc burner light source (Olympus Biosystems GMBH). Fluorescent images were 
captured with an Olympus Cell^R system attached to an IX-81 inverted fluorescent 
microscope. An Olympus Plan Apo N 60×/1.4 Oil objective was used. Images were taken 
with an F-view-II cooled CCD camera (Soft Imaging Systems) and the background subtracted 
using the Cell^R imaging software. 
Differential Scanning Calorimetry (DSC) 
Thermal analysis was carried out with a TA Q100 Differential Scanning Calorimeter (DSC) 
(TA Instruments) which was calibrated against an indium standard. An empty aluminium pan 
was the reference. Fiber samples (15-18 mg) were run at a 10 °C/min in three cycles under 
nitrogen atmosphere (flow rate 50 ml/min). In the first cycle, samples were heated from -80 
°C to 180 °C and isothermed for 1 min, cooled back to -80 °C and isothermed for 5 min. 
Finally, the samples were heated for a second time at 10 °C/min to 180 °C. The crystalline 
melting temperature (Tm) and the glass transition temperature (Tg) were recorded in the 
second heating cycle. 
Release of Antimicrobial Peptides and Degradation of Nanofibers 
Nanofibers (25 mg) were placed in 2 ml sterile phosphate buffered saline (PBS, pH 7.4) and 
incubated at 37 °C on an orbital shaker (30 rpm). At pre-determined time intervals the PBS 
was replaced with 2 ml sterile PBS (pH 7.4). The protein concentration in each sample was 
determined by using the BCA protein assay kit as described before. The initial concentration 
of bacteriocin in the nanofibers was determined by dissolving 25 mg fibers in DMF. This 
suspension was diluted in PBS 7.4 before the protein concentration was determined by using 
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the BCA protein assay kit as described before. Nanofibers were freeze-dried and then 
visualized by SEM. Changes in the weight of nanofibers were recorded. 
Antimicrobial Activity Tests 
Enterococcus faecium HKLHS (lab culture collection) was cultured in MRS broth at 37 °C 
for 24 h. Listeria monocytogenes EGD-e (obtained from Dr. Colin Hill, Cork, Ireland) was 
cultured in Listeria enrichment broth (Merck, Germany), supplemented with chloramphenicol 
(7.5 μg/ml), at 37 °C for 24 h. Both strains were used as sensitive organisms in antimicrobial 
determinations. Antimicrobial activity of the PEO 50:PDLLA 50 blend was determined using 
a modified Kirby Bauer method. Sections of approximately 1 cm
2
 nanofibrous membrane 
were placed on agar plates seeded either with E. faecium HKLHS or L. monocytogenes EGD-
e. The plates were incubated at 37 °C for 24 h and then inspected for the presence of 
inhibition zones. In a separate experiment, 25 mg of PEO 50:PDLLA 50 nanofibers, 
containing plantaricin 423, was placed in 50 ml MRS broth, inoculated with E. faecium 
HKLHS (10
5
 cfu/ml) and incubated at 37 °C for 12 h. Changes in optical density readings 
were recorded at 600 nm. Activity of bacteriocins after electrospinning was determined by 
placing 25 mg of PEO 50:PDLLA 50 nanofibers containing either plantaricin 423 or 
bacteriocin ST4SA, separately, in PBS pH 7.4 and incubated for 18 h at 37 °C. Released 
bacteriocin concentration was determined by BCA as previously described, diluted and 10 µl 
spot on plates seeded with E. faecium HKLHS. Plates were incubated at 37 °C for 24 h and 
then inspected for the presence of inhibition zones. Plantaricin 423 and bacteriocin ST4SA 
not electrospun served as controls. 
Results 
Nanofibers produced from blends of PEO and PDLLA, containing plantaricin 423, have a 
regular texture and smooth surface, as revealed by scanning electron microscopy (Fig. 1). The 
PEO 90:PDLLA 10 blend produced fibers ranging from 200 to 450 nm, with most of the 
fibers in the 300-350 nm range (Fig. 1F). Fibers with similar dimensions were produced from 
the PEO 50:PDLLA 50 blend (Fig. 1D). Fibers with slightly less variation (200-400 nm) and 
mostly in a smaller size range (250-300 nm) were produced from the PEO 70:PDLLA 30 
blend (Fig. 1E). Mean fiber diameters ranged from 361 ± 83, 286 ± 34 and 336 ± 32 nm for 
the PEO 90:PDLLA 10, PEO 70:PDLLA 30 and PEO 50:PDLLA 50 blend, respectively.  
Fluorescent microscopy images have shown that PEO and PDLLA are homogenously 
distributed in the fiber structure and indicate a large degree of miscibility when used in a 
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50:50 combination (Fig. 2). This blend was selected based on characteristics best suited for a 
drug delivery system, as discussed in this chapter. 
It can be seen that the DSC curve of the PEO 50:PDLLA 50 blend yielded a single 
glass transition temperature (Tg) of 9 °C, which falls between the Tg values recorded for PEO 
(-54 °C) and PDLLA (49 °C) (Fig. 3). DSC curves provide a good indication of the 
macromolecular nature of the polymer, i.e., crystallinity, Tg and crystalline melting point. In 
our study, PDLLA had no melt endothermic response as expected from an amorphous 
polymer, contrary to PEO where a melting endotherm was recorded at 64 °C. From the insert 
in Fig. 3, it is evident that a single Tg was detectible at 9 °C, which falls between both Tgs of 
PEO (-54 °C) and PDLLA (49 °C). It is therefore suggested that the blend is miscible in the 
amorphous phase. DSC analysis was also performed on the PEO 50:PDLLA 50 blend, 
containing plantaricin 423, and the Tg value decreased from 9 °C (in the blend without 
peptide) to -12 °C. This Tg was still between that of the component polymers and therefore 
also suggested to be miscible in the amorphous phase. 
Fluorescently labeled plantaricin 423 was electrospun into nanofibers prepared from a 
PEO 50:PDLLA 50 blend. The bacteriocin was unevenly distributed in these fibers, indicating 
that the peptide has better interaction with one of the polymers (Fig. 4). Due to the 
amphiphilic nature of bacteriocins, we expected the peptide to show better association with 
one of the two polymers. Fluorescent images of nanofibers prepared from a PEO 50:PDLLA 
50 blend are shown in Fig. 5. Signals of the plantaricin 423 and PEO are overlapping (Fig. 
5C), suggesting that the peptide is associated with the polymer. This was verified with the co-
localization of the signals (Fig. 5E). These results were confirmed with fluorescent images of 
labeled plantaricin 423 and PDLLA. Green and red fluorescent signals could still be 
differentiated in the overlay, indicating that the peptide is closer associated with PEO. These 
results were supported with much less co-localization seen between the signals from the 
fluorescently labeled PDLLA and plantaricin 423 (Fig. 5J). From cumulative release studies, 
it is evident that the PEO 90:PDLLA 10 blend released the highest concentration (78%) of 
plantaricin 423 (Fig. 6). An initial release of 46% was recorded within the first 2 h, followed 
by 32% over the following 8 days (Fig. 6). This could be ideal in the control of infections. A 
rapid release of antimicrobial peptides during the first 2 h would kill most of the pathogens, 
whereas a slow and constant release over the following few days would keep infection under 
control. The PEO 70:PDLLA 30 and PEO 50:PDLLA 50 blends yielded less promising 
results with 69% and 60% of the peptides being released over 8 days (Fig. 6). 
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SEM images taken from PEO 50:PDLLA 50 nanofibers, containing plantaricin 423, after 8 
days of incubation in PBS buffer (pH 7.4) did not reveal any significant structural changes or 
signs of deterioration of the fibrous structure (Fig. 7I-L), suggesting that these nanofiber 
scaffolds would be stable for at least 8 days. Slight textural changes have been recorded for 
the PEO 70:PDLLA 30 blend, containing plantaricin 423, after 8 days (Fig. 7E-H). However, 
significant morphological changes and signs of deterioration were observed for nanofibers 
prepared from the PEO 90:PDLLA 10 blend, containing plantaricin 423 (Fig. 7A-D). Fibrous 
structures were visible, but most of the nanofibers formed a film-like structure after 2 h. 
Nanofibers prepared from the PEO 90:PDLLA 10 blend showed high weight loss within the 
first few hours with only 24% of the original weight remaining. Eighty percent weight loss 
was seen over 8 days at 37 °C, whereas nanofibers prepared from the PEO 70:PDLLA 30 and 
PEO 50:PDLLA 50 blends lost approximately 60% and 40% of their original weight, 
respectively (Fig. 8). 
A clear zone of growth inhibition was recorded surrounding PEO 50:PDLLA 50 
nanofibers for at least 6 days (Fig. 9). This suggested that the nanofibers retained their 
antimicrobial activity for at least 6 days on solid medium. The peptides retained 88% of their 
original antimicrobial activity after 18 h of incubation at 37 °C in PBS pH 7.4. As little as 25 
mg nanofibers inhibited the growth of E. faecium HKLHS in 50 ml MRS broth for up to 10 h, 
whilst cells in the control (without nanofibers) reached stationary phase after 10 h (Fig. 10). 
Discussion 
Electrospinning is a versatile technique to produce large amounts of fibers, in the micrometer 
to nanometer range, in a short amount of time. A variety of natural and synthetic polymers 
have been electrospun into fibers and some have been used to control the release of various 
compounds (Chew et al., 2005, Kim et al., 2007, Maretschek et al., 2008, Min et al., 2004, 
Zhou et al., 2008). Blending hydrophilic and hydrophobic polymers directly in a suitable 
solvent before electrospinning is an easy way to change the hydrophobicity, thermal stability 
and mechanical strength of the fibers (Nijenhuis et al., 1996). Since blending is an attractive 
way to modify polymer properties, this method was chosen to modify the 
hydrophobicity/hydrophilicity of the electrospun fibers by the addition of PEO, to help 
facilitate the release of the bacteriocin from the nanofibers (See addendum 1).  
Fibers were all in the nanometer range and addition of bacteriocin did not influence 
the fiber structure as can be seen in Fig. 1. 
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Polymers were labeled to elucidate fiber morphologies after electrospinning. Fluorescent 
microscopy images showed that there is a large degree of miscibility between the PEO and 
PDLLA when these polymers are used in a 50:50 combination (Fig. 2). However, to confirm 
these results and to determine the miscibility of the polymers, DSC analysis was performed 
on the PEO 50:PDLLA 50 fiber blend, see Fig. 3. This fiber blend was chosen as it retained 
its structure the best, had the least amount of weight loss and still released enough bacteriocin 
to inhibit the growth of a sensitive strain. Nijenhuis et al. (1996) have studied thermal 
properties using DSC of polymer blends containing various ratios of PEO and the poly(L-
lactide) (PLLA) isomer. The results showed that blends containing up to 50 wt% PEO were 
miscible in the amorphous phase. In this work, PDLLA which is an amorphous grade unlike 
the semi crystalline poly(D-lactide) PDLA was used. A good indication of a miscible polymer 
blend is the shift of the Tg to a value between the Tgs of the pure polymers. The Tg value of a 
mixed phase is determined by the weight fraction of each polymer in that phase, and by the 
Tgs of the pure polymers. DSC curves of the second heating cycle of the PEO 50:PDLLA 50 
blend and the corresponding homopolymers are shown in Fig. 3. A single Tg (9 °C) can be 
seen that is between the Tg values for PEO (-54 °C) and PDLLA (49 °C) which suggests that 
the PEO 50:PDLLA 50 blend is miscible in the amorphous phase. DSC analysis performed on 
the PEO 50:PDLLA 50 blend, containing plantaricin 423, revealed that the Tg value still fell 
between the Tg of the component polymers and is therefore still miscible to an extent. It could 
be due to the peptide that is more associated with the PEO domains or simply restricting chain 
mobility. Investigation of the distribution of bacteriocins in the final fiber structure after 
electrospinning could yield important information in designing polymeric drug delivery 
systems for these peptides. 
Fluorescent microscopy images revealed that the bacteriocin was better associated 
with PEO than with PDLLA, even though the peptide was associated with both these 
polymers (Fig. 5). Bacteriocins are amphiphilic peptides with both hydrophilic and 
hydrophobic residues (Cotter et al., 2005). Because of this amphiphilic nature it is possible 
for the peptide to interact better with one polymer than with the other. These results indicate 
that the bacteriocin is better associated with the hydrophilic polymer, in this case PEO, but 
were also associated with the PDLLA to a lesser extent. This would explain the high initial 
burst release within the first few hours.  
Cumulative release studies revealed that nanofibers with a higher PEO content showed 
a higher release of the bacteriocin than those with a lower PEO content (Fig. 6). An initial 
burst release was seen within 2 h, after which a more sustained release was seen. This could 
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be an ideal release profile in the control of infections. A rapid release of antimicrobial 
peptides during the first 2 h would kill most of the pathogens, whereas a slow and constant 
release over the following few days would keep infection under control. The PEO 70:PDLLA 
30 and PEO 50:PDLLA 50 blends released lower amounts of the peptide, with the PEO 
70:PDLLA 30 and PEO 50:PDLLA 50 blends releasing 69% and 60% of plantaricin 423, 
respectively (Fig. 6). Blends of different polymers have earlier shown to facilitate the release 
of molecules from electrospun fibers. Lysozyme release from nanofibers was facilitated by 
blending PEO and poly(ε-caprolactone) (PCL), with a 90:10 blend releasing most of the 
lysozyme with a high initial burst release (Kim et al., 2007). Higher concentrations of 
cytochrome C were also released from fibers consisting of poly(L-lactide) PLLA and high 
concentrations of both poly(L-lysine) (PLL) and poly(ethylene imine) (PEI), respectively 
(Maretschek et al., 2008). Fibers containing 50% PLL released most of the protein (75%) 
with a high initial burst release. 
SEM images revealed that as the PEO content increased, significant morphological 
changes can be seen as the incubation time increased (Fig. 7) The PEO 90:PDLLA 10 blend 
showed the most significant morphological changes over the 8 day period. This could be due 
to the high content of PEO in the nanofibers as PEO swells readily in an aqueous environment 
and dissolves easily. The resulting destruction of the nanofiber scaffold explains the higher 
release of plantaricin 423 as observed over 8 days (Fig. 6). Nanofibers retained their structure 
better in the PBS buffer (pH 7.4), as the PEO content decreased. This can be observed in the 
PEO 50:PDLLA 50 blend, with this blend showing no significant signs of structural changes 
or deterioration in the buffer medium (Fig. 7I-L). Slight structural changes were seen for the 
PEO 70:PDLLA 30 blend after 8 days (Fig. 7E-H). These results suggest that the PEO 
50:PDLLA 50 blend nanofibers would be stable for at least 8 days and show no significant 
signs of degradation. The ideal nanofiber drug delivery systems has to retain its structure, 
have high oxygen permeability, variable pore size and a high surface to volume ratio. 
Nanofibers prepared from the PEO 90:PDLLA 10 blend showed very high weight loss over 
the 8 day period, which is not very desirable (Fig. 8). The PEO 70:PDLLA 30 showed lower 
weight loss, however the PEO 50:PDLLA 50 showed the best results and lost the least amount 
of its original weight (Fig. 8). It is very important that the nanofiber scaffolds retain their 
integrity and with this in mind, the PEO 50:PDLLA 50 would be the preferred choice as drug 
delivery system in this work. 
Bacteriocins retained their activity after electrospinning and were able to inhibit the 
growth of a sensitive strain on solid media as well as in liquid broth (Fig. 9 and 10). The 
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bacteriocins showed activity on the solid media for at least 6 days of consecutive transfer. 
Growth inhibition in liquid broth was observed and may be obtained over longer periods of 
time by electrospinning higher concentrations of bacteriocin in the nanofibers, by using more 
nanofibers (weight), or by replacing the nanofibers in the broth with new nanofibers at certain 
time intervals. Only 25 mg of nanofibers, containing plantaricin 423, was able to inhibit 
actively growing cells of E. faecium HKLHS, indicating the potent antimicrobial effect of this 
bacteriocin. The difference in antimicrobial activity and release on solid media and in liquid 
broth gives an indication that there is a big difference in release profile on solid media and in 
a buffer/liquid medium. During release studies in a buffer medium, a high concentration 
gradient is created (such as in the case of the method used for determining release) by 
replacing the old buffer with new buffer at each sampling point. This can increase the rate of 
diffusion of the peptide from the nanofiber scaffold to the buffer medium. The detection limit 
of the protein assay is also in µg/ml, whereas the bacteriocins could still be active at lower 
concentrations of ng/ml. However, the concentration gradient can be much lower on solid 
media, resulting in lower release profiles and thus leads to increased periods of antimicrobial 
activity. 
Bacteriocins remained active after electrospinning into nanofiber scaffolds. This 
technique provides the option to electrospin high concentrations of antimicrobial peptides into 
nanofibers. The rate at which these peptides are released is controlled by selection of the 
correct combination of polymers. The degradation rate and mechanical properties of PDLLA 
can be improved by blending with a hydrophilic polymer such as PEO. Antimicrobial 
peptides electrospun into nanofibers may have potential applications in the pharmaceutical 
and food industries to control microbial growth. 
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Fig. 1 SEM images of electrospun nanofibers containing plantaricin 423 (A-C) and fiber 
diameter distributions of the electrospun nanofibers (D-F). (A and D) PEO 50:PDLLA 50 (B 
and E) PEO 70:PDLLA 30 (C and F) PEO 90:PDLLA 10. 
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Fig. 2 Fluorescent images of PEO and PDLLA labeled with RBITC and FITC, respectively. 
(A) Fluorescent image of PEO, (B) fluorescent image of PDLLA, (C) overlay of the 
fluorescent signals, (D) optical image of nanofibers with fluorescent signals and (E) co-
localization of the two signals, indicating miscibility between PEO and PDLLA. 
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Fig. 3 Differential Scanning Calorimetric (DSC) thermogram of the PEO 50:PDLLA 50 
blend, as well as the component polymers, PEO and PDLLA. 
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Fig. 4 Fluorescent images of plantaricin 423 labeled with RBITC and electrospun into 
nanofibers consisting of PEO 50:PDLLA 50. (A) Fluorescent image of plantaricin 423 labeled 
with RBITC, (B) optical image of nanofibers and (C) optical image of nanofibers with 
fluorescent signal. 
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Fig. 5 Fluorescent images of labeled plantaricin 423 and polymers electrospun into nanofibers 
consisting of PEO 50:PDLLA 50. (A) Fluorescent image of PEO labeled with RBITC, (B) 
fluorescent image of the bacteriocin labeled with FITC, (C) overlay of the fluorescent images, 
(D) optical image of nanofibers with fluorescent signals, (E) co-localization of the signals, (F) 
fluorescent image of bacteriocin labeled with RBITC, (G) fluorescent image of PDLLA 
labeled with FITC, (H) overlay of the two fluorescent images, (I) optical image of nanofibers 
with fluorescent signals and (J) co-localization of the two signals. 
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Fig. 6 Cumulative release of plantaricin 423 from electrospun PEO:PDLLA nanofiber blends. 
These nanofibers showed a high initial burst release and a more sustained release of 
bacteriocin over an 8-day period. 
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Fig. 7 SEM images of PEO:PDLLA blend nanofibers, containing plantaricin 423, incubated 
in PBS buffer pH 7.4 for different time intervals. Significant morphological changes are seen 
in the PEO 90:PDLLA 10 blend (A-D). The PEO 70:PDLLA 30 blend showed some 
morphological changes, however, the fiber structure stayed more or less intact (E-H). The 
PEO 50:PDLLA 50 blend showed very little morphological changes and the nanofiber 
structure stayed intact (I-L).  
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Fig. 8 Percentage of original weight of nanofibers remaining after incubation at 37 °C for 8 
days.  
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Fig. 9 Antimicrobial activity tests of PEO 50:PDLLA 50 blend nanofibers containing 
plantaricin 423 (A) and bacteriocin ST4SA (B). Modified Kirby Bauer tests were performed 
by placing approximately 1 cm
2
 of fiber on plates seeded with target strains. E. faecium 
HKLHS and L. monocytogenes EGD-e served as target strains for plantaricin 423 and for 
bacteriocin ST4SA, respectively. A clear zone of inhibition can be seen surrounding the fibers 
containing bacteriocins after incubation. 1-PEO 50:PDLLA 50 blend nanofibers containing 
plantaricin 423, 2-PEO 50:PDLLA 50 blend nanofibers without plantaricin 423, 3-PEO 
50:PDLLA 50 blend nanofibers containing bacteriocin ST4SA and 4- PEO 50:PDLLA 50 
blend nanofibers without bacteriocin ST4SA. 
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Fig. 10 Growth inhibition of E. faecium HKLHS by PEO 50:PDLLA 50 blend nanofibers 
releasing plantaricin 423. 
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Evaluation of a Nisin-eluting Nanofiber Scaffold to Treat S. aureus-Induced Skin 
Infections in Mice 
Abstract 
Antibiotic resistance amongst pathogens is increasing and alternative treatments need to be 
explored. An antimicrobial nanofiber wound dressing was produced by co-electrospinning 
nisin into poly(ethylene oxide) and poly (D,L-lactide) (50:50) blend nanofibers. Active nisin 
diffused from the nanofiber wound dressings for at least 4 days in vitro, as shown with 
consecutive transfers onto plates seeded with methicillin-resistant strains of Staphylococcus 
aureus. The nisin-containing nanofiber wound dressing significantly reduced S. aureus Xen 
36 bioluminescence and cell numbers in a murine skin infection model. Furthermore, the 
wound dressings stimulated wound closure of excisional wounds and no side effects could be 
observed. Nisin-containing nanofiber wound dressings have the potential to treat S. aureus-
skin infections and accelerate the wound healing process. 
Introduction 
Injury to skin provides a perfect site for microbial invasion, leading to minor skin infections 
which can easily progress into life-threatening infections. With an infection, the processes 
normally associated with wound healing, i.e. homeostasis, inflammation, new tissue 
formation, remodelling and maturation, will be hampered (Guo and DiPeitro, 2010, Gurtner et 
al., 2008, Nishio et al., 2008). Gram-positive and Gram-negative bacteria, fungi and yeasts 
have been associated with skin infections (Church et al., 2006, Vindenes and Bjerknes, 1995). 
Staphylococcus aureus is a virulent pathogen responsible for superficial and invasive skin and 
soft-tissue infections (SSTIs) (Baggett et al., 2003, Daum, 2007, Fridkin et al., 2005). 
Widespread use of antibiotics have led to an increase in antibiotic resistance in S. aureus, 
amongst others, with the emergence of health care-associated methicillin-resistant S. aureus 
(HA-MRSA) and community-acquired MRSA (CA-MRSA) (Kim, 2009, Naimi et al., 2003). 
Vancomycin-resistant strains of S. aureus (VRSA) have also emerged, as well as the more 
recent linezolid-resistant S. aureus (LRSA) (Chang et al., 2003, Endimiani et al., 2011, 
Tsiodras et al., 2001, Walsh, 1999). It is thus important to search for alternative antimicrobial 
compounds active against S. aureus. 
Lantibiotics are extensively post-translationally modified bacteriocins and contain 
unusual amino acids as well as meso-lanthionine(s) and/or β-methyllanthionine(s) (Willey and 
van der Donk, 2007). Nisin A, produced by some strains of Lactococcus lactis, is the best 
studied lantibiotic and consists of 34 amino acids. During post-translational modification, 
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serine and threonine residues in the precursor peptide are dehydrated to form 2,3-
didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb), respectively. Subsequent 
cyclization results in the formation of one meso-lanthionine (Ala-S-Ala) and 4 β-
methyllanthionines (Abu-S-Ala) in the mature peptide (Willey and van der Donk, 2007). 
Nisin has a dual mode of action by targeting the pyrophosphate moiety of the cell wall 
precursor lipid II and, by doing so, prevents polymerization of murein subunits during cell 
wall synthesis (Hsu et al., 2004, Willey and van der Donk, 2007). Once bound to lipid II, 
nisin also forms pores in the cell membrane (Brötz et al., 1998). Nisin is active against 
various Gram-positive bacteria, including MRSA, vancomycin-resistant enterococci (VRE), 
heterogeneous vancomycin-intermediate S. aureus (hVISA), Streptococcus pneumoniae and 
Clostridium difficile (Bartoloni et al., 2004, Piper et al., 2011, Severina et al., 1998). Nisin 
also inhibits the outgrowth of Bacillus and Clostridium spp. endospores (Gut et al., 2011, 
Rayman et al., 1981).  
Electrospinning is a versatile technique to produce fibers with very small diameters (in 
the nanometer to micrometer range), which have high oxygen permeability, variable pore size, 
a high surface area to volume ratio and are morphologically similar to the extracellular matrix 
(Li et al., 2002, Smith and Ma, 2004, Yang et al., 2005, Zhou et al., 2008). Electrospun 
nanofibers are thus ideal as wound dressing materials. Antimicrobial compounds have been 
electrospun into nanofibers to generate antimicrobial materials for potential medical 
applications (Kim et al., 2004, Rujitanaroj et al., 2008). Electrospinning of bacteriocins into 
nanofibers and the use of the electrospun nanofibers as a drug delivery system for bacteriocins 
in the food and medical industries have only recently been reported (Dheraprasart et al., 2009, 
Heunis et al., 2010, 2011).  
In this chapter we investigated the feasibility of co-electrospinning commercially 
available nisin A (Nisaplin
®
) into nanofibers consisting of a blend of poly(ethylene oxide) and 
poly(D,L-lactide). Wound dressing were evaluated for antimicrobial activity, their ability to 
treat S. aureus skin infections, as well as their effect on wound healing.   
Materials and Methods 
Materials 
Poly(D,L-lactide) (PDLLA, 75 000-120 000 Da) and poly(ethylene oxide) (PEO, 200 000 Da) 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). Nisaplin
®
 was obtained from 
(Danisco, Copenhagen, Denmark). All other reagents were of analytical grade. Protein 
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concentrations were determined by using the Micro-bicinchoninic Acid (BCA) kit (Pierce, 
Rockford, IL) and readings were recorded at 562 nm. 
Electrospinning of nanofibers 
Nisaplin
®
 was suspended in N,N-dimethylformamide (DMF) to obtain 20 mg/ml nisin and 
centrifuged (8000g, 5 min). The supernatant, containing nisin, was used as solvent for 24% 
(w/v) PEO:PDLLA (50:50). The solution was heated to 40 °C on a hot plate and then 
electrospun using a gravity system as described by Heunis et al. (2010). A constant electric 
field of +10 kV was applied to the polymer solution and -5 kV to the collector. The collector 
was placed 15 cm from the polymer solution. The relative humidity was kept constant 
between 50 and 54% and the temperature between 28 and 30 °C. Nisin-containing nanofibers 
are further referred to as NF. Nanofibers electrospun without nisin served as control (CF). 
Scanning electron microscopy of electrospun fibers 
Images of the nanofibers were recorded with a Leo
®
 1430VP Scanning Electron Microscope 
(SEM). Samples were coated with a thin layer of gold to increase conductivity. Fiber 
diameters were determined using SEM Image Studio Software (version 10.1).  
Release of nisin and in vitro antimicrobial activity tests 
S. aureus Xen 29, 30, 31 and 36 (Caliper Life Sciences, Hopkinton, MA) was cultured 
overnight in Brain Hart Infusion (BHI) broth (Biolab Diagnostics, Midrand, South Africa), 
containing 200 μg/ml kanamycin to maintain the native plasmid containing the lux operon. 
Incubation was at 37 °C. Antimicrobial activity was assessed on BHI soft agar containing 
approximately 10
5 
cfu/ml of one of these strains. Electrospun nanofibers (1 cm
2
), containing 
approximately 768 μg/ml nisin, were placed on the surface of seeded agar plates and 
incubated overnight at 37 °C. Nanofibers that inhibited the growth of the S. aureus strains, i.e. 
with surrounding zones of growth inhibition, were transferred to a new plate seeded in the 
same way and incubated at 37 °C for 24 h. This process was repeated until no antimicrobial 
activity was recorded. 
Animals 
Approval to conduct research on mice was granted by the Ethics Committee of the University 
of Stellenbosch (Ref: 10 NM_DIC02). Adult male BALB/c mice (weighing 20 to 30g) were 
fed a standard rodent diet, housed in separate cages and kept under controlled environmental 
conditions (12 h light-dark cycles, 20-22 °C).  
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Skin injury and infection with S. aureus  
The dorsal hair of mice was removed with Veet Hair Remove Lotion (Reckitt Benckiser, 
Elandsfontein, South Africa). The next day the mice were anaesthetized with 2% (v/v) 
isoflorane in O2 (Isofor, Safe Saline Pharmaceuticals, Florida, South Africa) and full-
thickness excisional wounds (5 mm in diameter) were made on the dorsal surface of each 
mouse, using a sterile biopsy punch (Stellenbosch Medical Suppliers, Stellenbosch, South 
Africa). Mice received buprenorphine (0.03 mg/kg of body weight, Temgesic, Schering-
Plough (Pty) Ltd., Woodmead, South Africa) subcutaneously as analgesic directly before 
injury and for the first 4 days of the experiment. Each of the wounds was infected with 10 µl 
of 10
8
 cfu/ml S. aureus Xen 36 directly after the punch biopsy. 
Treatment of S. aureus infection 
Treatment followed 1 h after infection. Wounds of mice (n=7) were covered with NF wound 
dressings of 1 cm
2
 and were labeled the NF group (NFG). Wounds of control mice (n=7) were 
covered with CF wound dressings of the same size and were labeled the CF group (CFG). 
Micropore™ surgical tape (Alpha Pharm, Stellenbosch, South Africa) was used to keep the 
nanofiber dressings in contact with the wounds. Wound dressings were changed on the second 
and fourth day of the trial. 
Monitoring of the bacterial infection 
Signal strength of photons transmitted through the nanofiber dressings was determined prior 
to in vivo bioluminescent imaging. Two hundred µl (10
8
 cfu/ml) of S. aureus Xen 36 cells was 
placed into a microtiter plate and the wells were covered with nanofibers, which was 
moistened with phosphate buffered saline pH 7.4 (PBS). Bioluminescent readings were 
recorded using the In Vivo Imaging System (IVIS
®
 100) of Caliper Life Sciences (Hopkinton, 
MA, USA). Image software
®
 (version 3.0, Caliper Life Sciences, Hopkinton, MA) was used 
to quantify the photons emitted from regions of interest (ROIs). The values obtained were 
expressed as log10 photons per second per cm
2
 per steradian (p s
-1 
cm
-2 
sr
-1
). For in vivo 
bioluminescent imaging, mice were anaesthetized with 2% (v/v) isoflorane in O2 and 
bioluminescent readings were recorded, every 24 h, through the bandages for 1 min using the 
IVIS
®
 100. Nanofiber wound dressings were moistened with 50µl PBS prior to 
bioluminescent imaging. Quantification of the photons emitted was achieved as described 
before and ROIs was set at 17.5 x 17.5 pixels.   
Stellenbosch University http://scholar.sun.ac.za
150 
 
Viable S. aureus Xen 36 cells adsorbed to the nanofiber wound dressings were determined by 
soaking the wound dressings in sterile saline, followed by serial dilution and plating on BHI 
plates, containing 200 µg/ml kanamycin, on day 2, 4 and 7. The plates were incubated at 37 
°C for 24 h and viable cells determined. Wounds were digitally photographed daily, to 
investigate the influence of the wound dressings on wound closure, and images were analysed 
with ImageJ (Scion Corp., Frederick, MD, USA). Changes in wound size was expressed as a 
percentage of the original wound size, by using the equation DN/D0 x 100% (DN = wound size 
on the day of measurement and D0 = the wound size on day 0). On day 7 the mice were 
euthanized with an overdose of pentabarbitone sodium (Euthapent, Kyron Laboratories (Pty) 
Ltd., Benrose, South Africa) and wounds were excised to determine the number of viable S. 
aureus Xen 36 cells in the wounds. Excised wounds were homogenised, serially diluted in 
sterile saline and plated onto BHI plates, supplemented with 200 µg/ml kanamycin, and 
incubated at 37 °C for 24 h.  
Effect of nanofiber wound dressings on closure of uninfected wounds 
Punch biopsies were performed on mice as previously described. None of these mice were 
infected with S. aureus. The wounds of mice (n=3) were covered with NF wound dressings, 
as described before. Wounds in control groups were either covered with CF wound dressings 
(n=3) or only covered with gauze (n=3). Micropore™ surgical tape was used to keep all 
wound dressings in contact with the wounds. Wounds were digitally photographed daily and 
wound closure determined as described before. Wounds were excised for histological analysis 
on day 7 and fixed in 4% formaldehyde in 0.1M PBS buffer pH 6.5. Wound tissue samples 
were processed using automated procedures to impregnate and subsequently embed in 
paraffin wax, 5μm sections were prepared with a rotary microtome and manually stained with 
hematoxylin and eosin (H&E).  
Statistical analysis 
Statistical analyses of the data and comparison between groups were performed using one-
way ANOVA and/or unpaired two-tailed t-tests. Statistica Data Analysis Software (version 
10, StatSoft Inc) or GraphPad Prism Software (version 5.04, GraphPad Software Inc, 
California, USA) was used. A statistically significant difference was considered when P < 
0.05.  
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Results 
Nanofibers electrospun from a 24% (w/v) solution of PEO:PDLLA (50:50) had an average 
diameter of 466 ± 104 nm, whereas nanofibers co-electrospun with nisin had an average 
diameter of 330 ± 79 nm (Fig. 1).  
Nisin remained active after electrospinning. Highest antimicrobial activity, based on 
diameter of inhibition zones, was recorded on day one against S. aureus Xen 29, MRSA Xen 
30, MRSA Xen 31 and S. aureus Xen 36 (Fig. 2A). NF dressings inhibited the growth of S. 
aureus Xen 29 and MRSA Xen 30 for at least 4 days, as observed with the consecutive 
transfer to plates seeded with the same target organism (Fig. 2). Growth of Xen 31 was 
inhibited for 5 consecutive days (Fig. 2). The largest zone of growth inhibition (23 mm in 
diameter) was recorded against S. aureus Xen 36 after day one (Fig. 2). Growth inhibition of 
Xen 36 continued for 9 consecutive days (Fig. 2). Xen 36 was selected as target strain in 
further experiments. CF dressings did not inhibit the growth of any of the 4 target strains (Fig. 
2). Nisin remained active in the nanofibers when stored at 4 °C for 8 months. Inhibition zones 
of 21 mm were observed after 24 h of incubation, when the nanofibers (stored at 4 °C for 8 
months) were placed on plates seeded with S. aureus Xen 36.  
The bioluminescent signal produced by S. aureus Xen 36 was transmitted through 
PEO:PDLLA nanofiber wound dressings, which would make in vivo imaging through the 
nanofiber wound dressings possible. Bioluminescent signal decreased from 2.0 x 10
6
 to 1.6 x 
10
6
 p s
-1 
cm
-2 
sr
-1 
after transmission through moistened nanofiber dressings. NF wound 
dressings significantly reduced the bioluminescent signal emitted from S. aureus Xen 36 
during 7 days of bioluminescent imaging (NFG) (Fig. 3). Mice receiving CF wound dressings 
(CFG), however, showed stable bioluminescence over the 7-day period. 
The number of viable S. aureus cells present on NF wound dressings declined over the 
7-day period. Average cell numbers per wound dressing of the NF wound dressings declined 
from 2.0 x 10
3
 on day 2 to 1.7 x10
2
 and <25 cfu/wound dressing on days 4 and 7, 
respectively. Only 20 cfu were detected on one wound dressing (on day 7) of a mouse that 
was treated with NF wound dressings. Cell numbers on CF wound dressings, on the other 
hand, declined from 6.9 x 10
7 
on day 2 to 1.8 x 10
6
 and 1.2 x 10
6
 cfu/wound dressing on days 
4 and 7, respectively.  
The number of viable S. aureus cells was reduced in wounds covered with NF wound 
dressings and were significantly lower, compared to control wounds. The cell numbers of S. 
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aureus Xen 36 declined to 4.3 x 10
2
 cfu/wound on day 7 when treated with NF dressings, 
compared to 2.2 x 10
7
 in wounds treated with CF dressings (Fig. 4B). None of the mice in the 
NF group had bacterial counts higher than 10
4 
cfu/wound, whereas all of the mice in the CF 
group had cell counts higher than 10
6 
cfu/wound. No significant differences were observed in 
wound closure during 7 days of treatment with NF wound dressings or CF wound dressings. 
On average, wounds in the NF group showed an 84% reduction in wound size on day 7, 
whereas wounds treated with control nanofibers showed a 79% reduction in wound size.  
A significant difference in wound area was observed in uninfected wounds covered 
with CF, compared to wounds covered with gauze during the 7 days. A significant difference 
was, however, only observed in wound closure of mice treated with NF wound dressings, 
compared to wounds that were covered with gauze, from day 4 until day 7 of the experiment 
(Fig. 6B). No difference was observed in wound closure between NF- and CF-treated wounds. 
Average wound sizes on day 7 ranged from 26.2 ± 3.9%, 8.7 ± 3.2% and 9.2 ± 4.6% of the 
original wound area for wounds covered with gauze, CF- and NF-wound dressings, 
respectively. Histological analysis revealed that wounds covered with gauze exhibited 
characteristics of re-epithelialization and neovascularization in the wound bed. However, 
tissues surrounding the wounds showed prolonged inflammatory infiltration, with 
(polymorphonuclear) neutrophils still visible on day 7. Wounds treated with CF wound 
dressings showed signs of re-epithelialization, keratinization and wound vascularization. 
Some signs of neovascularization could also be observed. Neutrophils were only present in 
one of three wounds on day 7. NF-treated wounds showed presence of connective tissue 
formation, re-epithelialization, keratinization and hair follicles could be observed. None of 
these wounds showed any signs of neutrophil infiltration on day 7. The NF-treated group is 
the only group in which clear fibrotic scar formation was evident, indicating that end stages of 
repair have been reached. 
Discussion 
Skin infections caused by antibiotic-resistant pathogens are problematic and delays the 
general wound healing process. Previously, PEO 50:PDLLA 50 nanofibers have been 
identified as the best scaffold for further analysis as potential wound dressing material for 
medical applications (Heunis et al., 2011). PEO 50:PDLLA 50 nanofibers electrospun with 
nisin had a mean fiber diameter of 330 ± 79 nm, which corresponded well with that obtained 
previously (Heunis et al., 2011, previous chapter). Nanofibers electrospun without nisin had a 
larger diameter. During electrospinning a high voltage is applied to a polymer solution or melt 
in a capillary and once the surface tension is overcome a polymer jet is ejected from the 
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capillary, which undergoes elongation and produces very thin fibers. An added advantage of 
electrospinning is the possibility to co-electrospin a variety of bioactive compounds into the 
nanofibers, by dissolving them directly in the solvent before electrospinning. Antibiotics, 
growth factors, antimicrobial peptides, silver nanoparticles, as well as living bacteria have 
been electrospun into a variety of natural and synthetic fibers, as well as blends thereof (Chew 
et al., 2005, Heunis et al., 2010, Kenawy et al., 2002, Kim et al., 2004, López-Rubio et al., 
2009, Luu et al., 2003, Maretschek et al., 2008, Rujitanaroj et al., 2008). The addition of 
some molecules to a solution before electrospinning can result in a reduction of fiber 
diameter. PCLEEP (ε-caprolactone and ethyl ethylene phosphate copolymer) fibers showed a 
reduction in fiber diameter from 5.01 µm to 2.8 µm when electrospun with bovine serum 
albumin (BSA) (Chew et al., 2005). The addition of Mefoxin
®
 resulted in decreased fiber 
diameters (from 360 nm to 260 nm) when electrospun with PLGA/PLA/PEG-b-PLA(Kim et 
al., 2004). Dheraprasart et al. (2009) however reported on a slight increase in fiber diameter 
when gelatin solutions were electrospun with nisin, however, the increase was not statistically 
significant. Addition of molecules to a solution before electrospinning may alter the 
conductivity, surface tension and possibly the viscosity of the solution and thus have an 
influence on the morphology and diameter of fibers formed during electrospinning.  
In this study, antimicrobial activity was assessed on solid media to simulate topical 
conditions such as wounds. Nisin released from the PEO 50:PDLLA 50 nanofibers showed 
antimicrobial activity for a minimum of 4 days against S. aureus Xen 29 and MRSA Xen 30. 
The longest activity was observed against S. aureus Xen 36 for 9 days. An initial burst release 
with a sustained release of nisin was observed, which could be ideal to treat infections. 
Bacteria initially colonizing the wound could be killed or inhibited with the initial release of 
nisin, whereas the sustained release could help to prevent further infection. Similar results 
have been reported for bacteriocins released from PEO 50:PDLLA 50 blend nanofibers, with 
a high initial burst release followed by a sustained release (Heunis et al., 2011). Bacteriocins 
released from the nanofibers inhibited the growth of a sensitive strain for up to 6 days when 
assessing antimicrobial activity on agar plates. Nisin released from electrospun gelatin 
nanofibers reduced S. aureus and Listeria monocytogenes numbers over 48 h in liquid 
medium, but was unable to reduce Salmonella typhimurium numbers (Dheraprasart et al., 
2009). Release of molecules/drugs from nanofibers, when mixed in the solution before 
electrospining, depends on various factors including solubility, polymer drug interaction, 
dissolution/degradation rate of the polymer/polymer blend nanofibers, as well as the 
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experimental conditions (Heunis et al., 2011, Kenawy et al., 2002, Kim et al., 2007, Zeng et 
al., 2003). 
Survival rates of mice infected with S. aureus Xen 36 was 100% in both NF- and CF-
wound dressing groups. This was ideal and offered the possibility to monitor the infection in 
real time as it progressed over the 7-day period with bioluminescent imaging, using the 
IVIS
®
. A statistically significant reduction in bacterial bioluminescence, cell numbers on the 
NF wound dressings, as well as cell numbers in infected wounds were observed when treated 
with NF wound dressings, as compared to CF wound dressing-treated groups. All of the mice, 
which were treated with NF wound dressings, had bacterial counts lower than 10
4
 cfu/wound. 
Our results correlate well with previous published reports on the treatment of bacterial 
infected wounds and reduction of viable cell numbers in vivo. Chitosan acetate bandages 
significantly reduced bacterial bioluminescence of lux-tagged P. aeruginosa and P. mirabilis 
in a murine burn wound infection model (Dai et al., 2009). Survival rates of mice were 73% 
and 66.7% when treated with chitosan acetated bandages, 27.3% and 62.5% when treated 
silver dressings and 13.3% and 0% in control groups for P. aeruginosa and P. mirabilis, 
respectivley (Dai et al., 2009). Kumari et al. (2010) reported that animals with K. pneumoniae 
infected burn wounds, which were treated with either honey or aloe vera gel, had better 
survival rates than control animals over a 7-day period. Survival rates of 33.3% and 26.7% 
were reported for mice treated with honey and aloe vera gel, respectively, and 0% in control 
animals. Animals treated only with Knp 5 phage showed the highest survival rates and no 
additional beneficial effects was observed when Kpn5 phage was used in combination with 
aloe vera gel or honey (Kumari et al., 2010). Nanoemulsion compound NB-201 decreased 
bacterial cells of P. aeruginosa-infected burn wounds from 7.9 x 10
7
 to 6.5 x 10
4
 in rats 
(Hemmila et al., 2010). Nitric oxide nanoparticles showed similar results and caused a 
statistically significant reduction in MRSA counts in excisional wounds (Martinez et al., 
2009). A proline-rich synthetic peptide, designated A3-APO, showed potential as treatment 
for burn wound infections and decreased the bacterial load of wounds infected with different 
cell numbers of Acinetobacter baumannii (Ostorhazi et al., 2010). Bacterial counts of mice, 
infected with 2 x 10
11
 cfu/wound, were in the range of 10
7
 for control animals and below 10
3
 
for the majority of A3-APO-treated animals (Ostorhazi et al., 2010). Further studies revealed 
that the peptide reduced MRSA counts in burn wounds from 10
7
 to 10
4
 cfu/mg tissue and 
increased survival of mice infected with a cocktail of A. baumanni, K. pneumonia and P. 
mirabilis (Ostorhazi et al., 2011). 
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The optimal wound dressing should not just be able to treat infection, but also have a 
beneficial effect on wound healing and speed up the process to minimise recovery time. 
Autografts, xenografts and allografts have been used in the treatment of excisional wounds, 
however, some problems have been identified. These include limited availability of autografts 
in severely injured patients, whereas xenografts and allografts have problems associated with 
disease transmission and immune response (Kumbar et al., 2008). Tissue engineering has 
resulted in the generation of various scaffolds to treat excisional wounds and promote wound 
healing. Chitosan have shown promise in the form of chitosan hydrogels, chitosan acetate 
bandages, as well as chitosan-(polyvinyl alcohol) nanofibers. Chitosan acetate bandages 
reduced inflammation and promoted accumulation of fibrous material in full-thickness 
excisional wounds (Burkatovskaya et al., 2008). However, this did not have an added positive 
effect on wound closure in infected or uninfected wounds as compared to the control groups. 
Chitosan hydrogels containing DMEM/F12 (medium-Az-CH-LA) and a collagen sponge had 
similar wound healing profiles when applied to full-thickness wounds after dermal burns in 
rats (Kiyozumi et al., 2007). Chitosan hydrogels containing DMEM/F12 (medium-Az-CH-
LA) however did show more rapid neovascularization and the granulation tissue thickness 
was more prominent than in the collagen sponge treated groups (Kiyozumi et al., 2007).  
Although the main purpose of the study was to determine if NF wound dressings could treat 
S. aureus-induced infections, the effect of the NF- and CF-wound dressings on wound closure 
was also investigated. No difference in wound closure of infected wounds treated with NF- or 
CF-wound dressings was observed. Studies have actually revealed that S. aureus-infected 
wounds show improved wound closure over uninfected or infected and treated wounds 
(Burkatovskaya et al., 2008). However, we did not notice this effect. Even though there was 
no significant difference in wound closure, the wounds that were treated with NF wound 
dressings had significantly less of a bacterial burden than CF wound dressing-treated wounds, 
as previously discussed. A statistically significant difference was, however, observed in 
wound closure of uninfected wounds treated with NF- or CF-wound dressings, as compared to 
control, gauze covered wounds. CF wound dressings, as well as NF wound dressings, showed 
a positive influence on wound healing, as determined by histological analysis. Hyaluronic 
acid nanofibers was shown to be effective in promoting wound healing of full-thickness 
excisional wounds in pigs and chitosan-poly(vinyl alcohol) nanofibers only showed a positive 
influence on wound healing when used in combination with R-Spondin I, a novel growth 
factor (Sundaramurthi et al., 2012, Uppal et al., 2011). Curcumin loaded poly(ɛ-caprolactone) 
(PCL) also showed improved wound healing from day 6 as compared to plain PCL over a 10 
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day period in a diabetic murine model (Merrell et al., 2009). Other studies have also revealed 
that some nanofibers do not have an added positive influence over control groups on wound 
closure, however, histological analysis usually reveals that the wound healing process has 
been stimulated more in the nanofiber-treated groups (Lui et al., 2010, Rho et al., 2006). The 
addition of growth factors to the nanofibers usually accelerates wound closure as compared to 
control nanofiber treated groups, as would be expected (Choi et al., 2008, Sundaramurthi et 
al., 2012). The major factors of a nanofiber scaffold which positively influences wound 
healing thus seems to include hydrophobicity/hydrophilicity ratios of the nanofiber scaffolds 
which will influence attachment to the wound and prevent excessive fluid build-up, porosity 
influencing air and moisture permeability, as well as the benefit of bioactive molecules co-
electrospun into or bound to the surface of the nanofibers (Lui et al., 2012). Our nanofiber 
scaffolds have good wettability, good hydrophobicity/hydrophilicity ratios because of the 
blending of two hydrophobic/hydrophilic polymers before electrospinning, it retains its 
fibrous structure and its porosity upon incubation and thus have the potential as good overall 
scaffold to positively influence wound healing (Heunis et al., 2011). This was, however, a 
preliminary study on wound healing of uninfected wounds and the exact influence of the 
nanofibers and/or the peptide on wound healing warrants further investigation. It can also not 
be ruled out that nisin can have an influence on wound healing, as cationic antimicrobial 
peptides play a role in the innate immune response (Barak et al., 2005). Plantaricin A, a 
bacteriocin produced by Lactobacillus plantarum, has been shown to increase cell 
proliferation, enhance migration and influenced the expression of TGF-β1, FGF7, VEGF-A 
and IL-8 in vitro in human keratinocytes (Pinto et al., 2011). Plantaricin A was further shown 
to promote antioxidant defences and increased the expression of FLG, IVL and HBD-2 in 
NCTC 2544 keratinocytes (Marzani et al., 2012). Decreased expression of TNF-α was also 
observed in plantaricin A treated cells. More recently, nisin Z was shown to have 
immunomodulatory activities and modulated the host immune response similar to natural host 
defense peptides (Kindrachuk et al., 2012). Nisin Z mediated host protective immunity and 
conferred protection against Gram-positive and Gram-negative bacterial infections.  
In conclusion, nisin was successfully co-electrospun into PEO 50:PDLLA 50 
nanofibers and released nisin was able to inhibit the growth of S. aureus strains over a 
prolonged period of time. NF wound dressings were able to significantly reduce the bacterial 
burden of S. aureus-induced skin infections in a murine model. NF- and CF-wound dressings 
was able to significantly reduce wound closure of excisional wounds over 7 days in mice and 
showed no negative side effects on wound healing in a preliminary study. Nisin-containing 
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PEO:PDLLA nanofibers are thus suitable wound dressing materials to not only reduce the 
bacterial burden of S. aureus infected wounds, but also potentially decrease healing time of 
excisional wounds. As far as we could determine this is the first report of the in vivo 
evaluation of an antimicrobial peptide electrospun into nanofibers to treat skin infections 
induced by bacteria. Future research should include the combination of growth factors, anti-
inflammatory agents, as well as antimicrobials to generate an optimal wound dressing which 
can treat infections and reduce time needed for wounds to heal.  
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Fig. 1 Scanning electron microscopy (SEM) images of PEO 50:PDLLA 50 nanofibers 
electrospun (A) without and (B) co-electrospun with nisin. Distribution of fiber diameters in 
samples electrospun without nisin (CF) and with nisin (NF) are shown in (C).  
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Fig. 2 Antimicrobial activity of PEO 50:PDLLA 50 nanofibers (A). The nanofiber sample 
placed in the top part of each petri-dish contained nisin (NF), whereas the sample placed 
below had no nisin (CF). The target strains of S. aureus were obtained from Caliper Life 
Sciences, Hopkinton, MA. Growth inhibition, depicted in zone diamemeter, as monitored 
over 10 days in NF is shown in (B). 
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Fig. 3 Bioluminsecent images (A) and bioluminescent measurements (B) of mice infected 
with 10 μl of 108 cfu/ml S. aureus Xen 36 and treated with nisin-containing PEO 50:PDLLA 
50 nanofiber wound dressings (NFG-nisin fiber group) and control nanofiber wound 
dressings (CFG-control fiber group). * p<0.0001 as compared to CFG. 
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Fig. 4 (A) Colony forming units of S. aureus Xen 36 recovered from PEO 50:PDLLA 50 
nanofiber wound dressings on day 2, 4 and day 7 of the experiment and (B) viable S. aureus 
Xen 36 in excised wounds on day 7. (NFG-nisin fiber group, CFG-control fiber group).         
* p<0.0001 as compared to CFG. 
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Fig. 5 Images of S. aureus Xen 36-infected wounds on the dorsal surface of mice treated with 
control PEO 50:PDLLA 50 nanofibers or nisin-containing nanofibers (A) and wound closure, 
expressed as a percentage, over 7 days (B). (CFG-control fiber group and NFG-nisin fiber 
group). Distance between blue lines indicates 1mm. 
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Fig. 6 Images of uninfected wounds, on the dorsal surface of mice, that received gauze 
(control), control PEO 50:PDLLA 50 nanofibers (CFG-control fiber group) or nisin-
containing nanofibers (NFG-nisin fiber group) as wound dressings (A). Wound closure of 
wounds that received gauze, control nanofibers or nisin-containing nanofibers as wound 
dressings are shown in (B). * p<0.05 as compared to wounds covered with gauze. Distance 
between blue lines indicates 1mm. 
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Fig. 7 Skin sections (stained with H&E) of excisional wounds covered with gauze (A-wound 
bed and B-tissue adjacent to wound bed), control PEO 50:PDLLA 50 nanofibers (C-wound 
bed and D-tissue adjacent to wound bed) and nisin-containing nanofibers (E and F, both of 
wound bed) on day 7. 1-re-epithelialization, 2-neovascularization, 3-neutrophils, 4-
keratinization, 5-hair follicle and 6-fibrosis (fibrotic scar formation). Scale bar = 20 µm. 
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Nisin-containing Nanofiber Scaffolds as Potential Wound Dressing Material for Burn 
Wound Infections: Trial and Error 
Abstract 
Bacteriocins show great potential as alternatives to conventional antibiotics, especially with 
the increase in antibiotic-resistant pathogens. Antimicrobial nanofibers were prepared by co-
electospinning nisin F into nanofibers consisting of poly(D,L-lactide) and poly(vinyl alcohol). 
These nanofibers could inhibit the growth of S. aureus for 2 days on agar plates. However, the 
nisin F-containing nanofibers were unable to reduce S. aureus bioluminescence in burn 
wound infections in mice. A nisin F solution could reduce S. aureus bioluminescence in 
infected burn wounds, however, did not reduce S. aureus viable cells on the same wounds. 
Nisin A was successfully co-electrospun into nanofibers consisting of poly(ethylene oxide) 
and poly (D,L-lactide) and retained activity after electrospinning. Nisin A-containing 
nanofibers were only able to reduce S. aureus bioluminescence once the burn wounds were 
debrided. Necrotic skin forms a barrier which seems to prevent the nisin from treating the 
infection. Burn wound debridement is thus important for successful treatment of bacterial 
burn wound infections with nisin. 
Introduction 
Thermal injury generates wounds that are perfect niches for microbial colonization, as it is a 
protein rich area which will sustain microbial growth (Altoparlak et al., 2004). It also destroys 
the protective skin barrier, which can lead to infection (Church et al., 2006). In the United 
States the cost involved in hospitalized fire and burn injuries amounts to more than 7.5 billion 
US dollars per annum and represents 2% of the total cost of injuries (CDC, 2011). From an 
estimated 1.1 million patients submitted to hospitals in the USA with burn injuries, 10 000 die 
due to infections (CDC, 2006). In South Africa 1223 patients with burn injuries have been 
admitted to the Red Cross War Memorial children’s hospital trauma unit in 2011. This 
represented 14.7% of all reported injuries (Red Cross Trauma Unit, 2011). 
Burn wound infections are difficult to treat, even with the advances in modern 
medicine (Dai et al., 2009). Initial infection of a burn wound is usually caused by Gram-
positive bacteria present in sweat glands and hair follicles (Altoparlak et al., 2004, Nasser et 
al., 2003). Secondary infection, which usually occurs within the first 5 to 7 days, is caused by 
bacteria, fungi and yeasts form the gastrointestinal- and upper respiratory-tract of the patient 
or can be acquired from the hospital environment (Altoparlak et al., 2004, Church et al., 
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2006, Erol et al., 2004, Vindenes and Bjerknes, 1995). Burn victims are thus in need of 
specialized care to prevent infection, especially in cases where wounds cover most of the 
body surface area. Staphylococcus aureus, normally present on skin, is commonly isolated 
from infected burn wounds (Guggenheim et al., 2009, Santucci et al., 2003). Pseudomonas 
aeruginosa, Acinetobacter spp., coagulase-negative staphylococci, Candida spp., Escherichia 
coli, Enterococcus spp. and Klebsiella pneumoniae have also been isolated from infected burn 
wounds (Chim et al., 2007, Guggenheim et al., 2009, Santucci et al., 2003). Antibiotic 
resistance in bacterial pathogens is on the increase and alternative treatments need to be 
explored (Neu, 1992). Various alternative treatments have been investigated to treat burn 
wound infections and include chitosan acetate bandages, chitosan hydrogels, natural 
antimicrobial agents (honey and aloe vera gel), Klebsiella bacteriophage Kpn 5 suspended in 
hydroxy propyl methyl cellulose hydrogels (E464, or HPMC) and nanoemulsions 
(Burkatovskaya et al., 2008, Dai et al., 2009, Hemmila et al., 2010, Kumari et al., 2010, 
Ribeiro et al., 2009). 
The potential biomedical applications of bacteriocins have recently been reviewed 
(Dicks et al., 2011). Lantibiotics (lanthionine-containing bacteriocins) have great potential, 
especially as anti-staphylococcal agents. Nisin A is the best studied of all lantibiotics and is 
commercially available as Nisaplin
® 
and Novasin
TM
. Nisin targets the pyrophosphate moiety 
of lipid II and inhibits bacterial cell wall synthesis (Hsu et al., 2004, Willey and van der 
Donk, 2007). It also form pores in cells, which is facilitated by first binding to lipid II (Brötz 
et al., 1998). Nisin F, a natural nisin variant, was isolated from Lactococcus lactis spp. lactis 
F10 and differs from nisin Z by having one amino acid substitution (isoleucine to valine at 
position 30) (de Kwaadsteniet et al., 2008). Of all nisin variants tested, nisin F was the most 
active against strains of S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-
resistant enterococci (VRE) and vancomycin-intermediate S. aureus (VISA) (Piper et al., 
2011). Nisin F repressed the growth of S. aureus in the upper respiratory tract of 
immunocompromised rats (de Kwaadsteniet et al., 2009) and prevented growth of S. aureus 
in vivo when incorporated into brushite bone cement (van Staden et al., 2012). Nisin F was, 
however, ineffective in the treatment of subcutaneous (de Kwaadsteniet et al., 2010) and 
intraperitoneal (Brand et al., 2010) S. aureus infections in mice. 
Recently, the co-electrospinning of bacteriocins into nanofibers has been reported with 
potential biomedical and food applications (Dheraprasart et al., 2009, Heunis and Dicks, 
2010, Heunis et al., 2010, 2011). Nisin A, co-electrospun into PEO:PDLLA nanofibers, 
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significantly reduced the cell numbers of S. aureus in full-thickness excisional wounds in 
mice (as shown in the previous chapter). 
In this chapter wound dressings were prepared by co-electrospinning nisin F and nisin 
A into nanofibers. The ability of the wound dressings to control S. aureus infection in burn 
wounds was studied using a murine model. 
Materials and Methods 
Isolation and partial purification of nisin F 
L. lactis spp. lactis F10 was cultured in MRS broth (Biolab, Biolab Diagnostics, Midrand, 
South Africa) at 30 °C for 24 h. Cells were harvested (8000g, 10 min, 4 °C), the pH of the 
cell-free supernatant adjusted to between pH 6.5-7.0 with 10M NaOH and then heated at 80 
°C for 10 min to inactivate proteolytic enzymes. Peptides were precipitated from the cell-free 
supernatant with 70% saturated ammonium sulphate, desalted against distilled water by using 
a 1000 Da cut-off dialysis membrane (Spectrum Inc., CA, USA) and freeze-dried. Peptides 
were stored at -20 °C. 
Electrospinning of nanofibers 
Poly (D,L-lactide) (PDLLA, 75 000-120 000 Da) and partially hydrolyzed poly(vinyl alcohol) 
(PVA, 87-89% hydrolysed, 146 000-186 000 Da) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA). All other chemicals were of analytical grade. PVA solutions, 10-20% 
(w/v), were prepared in dimethylsulfoxide (DMSO). The PVA was dissolved by heating the 
solution to 40 °C. Freeze-dried crude nisin F (50 mg/ml, 12 800 AU/ml as determined against 
S. aureus Xen 36) was dissolved in N,N-dimethylformamide (DMF) and centrifuged (6000g, 
1 min) to obtain the supernatant, which was used as solvent for the PDLLA (10-20%, w/v). 
The PVA in DMSO was mixed with the PDLLA solution in a ratio of (30:70) and co-
electrospun as described by Heunis et al. (2010). These fibers were designated NFNF (nisin 
F-containing nanofibers). The controls contained no nisin F (NFCF). The voltage applied at 
the anode was +10kV and at the cathode (collector) -5kV. The distance between the anode 
and cathode was 15 cm and the relative humidity was controlled at 20-30%.  
 In another experiment nisin A (Nisaplin
®
) was dissolved in DMF to obtain 20 mg/ml 
of nisin in the solution and centrifuged (6000g, 2 min). The supernatant served as solvent for 
24% (w/v) PDLLA blended with PEO (50:50). Solutions were heated to 40 °C on a hot plate 
and then electrospun as before. The relative humidity was kept constant between 50-55% and 
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the temperature between 27-30 °C. These nanofibers were designated NANF (nisin A-
containing nanofibers). Control nanofibers contained no nisin A and were designated NACF. 
Scanning electron microscopy of electrospun fibers 
Images of the nanofibers were recorded with a Leo
®
 1430VP Scanning Electron Microscope 
(SEM). Samples were coated with a thin layer of gold to increase conductivity. Fiber diameter 
was determined by using the SEM Image Studio Software (version 10.1).  
Release of antimicrobial peptides and in vitro antimicrobial activity tests 
S. aureus Xen 36 was cultured in BHI broth (Biolab Diagnostics, Midrand, South Africa), 
supplemented with 200 μg/ml kanamycin for selection, and incubated at 37 °C for 24 h. The 
NFNF was tested for antimicrobial activity by placing 1.5 cm
2
 of fibers on an agar plate 
seeded with S. aureus Xen 36. The plates were incubated for at 37 °C for 24 h, after which 
they were inspected for the formation of inhibition zones. The fibers were then placed on a 
new plate seeded with S. aureus Xen 36 and incubated for another at 37 °C for 24 h, after 
which they were once again inspected for the formation of inhibition zones. This was done 
repeatedly until no antimicrobial activity (inhibition zones) was observed. NANF were tested 
for antimicrobial activity by placing 1 cm
2
 of fibers on an agar plate seeded with S. aureus 
Xen 36 and incubated for at 37 °C for 24h. 
Preliminary in vivo experiments  
Animals 
Approval to conduct research on mice was granted by the Ethics Committee of the University 
of Stellenbosch (Ref: 10 NM_DIC02). Adult male BALB/c mice (weighing 20 to 30g) were 
fed a standard rodent diet, individually housed in animal cages and kept under controlled 
environmental conditions (12 h light-dark cycles, 20-22 °C).  
Burn injury and infection  
The dorsal hair of mice was removed with Veet Hair Remove Lotion (Reckitt Benckiser, 
Elandsfontein, South Africa).The following day, the mice were anesthetized with 2% (v/v) 
isoflorane in O2 (Isofor, Safe Saline Pharmaceuticals, Florida, South Africa) and a burn was 
induced on the hairless dorsal surface of each mouse (n=3) with a brass rod (1 cm in 
diameter), pre-heated to 94 °C. Mice received buprenorphine (Temgesic, 0.03 mg/kg of body 
weight, Schering-Plough (Pty) Ltd., Woodmead, South Africa) subcutaneously as analgesic 
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directly before the burn and until day 4 of the experiment. A burn induced for 60 s resulted in 
reproducible burns and was used in subsequent experiments. Mice (n=3) were infected with 
10 µl of 10
8
-10
10
 cfu/ml S. aureus Xen 36, 1 h after the burns were induced. 
Treatment of burn wounds 
A NFNF wound dressing, of approximately 1.5 cm
2
, was placed over the S. aureus-infected 
burn wound area 5 min after the infection.
 
Nanofiber wound dressings without nisin (NFCF) 
served as control. Micropore™ surgical tape (Alpha Pharm, Stellenbosch, South Africa) was 
used to keep the nanofibers in contact with the wound area until the dressings were changed 
on days 2 and 4 of the experiment. In another experiment, burn wounds of mice (n=3) were 
treated with 10 µl nisin F (12 800 AU/ml, suspended in sterile distilled water) 5 min after 
infection and on days 2, 3 and 4 of the experiment. Mice (n=3) in control groups received 
sterile saline on the same days. Mice were euthanized with an overdose of pentabarbitone 
sodium (Euthapent, Kyron Laboratories (Pty) Ltd., Benrose, South Africa) on day 5 and the 
burn wounds excised to determine S. aureus cell numbers. The burn wounds were 
homogenised, the cell suspension serially diluted and plated onto BHI agar supplemented 
with 200 µg/ml kanamycin. Plates were incubated for at 37 °C for 24 h. 
In another experiment, burn wounds was induced, as previously described, and some 
of the wounds were debrided after burn injury with scissors and forceps. Debrided and non-
debrided wounds (n=2) were infected with 10 µl of 10
8
 cfu/ml S. aureus Xen 36 and left for 1 
h for the infection to establish. Wounds were subsequently treated once with NANF. 
Bioluminescent imaging 
Signal strength of photons transmitted through the nanofiber dressings was determined prior 
to in vivo bioluminescent imaging. S. aureus Xen 36 cells (10
7
 cfu/ml) was placed into a 
microtiter plate and the wells were covered with nanofibers, which was moistened with 
phosphate buffered saline pH 7.4 (PBS). Bioluminescent readings were recorded using the In 
Vivo Imaging System (IVIS
®
 100) of Caliper Life Sciences (Hopkinton, MA, USA). Image 
software
®
 (version 3.0, Caliper Life Sciences, Hopkinton, MA) was used to quantify the 
photons emitted from regions of interest (ROIs). The values obtained were expressed as log10 
photons per second per cm
2
 per steradian (p s
-1 
cm
-2 
sr
-1
). For the in vivo experiment, mice 
were anaesthetized with 2% (v/v) isoflorane in O2 and wound dressings were moistened with 
PBS buffer prior to bioluminescent imaging. Readings were recorded, every 24 h, through the 
wound dressings using the IVIS
®
 100. Micropore™ tape was removed before bioluminescent 
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imaging from mice that were treated with 10 µl of nisin F or sterile saline, as well as mice that 
were treated with NANF wound dressings. Living Image software
®
 (version 3.0, Caliper Life 
Sciences) was used to quantify the photons emitted from regions of interest (ROIs) pre-set at 
23.6 x 23.6 pixels. The values obtained were expressed as log10 photons per second per cm
2
 
per steradian (p s
-1 
cm
-2 
sr
-1
).  
Results 
Nanofibers electrospun from a 10% (w/v) PDLLA 70:PVA 30 solution with and without nisin 
F (50 mg/ml, 12 800 AU/ml) had a bead-on-string morphology (Fig. 1). Uniform nanofibers 
with a smooth surface morphology were obtained when the PDLLA 70:PVA 30 concentration 
was increased to 20% (w/v) (Fig. 2A, C). The diameter of nanofibers without nisin F ranged 
from 100 nm to 350 nm, with a mean diameter of 186 ± 37 nm (Fig. 2B). The diameter of 
nanofibers containing nisin F ranged from 200 nm to 500 nm, with a mean diameter of 321 ± 
54 nm (Fig. 2D). 
Nisin F released from the nanofibers inhibited the growth of S. aureus Xen 36 for 2 
days on agar plates. The size of the inhibition zones were more-or-less the same over the first 
2 days (21.75 mm on day 1 and 18.25 mm on day 2). No inhibition zones were recorded on 
day 3 (Fig. 3), indicating that nisin F was released from the nanofibers with a high initial burst 
during the first 2 days of incubation. 
Burn wounds induced at 94 °C for 10 s did not result in severe burn damage. 
However, after 25 s much more damage to the epidermis was visible (Fig. 5B). Burns at 94 °C 
for 60 s induced severe damage to the epidermis and could potentially create an optimal area 
for microbial colonization (Fig. 5C). Burn wounds were easily infected by S. aureus Xen 36 
when 10 μl of 108-1010 cfu/ml of bacteria was applied to the wounds and infections remained 
stable for 7 days (Fig. 6).  
The bioluminescent signal decreased from 6.9 x 10
6
 to 1.9 x 10
6 
p s
-1 
cm
-2 
sr
-1 
when 
covered with nanofibers. No significant differences in in vivo bioluminescent signals were 
observed over 5 days between burn wounds that were treated with NFNF- and NFCF-wound 
dressings (Fig. 7 and 8). 
Further optimization was done to determine if burn wound infections can be treated 
with a nisin F solution or nisin A-containing nanofibers. The following are result obtained 
from further optimization experiments. Firstly, mice (n=3) were infected and treated with 
nisin F, as previously described. A slight decrease in bioluminescent signal was recorded 
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from day 3 after treatment with nisin F (Fig. 9B). Bioluminescent signal from treated groups 
was lower than control groups until the end of the trial (day 5). No significant difference was, 
however, observed in cell counts between treated and control groups (Fig. 10). The colony 
forming units per wound were 2.0 x10
7
 and 5.2 x 10
7
 for the control and treated group, 
respectively.  
NANF wound dressings inhibited the growth of S. aureus Xen 36 in vitro (Fig. 12). S. 
aureus Xen 36 bioluminescence was reduced in vivo, but only when the burn wounds were 
debrided before infection and treatment with NANF (Fig. 13).  
Discussion 
All of the fibers electrospun in this study were in the nanometer range, with the NFCF having 
slightly smaller fiber diameters than the NFNF (Fig. 2). Increase in polymer concentration 
resulted in nanofibers with more uniformity. Various factors influence the morphology of the 
fibers that are formed during electrospinning which can include, viscosity, elasticity, 
conductivity and surface tension of the solution, strength of the electric field, distance 
between the needle tip and collector, humidity as well as temperature (Deitzel et al., 2001, 
Huang et al., 2003). Polymer concentration and molecular weight is also very important. It 
has been shown that PLLA of 1% (w/w) produces a bead-on-string morphology when 
electrospun, whereas 3% (w/w) PLLA forms nanofibers with a much more smooth structure 
(Maretschek et al., 2008). PEO electrospun at 4wt% in water also had more of a beaded 
structure as compared to fibers electrospun from a 10wt% solution (Deitzel et al., 2001). 
NFNF inhibited the growth of S. aureus Xen 36 for only 2 consecutive days. The area 
of the fibers decreased dramatically after one day of incubation and a slight decrease was seen 
on day 2, as compared to day one. The high burst release, within the first 2 days, could be 
ascribed to the dissolution of the PVA, as this polymer is highly soluble in aqueous 
environments. Nisin F on the surface could also easily be released by diffusion from the 
fibers. These results suggests that PDLLA 70:PVA 30 nanofibers can serve as a delivery 
system for nisin F, if only for a short time. 
Burn wounds, as well as bacterial numbers needed for stable infection, were optimized 
before the nanofibers could be investigated as wound dressing in an in vivo murine model. 
Burn wounds with severe epidermal damage could be induced in mice, which could easily be 
infected with S. aureus Xen 36 (Figs. 5 and 6). A 60 s burn at 94 °C produced an optimal 
wound for infection. All the mice survived the burn injury and infection over the 7-day 
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period. This made bioluminescent imaging and thus real time monitoring of the infection 
possible in the same animal over the course of the experiment. Dai et al. (2009) induced burn 
wounds successfully in mice with a heated brass bar at (92-95 °C). Fatal infections were 
induced by applying 10
7
 cfu P. aeruginosa to a 10 s burn, as well as applying 10
8
 cfu of P. 
mirabilis to a 30 s burn. In this study we wanted to compare bioluminescent measurements of 
control groups to treated groups and thus needed our control group to survive, i.e. for 
comparative purposes. 
The NFNF wound dressings were unable to treat the S. aureus-induced burn wound 
infections (the bioluminescent signals did not differ between treated groups). This could be 
due to the inability of the nisin F to reach the S. aureus cells and the peptide could thus not 
exert its antimicrobial activity. It could also be that the concentration of nisin F released from 
the fibers was not high enough to inhibit S. aureus growth in vivo, as the burn wound is 
relatively dry as compared to human burn wounds (Dai et al., 2009). However, the wound 
dressings were moistened daily before readings were taken to facilitate nisin F release and to 
maximize transmission of the bioluminescent signal through the bandages. When a nisin F 
solution was applied to the burn wound, it reduced the bioluminescent signal of S. aureus Xen 
36. However, nisin F was unable to decrease S. aureus cells in the burn wound. Various 
factors influence the bioluminescent signal emitted by lux-tagged pathogens, including 
oxygen availability, adenosine-5'-triphosphate (ATP) and tissue depth (Andreu et al., 2010). 
Oxygen and adenosine-5'-triphosphate (ATP) is essential as they are needed by the enzyme 
luciferase to oxidize the luciferin and reduced flavin mononucleotide (FMNH2) (Meighen, 
1991). Tissue depth and oxygen could not play a role in the bioluminescent reaction, as the 
infection was topical. The nisin F thus seemed to have more of an effect on the metabolic 
state of S. aureus Xen 36 in vivo, rather than a bactericidal effect. 
NANF wound dressings reduced the bioluminescent signal in debrided burn wounds. 
The wound dressing was, however, unable to reduce bacterial bioluminescence on non-
debrided burn wounds. It would thus seem that the damaged tissue formed during burn injury 
hampers the efficacy of the peptide to penetrate the wound and interact with the S. aureus 
cells. Further investigation of NANF wound dressings is needed on open (excisional) wounds 
as this was a preliminary optimization trial with only two mice (this was addressed in the 
previous chapter).  
Burn wounds have successfully been induced in mice and stable S. aureus-induced 
burn wound infections was achieved. Nisin F was released from the fibers in the active form 
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and inhibited the growth of S. aureus Xen 36 in vitro. However, it was unable to treat S. 
aureus-induced burn wound infections in vivo. A nisin F solution was shown to be ineffective 
in treating and/or repressing the growth of S. aureus Xen 36 in vivo in burn wounds. NANF 
wound dressings could only treat debrided burn wounds. This would indicate that these fibers 
would be better at treating open excisional wounds instead of wounds were damaged 
(necrotic) tissue could prevent antimicrobial penetration of the wound, unless wound 
debridement is performed.  
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Fig. 1 SEM images of electrospun nanofibers at a concentration of 10% (w/v) PDLLA 70: 
PVA 30, with (A) and without (B) nisin F. 
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Fig. 2 SEM images of electrospun nanofibers with the distribution in fiber diameters. (A) 20% 
(w/v) PDLLA 70:PVA 30 fibers without nisin F, (B) fiber diameter distribution of 20% (w/v) 
PDLLA 70:PVA 30 fibers without nisin F (mean = 186 ± 37 nm), (C) 20% (w/v) PDLLA 
70:PVA 30 fibers with nisin F and (D) fiber diameter distribution of 20% (w/v) PDLLA 
70:PVA 30 fibers with nisin F (mean = 321 ± 54 nm).  
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Fig. 3 Antimicrobial activity of electrospun 20% (w/v) PDLLA 70:PVA 30 nanofibers against 
S. aureus Xen 36 (A) Control fibers, without nisin F, (B) antimicrobial activity after 1 day of 
incubation at 37 °C and (C) antimicrobial activity after day 2 of incubation at 37 °C. 
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Fig. 4 Diameter of inhibition zones formed surrounding nisin F-containing PDLLA 70:PVA 
30 nanofibers. 
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Fig. 5 Skin sections of mice burnt with a brass rod heated to 94 °C (A) control/unburnt skin, 
(B) burns induced for 25 s and (C) burns induced for 60 s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Stellenbosch University http://scholar.sun.ac.za
188 
 
0
1
2
3
4
5
6
7
8
9
10
0 1 2 3 4 5 6 7
B
io
lu
m
in
es
c
en
ce
 l
o
g
1
0
 (
p
 s
-1
 c
m
-2
 s
r-
1
) 
 
Time in Days 
  106 cfu/ml 107 cfu/ml 108 cfu/ml
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 (A) Bioluminescent images and (B) bioluminescence log10 values recorded from mice 
infected with 10 μl of 108-1010 cfu/ml S. aureus Xen 36, inoculated onto a burn wound that 
was induced by placing a brass rod (94 °C) for 60 s on the dorsal surface of the mice. 
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Fig. 7 Images and bioluminescent images from mice with a S. aureus Xen 36 (10 μl of 108 
cfu/ml) induced burn wound infection. (A) Image of a burn wound without wound dressing, 
(B) image of a nanofiber wound dressing covered with micropore tape, (C) image showing 
bioluminescent signal through the moistened nanofiber wound dressing and (D) 
bioluminescent images of mice infected with S. aureus Xen 36 (10
6
 cfu/ml) over a 5 day 
period. (D1) PDLLA 70:PVA 30 nanofibers without nisin F (NFCF) and (D2) PDLLA 
70:PVA 30 nanofibers with nisin F (NFNF).  
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Fig. 8 Bioluminescence log10 values from mice with an S. aureus Xen 36 (10 μl of 10
8
 cfu/ml 
cfu/ml) induced burn wound infection, treated with PDLLA 70:PVA 30 nanofibers without 
nisin F (CFG-control fiber group ) and with nisin F (NFG-nisin F fiber group). 
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Fig. 9 (A) Bioluminescent images and (B) bioluminescence log10 values from mice infected 
with 10 μl of 108 cfu/ml S. aureus Xen 36 inoculated onto a burn wound that was induced by 
placing a brass rod (94 °C) for 60 s on the dorsal surface of the mice. Mice were treated with 
10 µl nisin F 5 min after infection and on days 2, 3 and 4.  
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Fig. 10 Viable cells in burn wounds of mice infected with 10 µl 10
8
 cfu/ml S. aureus Xen 36, 
on day 5. Wounds were treated with either 10 µl nisin F or 10 µl saline 5 min after infection, 
and on days 2, 3 and 4.  
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Fig. 11 SEM image of electrospun PEO: PDLLA nanofibers containing nisin A (NANF). 
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Fig. 12 Antimicrobial activity of nisin A-containing PEO:PDLLA nanofibers against S. 
aureus Xen 36. PEO:PDLLA nanofibers with (1) and without (2) nisin A.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
2 
Stellenbosch University http://scholar.sun.ac.za
195 
 
0
1
2
3
4
5
6
7
8
0 1 2 3 5
B
io
lu
m
in
es
c
en
ce
 l
o
g
1
0
 (
p
s-
1
 c
m
-2
 s
r-
1
) 
 
Time in Days 
Burn Burn and debride
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 (A) Bioluminescent images and (B) bioluminescence log10 values from mice infected 
with 10 μl of 108 cfu/ml S. aureus Xen 36 inoculated onto a burn wound, which was either 
debrided or non-debrided and treated with PEO:PDLLA nanofibers, containing nisin A. 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
Probiotics are living organisms with health promoting properties and bacteriocin production 
can be considered as a very important probiotic trait (Dobson et al., 2012). Electrospinning is 
a versatile technique to incorporate a variety of bioactive compounds into polymeric 
nanofibers to facilitate release thereof, or to encapsulate living organisms including bacteria, 
viruses and even mammalian cells (Agarwal et al., 2008). In this study, the probiotic 
Lactobacillus plantarum 423 was successfully electrospun into poly(ethylene oxide) (PEO) 
nanofibers and only showed a slight reduction in viability, from 2.3 x 10
10
 to 4.7 x 10
8
 cfu/ml 
after electrospinning. L. plantarum 423 cells released from the nanofibers were still able to 
produce plantaricin 423. As far as we could determine this was the first report on the 
encapsulation of probiotic lactic acid bacteria (LAB) into electrospun nanofibers. Other 
studies have also demonstrated the feasibility of co-electrospinning viable bacterial cells into 
nanofibers. Escherichia coli and Staphylococcus albus also survived co-electrospinning into 
poly(vinyl alcohol) (PVA) nanofibers and remained viable for three months at -20 and -55 °C 
(Sulalha et al., 2006). Micrococcus luteus showed better survival rates than E. coli when 
electrospun into PEO nanofibers with 74% surviving, where only 0.1% of the E. coli survived 
(Gensheimer et al., 2007). Bifidobacterium animalis Bb12, was successfully encapsulated into 
PVA nanofibers by using co-axial electrospinning (López-Rubio et al., 2009). B. animalis 
Bb12 remained viable for 40 days at room temperature and for 130 days at 4 °C in PVA 
nanofibers. Comparable survival rates to our study were obtained when Lactobacillus 
acidophilus FTDC 8933 was co-electrospun into nanofibers consisting of soluble dietary fiber 
and PVA (Fung et al., 2011). These results thus indicate that electrospun nanofibers can serve 
as a successful delivery system for bacteria, including probiotic LAB. 
 The increase in antibiotic resistance has placed an enormous burden on health care and 
treatment of bacterial infections is becoming more problematic. Bacteriocins have 
traditionally found application in the preservation of food products by preventing the growth 
of spoilage organisms. However, recently bacteriocins have received increased attention as 
alternatives to antibiotics to treat bacterial infections. As knowledge on host-microbe 
interactions expands with next-generation sequencing technologies and the human 
microbiome project, it is becoming apparent that we need to steer away from broad-spectrum 
antimicrobials as they can disrupt commensal populations (Cotter et al., 2012). This can also 
be related to the skin microbiota in which commensals, as those in the GIT, can protect the 
host from infection and prevent inflammatory conditions (Cogen et al., 2008). The fact that 
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bacteriocins have a relatively narrow spectrum of activity, as compared to some antibiotics, 
and that they are active against antibiotic-resistant pathogens has increased their potential use 
as next-generation antimicrobials. It is thus not surprising that this is an active field of 
research. The feasibility of incorporating bacteriocins into nanofibers was shown in this study 
by co-electrospinning plantaricin 423 into PEO nanofibers. Plantaricin 423 retained its 
activity after electrospinning and could still inhibit the growth of Enterococcus faecium 
HKLHS and Lactobacillus sakei DSM 20017
T
. Recently, nisin was shown to retain 
antimicrobial activity after co-electrospinning into gelatin nanofibers, with subsequent cross-
linking with saturated glutaraldehyde vapour (Dheraprasart et al. 2009). These nanofibers 
were investigated for food preservation.  
Plantaricin 423 and bacteriocin ST4SA were chosen as model bacteriocins to develop 
a nanofiber drug delivery system for bacteriocins, with the ultimate goal of generating an 
antimicrobial wound dressing. Plantaricin 423 showed low total release with an initial burst 
release from poly(D,L-lactide) (PDLLA) nanofibers, with negligible release thereafter. 
Plantaricin 423 release was only observed for 6 h. An initial burst release has also been 
reported for other molecules from electrospun nanofibers (Kenawy et al., 2002, Kim et al., 
2004, Peng et al., 2008). Core-shell structured nanofibers usually show a lower burst release 
profile (Maretschek et al., 2008, Yang et al., 2008). Hydrophilicity and hydrophobicity of the 
nanofiber scaffolds have been shown to influence the release profile of various drugs, as well 
as having an effect on cell attachment and proliferation in tissue engineering (Leung and Ko, 
2011, Maretschek et al., 2008). Polymer-drug interaction and solubility of molecules in the 
polymer solution will also influence the release profile of the drug (Kim et al., 2007, Zeng et 
al., 2003). 
Subsequently, a blending technique was employed to modify the properties of our 
nanofiber scaffold and this was achieved by blending PEO and PDLLA in various ratios 
before electrospinning. Blending polymers has previously been shown to modify properties of 
electrospun fibers (Kim et al., 2007, Maretschek et al., 2008, Nijenhuis et al., 1996). A PEO 
50: PDLLA 50 blend showed lower levels of structural degradation and reduced weight loss. 
It also showed a lower release profile than the other blends, but was still able to release 
enough plantaricin 423 and bacteriocin ST4SA to inhibit the growth of E. faecium HKLHS 
and Listeria monocytogenes EGD-e, respectively. The PEO 50:PDLLA 50 nanofiber scaffold 
was thus identified as the best candidate for further analysis as potential wound dressing.  
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Nisin A was successfully co-electrospun into PEO 50:PDLLA 50 nanofibers to generate an 
antimicrobial wound dressing, which was able to inhibit the growth of Staphylococcus aureus 
on agar plates for an extended period of time. Nisin A-containing nanofiber wound dressings 
were able to significantly reduce S. aureus bioluminescence, as well as viable cells of S. 
aureus in infected full-thickness excisional wounds in mice. S. aureus Xen 36 cell numbers 
was 4.3 x 10
2
 cfu/wound on day 7, when treated with nisin A-containing nanofiber wound 
dressings, whereas wounds treated with control nanofiber wound dressings had 2.2 x 10
7
 
cfu/wound. A 5 log10 reduction was thus obtained in the nisin A-containing nanofiber wound 
dressings treated groups, as compared to the control group. Increasing reports on in vivo 
antimicrobial efficacy of bacteriocins, especially lantibiotics, have emerged over the last few 
years (Bower et al., 2002, Brand et al., 2010, de Kwaadsteniet et al., 2009, 2010, Piper et al., 
2012, van Staden et al., 2012). The use of bacterocins in skin infections has also been 
proposed, although very few in vivo studies have been reported (Dawson et al., 2009, Valenta 
et al., 1996, Walsh et al., 2003). De Kwaadsteniet et al. (2010), reported on the inability of 
nisin F to treat subcutaneous S. aureus skin infections in mice. A synthetic peptide, A3-APO, 
was able to reduce viable cells of Acinetobacter baumannii and MRSA in burn wound skin 
infection models in mice (Ostorhazi et al., 2010, 2011). Other alternatives to antibiotics that 
have been investigated as treatment for skin infections include chitosan acetate bandages, 
natural antimicrobial agents (honey, aloe vera gel), Klebsiella bacteriophage Kpn 5 suspended 
in hydroxy propyl methyl cellulose hydrogels (E464, or HPMC), nanoemulsions and nitric 
oxide nanoparticles (Dai et al., 2009, Hemmila et al.,2010, Kumari et al., 2010, Martinez et 
al., 2009). As far as we could determine this is the first in vivo study evaluating the efficacy 
of nisin-containing nanofibers as antimicrobial wound dressing to treat bacterial infections in 
full-thickness excisional wounds.  
Nisin A-containing nanofiber wound dressings, as well as control wound dressings, 
improved wound healing of uninfected full-thickness excisional wounds in mice. Wounds 
covered with Nisin A-containing nanofiber wound dressings showed signs of re-
epithelialization, keratinization and formation of connective tissue. No neutrophils were 
observed in this group. However, neutrophils could be observed in all samples of control 
groups (covered with gauze) and one sample that received control wound dressings as 
treatment. Nanofibers have been extensively investigated as they have shown potential in 
tissue engineering and as wound dressings, where they promoted wound healing in vitro and 
in vivo (Chen et al., 2008, Choi et al., 2008, Dubský et al., 2012, Sundaramurthi et al., 2012, 
Tchemtchoua et al., 2011). It has also been shown that plantaricin A increased cell 
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proliferation, enhanced migration and influenced gene expression of genes in human 
keratinocytes (Pinto et al., 2011). More recently, nisin Z was shown to have 
immunomodulatory activities and modulated the host immune response (Kindrachuk et al., 
2012). The exact role of nisin, or other bacteriocins, in in vivo wound healing warrants further 
investigation to elucidate the mechanisms involved. 
Nisin F was shown to be unable to treat S. aureus-induced burn wound infections in 
mice, when released from PDLLA 70:poly(vinyl alcohol) (PVA) 30 nanofibers, as well as in 
solution. Nisin A-containing PEO 50:PDLLA 50 nanofiber wound dressings were only able to 
treat S. aureus-induced burn wound infections in mice when the wounds were debrided before 
infection. This indicates that the necrotic tissue forms a barrier, preventing the bacteriocins 
from reaching bacterial cells and thus negatively affects treatment. Debridement is performed 
in severely infected wounds or when wound healing is compromised, to expose healthy tissue. 
Debridement has been used in animal models when studying skin infections, especially those 
generated by deep dermal burns (Hemmila et al., 2010, Kiyozumi et al., 2007, Ribeiro et al., 
2009). 
In conclusion, nanofibers were shown to be a suitable drug delivery system for living 
probiotic LAB as well as for bacteriocins. Bacteriocins were successfully co-electrospun into 
nanofibers to generate an antimicrobial wound dressing. The bacteriocins retained their 
activity after electrospinning and were able to inhibit the growth of a sensitive strain once 
released from the nanofibers. Blending was shown to be an effective way to modify the 
release of bacteriocins from nanofibers and improved the overall properties of the wound 
dressings. Nisin-containing nanofiber wound dressings were able to treat S. aureus-induced 
full-thickness excisional skin infections in mice and improved wound healing of uninfected 
wounds. S. aureus-induced burn wound infections were more difficult to treat and 
debridement was necessary. Bacteriocin-eluting nanofiber scaffolds can thus serve as 
potential wound dressing to treat infections, as well as to improve healing of skin wounds. 
This work can be expanded with a comparative study, to compare the efficacy of the nisin-
eluting nanofiber wound dressings generated in this study with commercially available wound 
dressings. Future research should also include the combination of bacteriocins with growth 
factors, anti-inflammatory agents as well as other antimicrobials to generate an optimal 
wound dressing which can treat infections and reduce time needed for wounds to heal.  
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Release of Plantaricin 423 from Electrospun Poly(D,L-lactide) Nanofibers 
Introduction 
Electospinning is a versatile technique to produce fibers with very small diameters (Heunis et 
al., 2010, Kim et al., 2007, Maretschek et al., 2008, Zeng et al., 2003). Electrospun 
nanofibers can potentially serve as drug delivery systems for bacteriocins from lactic acid 
bacteria, with potential food and medical applications. Electrospinning of plantaricin 423 into 
poly(ethylene oxide) nanofibers (PEO) generated an antimicrobial nanofiber scaffold (Heunis 
et al., 2010). The PEO nanofibers are, however, highly soluble in water and would thus not be 
suitable as drug delivery system on its own. Here we investigate a more hydrophobic 
polymer, poly(D,L-lactide) as drug delivery system for plantaricin 423.  
Materials and methods   
Materials 
Poly (D,L-lactide) (PDLLA, 75 000-120 000 Da) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA). A Micro-bicinchoninic acid (BCA) assay kit was purchased from Pierce 
(Rockford, IL) for protein concentration determination. All other chemicals used were of 
analytical grade. 
Production and isolation of plantaricin 423 
Lactobacillus plantarum 423 was cultured in MRS broth (Biolab Diagnostics, Midrand, South 
Africa) at 37 °C for 24 h. Cells were harvested (8000g, 10 min, 4 °C), the pH of the cell-free 
supernatant adjusted between pH 6.5-7.0 with 10M NaOH and then heated at 80 °C for 10 
min. Plantaricin 423 was precipitated from the cell-free supernatant with 70% saturated 
ammonium sulfate (Sambrook et al., 1989) and desalted against distilled water by using a 
1000 Da cutoff dialysis membrane (Spectrum Inc., CA, USA). The sample was freeze-dried 
and stored at -20 
o
C. 
Electrospinning of nanofibers 
Freeze-dried plantaricin 423 (20 mg/ml) was dissolved in N,N-dimethylformamide (DMF) 
and centrifuged (6000g, 1 min). The supernatant was used to dissolve 43% (v/v) PDLLA and 
the solution was electrospun using a setup previously described (Heunis et al., 2010). During 
electrospinning a constant electric field of +10 kV was applied to the polymer solution and -5 
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kV to the collector. The distance between collector and polymer solution was 15 cm. The 
relative humidity was kept constant at 50-55%.  
SEM imaging of electrospun fibers 
Imaging of the nanofibers was accomplished using a Leo
®
 1430VP Scanning Electron 
Microscope (SEM). Prior to imaging the samples were coated with a thin layer of gold in 
order to make the sample surface conductive. The fiber diameter was determined by using the 
SEM Image Studio Software (version 10.1).  
Release of plantaricin 423 form PDLLA nanofibers 
Release studies were carried out in phosphate buffered saline (PBS buffer), pH 7.4. 
Nanofibers were collected and 25 mg were placed in sterile glass bottles containing 2 ml PBS 
buffer pH 7.4. The glass bottles, containing nanofibers, were incubated at 37 °C with constant 
agitation at 30 rpm. At pre-determined time intervals 2 ml PBS buffer pH 7.4 was removed 
from the glass bottles and replaced with fresh buffer. The protein concentration in the samples 
was determined by using the BCA protein assay kit by measuring the absorbance at 562 nm.  
Degradations studies 
Degradation studies were carried out by placing 25 mg of nanofibers in 2 ml sterile PBS 
buffer pH 7.4 in glass bottles. The glass bottles, containing nanofibers, were incubated at 37 
°C with constant agitation at 30 rpm. At pre-determined time intervals 2 ml PBS buffer pH 
7.4 was removed from the glass bottles. Nanofibers were freeze dried and weight loss in the 
sample was measured. Samples were subsequently visualized by SEM to investigate 
morphological changes.  
Labeling of plantaricin 423 
Plantaricin 423 was labeled with Rhodamine B isothiocyanate (RBITC). For labeling, 20 
mg/ml of RBITC was added to a plantaricin 423 solution in DMF, which was left to react for 
48 h at 4 °C with constant stirring in the dark.  The reaction product was dialyzed for three 
weeks against distilled water by using a 1000 Da cut off dialysis membrane (Spectrum Inc., 
CA, USA) to remove unbound RBITC. The sample was then freeze-dried and stored at -20 
°C. Labeled plantaricin 423 was electrospun into nanofibers as previously described and 
visualized with fluorescent microscopy. Nanofibers were excited at 572 nm by using a 
Xenon-Arc burner light source (Olympus Biosystems GMBH). Fluorescent images were 
captured with an Olympus Cell^R system attached to an IX-81 inverted fluorescent 
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microscope. An Olympus Plan Apo N 60×/1.4 Oil objective was used. Images were taken 
with an F-view-II cooled CCD camera (Soft Imaging Systems) and the background subtracted 
using the Cell^R imaging software. 
Results 
The nanofibers had a mean fiber diameter of 182 ± 25 nm, with most of the fibers in the 100-
250 nm range (Fig. 1A, B). Release studies from the PDLLA nanofibers revealed that there 
was an initial burst release that released ±18.0% of the total amount of plantaricin 423 within 
the first 2 h (Fig. 2 A, B). A release of bacteriocin was seen for up to 6 h, where after the 
release was negligible. The PDLLA nanofibers appeared to swell as the incubation time 
increased (Fig. 3 A-D). No significant morphological changes in the incubated PDLLA 
nanofibers were seen and the mesh retained its fibrous structure for 7 days of incubation. 
PDLLA nanofibers showed a slight decrease in weight during the first few hours of 
incubation, where after no significant decrease in weight was seen (Fig. 4 A, B). Up to 92% 
of the original weight remained in the samples after 7 days of incubation. Fluorescent images 
of RBITC-labeled plantaricin 423 showed that the bacteriocin was evenly distribution in the 
PDLLA nanofibers (Fig. 5). 
Discussion 
Electospinning of a 43% (w/v) solution of PDLLA, containing 20 mg/ml plantaricin 423, in 
DMF resulted in fibers in the nanometer range. Fiber diameters ranged from 65 nm to 375 
nm, with most of the fibers in the 150-200 nm range. The fast release of plantaricin 423 in the 
first 2 h could be ascribed to the fact some of the bacteriocin could be close to the surface of 
the fiber or that the bacteriocin was not completely entrapped within the fiber structure. These 
bacteriocins could then easily, by means of diffusion, be released into the buffer medium. The 
low percentage of bacteriocin release (27.5%) could also be ascribed to the slow degradation 
of PDLLA. This is supported by the fact that bacteriocin release was only seen up to 6 h and 
could thus not be as a result of nanofiber degradation, as little or no degradation was seen 
with SEM images and low weight loss was recorded. Other studies have also revealed that 
poly(lactic acid) on its own, is not very suitable for the controlled release of molecules 
because of its hydrophobicity. (Maretschek et al., 2008, Zeng et al., 2003). The PDLLA fibers 
appeared to swell as the incubation time increased (Fig. 5 A-D). No significant morphological 
changes in the incubated PDLLA nanofibers were seen and the mesh retained its fibrous 
structure for 7 days of incubation. The swelling could also have helped to facilitate the initial 
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release of bacteriocin so that bacteriocins, which had not been encapsulated or close to the 
surface of the fibers, could be released. 
PDLLA nanofibers showed a slight decrease in weight during the first few hours of 
incubation, where after no significant decrease in weight was seen (Fig. 7 A, B). This could 
also explain the initial release of bacteriocin from this mesh during the first few hours of 
incubation. After 6 h no significant release of bacteriocin from this scaffold, or weight loss 
was recorded. 
There are different ways to change the hydrophobicity of fibers. One method is to use 
emulsion electrospinning, where an aqueous solution containing a hydrophilic polymer is 
emulsified into a polymer solution in an organic phase. This emulsion can then be electrospun 
to form core-shell structured fibers. The higher the concentration of hydrophilic polymer in 
the aqueous solution, the lower the hydrophobicity will be and this will lead to a higher total 
amount of released molecule from the fibers. Cytochrome C has been encapsulated in 
nanofibers by emulsion electrospinning. (Maretschek et al., 2008) This was done by 
emulsifying an aqueous solution of cytochrome C in a chloroform solution containing PLLA. 
A low level of cytochrome C was released. Controlled release was obtained when PLLA was 
blended with poly(L-lysine) (PLL) and poly(ethylene imine) (PEI), hydrophilic polymers. A 
blend containing 50% PLL released most of the protein (75%) with a high initial burst release. 
Another method is to use co-axial electrospinning. During co-axial electrospinning two 
polymers in different solvents, where the one can be an organic solvent and the other one an 
aqueous solution, are electrospun with a specialized needle system to create core shell 
structured nanofibers (Jiang et al., 2005). Fibers electrospun with the co-axial setup are 
similar in structure to the emulsion spun fibers. These methods however have drawbacks, i.e. 
the emulsification step to prepare stable emulsions needed before emulsion electrospinning, as 
well as the specialized needle systems needed for co-axial electrospinning. 
 Blending polymers directly in a suitable solvent before electrospinning, is a much 
easier and less time consuming way to change the properties of the fibers formed by 
electrospinning. If phase separation occurs during fiber formation, it is possible that 
hydrophilic and hydrophobic domains will form in the fibers. The hydrophilic domains will 
dissolve faster than the hydrophobic domains in the fiber structure, generating pores that will 
help facilitate the release of the encapsulated molecule (Kim et al., 2007). Blending can easily 
be used to change the hydrophobicity, thermal stability and mechanical properties of the 
fibers (Nijenhuis et al., 1996). This method was chosen to improve the hydrophobicity of the 
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electrospun PDLLA fibers and to help facilitate the release of the bacteriocin from the 
electrospun nanofibers, as described in chapter 4.  
Plantaricin 423 was successfully electrospun into PDLLA nanofibers. Release of 
plantaricin 423 was seen, however only for up to a few hours, after which no significant 
release was seen. PDLLA fibers were able to retain their fibrous structure and original weight 
over a 7-day period. PDLLA nanofibers were shown to be unsuitable as delivery system for 
bacteriocins. Blending polymers with PDLLA could provide for a better delivery system for 
bacteriocins. 
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Fig. 1 SEM image of electrospun PDLLA nanofibers containing plantaricin 423 (A) and fiber 
diameter distribution of the electrospun nanofibers (B). 
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Fig. 2 Cumulative release of plantaricin 423 from electrospun PDLLAnanofibers.  
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Fig. 3 SEM images of PDLLA incubated in PBS buffer pH 7.4 for different time intervals. No 
significant morphological changes are seen, except that the nanofiber appears more swollen as 
the incubation time increased. 
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Fig. 4 Percentage original weight of PDLLA nanofibers remaining after incubation at 37 °C 
for 7 days. 
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Fig. 5 Images of RBITC-labeled plantaricin 423 electrospun into PDLLA nanofibers. (A) 
Flourescent image of RBITC-labeled plantaricin 423, (B) optical image of PDLLA nanofibes 
and (C) overlay of optical and fluorescent images. 
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